Human kidins220Pc

ABSTRACT

The present invention relates to human kidins220Pc, including all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are up-regulated in prostate cancer and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., prostate cancer. Human kidins220Pc is also involved in neurite outgrowth, making it a target for therapeutic approaches to neurodegenerative diseases, such as spinal cord injury.

DESCRIPTION OF THE DRAWINGS

[0001] FIGS. 1(A-E) shows the amino acid alignments of human kidins220Pc (“Pc473”; SEQ ID NO 2) and variants XM_(—)045362 (SEQ ID NO 3) and AB033076 (SEQ ID NO 4).

[0002] FIGS. 2(A-G) shows the amino acid alignments of human kidins2220 variants (XM_(—)045362, SEQ ID NO 3; and AB033076, SEQ ID NO 4) and rat variants (AF239045, SEQ ID NO 7; and AF313464, SEQ ID NO 6). The referenced numbers are GenBank identifiers.

DESCRIPTION OF THE INVENTION

[0003] The present invention relates to all facets of human kidins220Pc, polypeptides encoded by it, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. Human kidins220Pc is up-regulated in prostate cancer, making it useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, relating to prostate cancer. In addition, it is involved in signaling pathways associated with neurite outgrowth, making it useful to treat neurogenerative diseases, such as spinal cord injury, brain injury, and Parkinson's disease.

[0004] The identification of specific genes, and groups of genes, expressed in pathways physiologically relevant to the prostate and brain permits the definition of functional and disease pathways, and the delineation of targets in these pathways which are useful in diagnostic, therapeutic, and clinical applications. The present invention also relates to methods of using the polynucleotides and related products (proteins, antibodies, etc.) in business and computer-related methods, e.g., advertising, displaying, offering, selling, etc., such products for sale, commercial use, licensing, etc.

[0005] Human Kidins220Pc (kinase D-interacting substrate of 220 kDa) codes for a polypeptide containing 1715 amino acid. The nucleotide and amino acid sequences of Kidins220 are shown in SEQ ID NOS 1 and 2. It contains 11 ANK domains at about amino acid positions 37-66, 70-99, 103-132, 137-166, 170-199, 203-232, 236-265, 269-298, 302-331, 335-364, and 368-399. Four transmembrane domains are located at about amino acid positions 496-518, 525-547, 659-681, and 688-707. There is a SAM domain at about amino acids 1151-1223. It contains cAMP and cGMP protein kinase phosphorylation site motifs at about 880-883, 901-904, 1250-1253, 1438-1441, and 1524-1527; protein kinase C phosphorylation site motifs at about 167-169, 219-221, 233-235, 381-383, 471-473, 562-564, 590-592, 722-724, 791-793, 904-906, 939-941, 950-952, 998-1000, 1012-1014, 1034-1036, 1180-1182, 1298-1300, 1320-1322, 1351-1353, 1441-1443, 1567-1569, 1677-1679, and 1681-1683; ATP/GTP-binding site motif A (P-loop) at about amino acid positions 467-474; and tyrosine phosphorylation site motifs at 403-409 and 1397-1404. Its N- and C-terminus are cytoplasmic. A UniGene cluster is represented by Hs.9873.

[0006] There are several alternative forms of Kidins220Pc (e.g., different sequences as a result of alternative splicing, etc.). AB033076 (FIG. 1; SEQ ID NOS 4, 10, and 11) appears to a complete cDNA having an insertion of about 57 amino acids after human Kidins220Pc residue 1138 (SEQ ID NO 1), as well as containing an addition amino acid residue, Q, at about amino acid position 136. See, FIG. 1. AB033076 also has a six-amino acid extension at its N-terminus, LQLSVK (SEQ ID NO 5), which is not shown. XM_(—)045362 (FIG. 1; SEQ ID NOS 3, 8 and 9) is a partial and incomplete EST for human Kidins220Pc, missing from about amino acid 1138. See, FIG. 1. It contains the above-mentioned insertion, making it closer to the AB033076 variant. In addition to the Q residue at position 136, the following sequences (polypeptide and corresponding nucleotide) can be used to distinguish the different forms: 1138-1184 (SEQ ID NO 3), 1138-1176(SEQ ID NO 3), 1177-1184 (SEQ ID NO 3), 1138-1194 (SEQ ID NO 4), or 1177-1194 (SEQ ID NO 4).

[0007] There are several rat homologs of human Kidins220. AF313464 (FIG. 2; SEQ ID NO 6) shares about 92% amino acid sequence identity and 95% amino acid homology along its entire length. Like the human Kidins220Pcform, this rat homolog does not contain the amino acid insertion present in AB033076, but it does contain the Q residue at 136. AF239045 (FIG. 2; SEQ ID NO 7) is another rat homolog, closer to the AB033076 form, having about 91% amino acid sequence identity and 93% amino acid homology along its entire length to human kidins220Pc. A C. elegans homolog is NM_(—)069656 and a Drosophila homolog is AE003453.

[0008] All or part of Kidins220 is located in genomic DNA represented by GenBank ID: AC012495.8 and Contig ID: NT_(—)022194. The present invention relates to any isolated introns and exons that are present in the gene. Intron and exon boundaries can be routinely determined, e.g., using the polypeptide and genomic sequences disclosed herein.

[0009] Human Kidins220Pc maps to chromosomal band 2p25.1. Hereditary essential tremor (OMIM 602134) maps to this location. Nucleic acids of the present invention can be used as linkage markers, diagnostic targets, therapeutic targets, for this disorder, as well as any disorders or genes mapping in proximity to it.

[0010] Kidins220 was originally identified as a substrate protein kinase D (“PKD”), a serine/threonine kinase regulated by diacylglycerol signaling pathways. See, Iglesias, J. Biol. Chem., 275:40048-40056, 2000. It is phosphorylated by PKD at the serine at position 919, and its first physiologically-occurring substrate. See, Iglesias et al. Thus, human Kidin220Pc can used as a substrate in assays for PKD activity. See, e.g., Iglesias et al. for how such assays can be carried out.

[0011] In addition to its association with prostate cancer, Kidins220Pc expression can be affected in other tissues, as well. For example, Iglesias et al. reported that it is expressed at very high levels in the brain and has a role in neurite ougriwth, making it useful for the treatment and analysis of neurodegenerative diseases, including spinal cord injuries, Parkinson's disease, Alzheimer's disease, multiple sclerosis, traumatic head injury, etc. For example, modulation of human kidins220Pc can be utilized to regulate neurite outgrowth and subsequent synaptogenesis.

[0012] Nucleic Acids

[0013] A mammalian polynucleotide, or fragment thereof, of the present invention is a polynucleotide having a nucleotide sequence obtainable from a natural source. When the species name is used, e.g., human kidins220Pc, it indicates that the polynucleotide or polypeptide is obtainable from a natural source. It therefore includes naturally-occurring normal, naturally-occurring mutant, and naturally-occurring polymorphic alleles (e.g., SNPs), differentially-spliced transcripts, splice-variants, etc. By the term “naturally-occurring,” it is meant that the polynucleotide is obtainable from a natural source, e.g., animal tissue and cells, body fluids, tissue culture cells, forensic samples. Natural sources include, e.g., living cells obtained from tissues and whole organisms, tumors, cultured cell lines, including primary and immortalized cell lines. Naturally-occurring mutations can include deletions (e.g., a truncated amino- or carboxy-terminus), substitutions, inversions, or additions of nucleotide sequence. These genes can be detected and isolated by polynucleotide hybridization according to methods which one skilled in the art would know, e.g., as discussed below.

[0014] A polynucleotide according to the present invention can be obtained from a variety of different sources. It can be obtained from DNA or RNA, such as polyadenylated mRNA or total RNA, e.g., isolated from tissues, cells, or whole organism. The polynucleotide can be obtained directly from DNA or RNA, from a cDNA library, from a genomic library, etc. The polynucleotide can be obtained from a cell or tissue (e.g., from an embryonic or adult tissues) at a particular stage of development, having a desired genotype, phenotype, disease status, etc. A polynucleotide which “codes without interruption” refers to a polynucleotide having a continuous open reading frame (“ORF”) as compared to an ORF which is interrupted by introns or other noncoding sequences.

[0015] Polynucleotides and polypeptides (including any part of human kidins220Pc) can be excluded as compositions from the present invention if, e.g., listed in a publicly available databases on the day this application was filed and/or disclosed in a patent application having an earlier filing or priority date than this application and/or conceived and/or reduced to practice earlier than a polynucleotide in this application.

[0016] As described herein, the phrase “an isolated polynucleotide which is SEQ ID NO,” or “an isolated polynucleotide which is selected from SEQ ID NO,” refers to an isolated nucleic acid molecule from which the recited sequence was derived (e.g., a cDNA derived from mRNA; cDNA derived from genomic DNA). Because of sequencing errors, typographical errors, etc., the actual naturally-occurring sequence may differ from a SEQ ID listed herein. Thus, the phrase indicates the specific molecule from which the sequence was derived, rather than a molecule having that exact recited nucleotide sequence, analogously to how a culture depository number refers to a specific cloned fragment in a cryotube.

[0017] As explained in more detail below, a polynucleotide sequence of the invention can contain the complete sequence as shown in SEQ ID NO 1, degenerate sequences thereof, anti-sense, muteins thereof, genes comprising said sequences, full-length cDNAs comprising said sequences, complete genomic sequences, fragments thereof, homologs, primers, nucleic acid molecules which hybridize thereto, derivatives thereof, etc.

[0018] Genomic

[0019] The present invention also relates genomic DNA from which the polynucleotides of the present invention can be derived. A genomic DNA coding for a human, mouse, or other mammalian polynucleotide, can be obtained routinely, for example, by screening a genomic library (e.g., a YAC library) with a polynucleotide of the present invention, or by searching nucleotide databases, such as GenBank and EMBL, for matches. Promoter and other regulatory regions (including both 5′ and 3′ regions, as well introns) can be identified upstream or downstream of coding and expressed RNAs, and assayed routinely for activity, e.g., by joining to a reporter gene (e.g., CAT, GFP, alkaline phosphatase, luciferase, galatosidase). A promoter obtained from the human kidins220Pc can be used, e.g., in gene therapy to obtain tissue-specific expression of a heterologous gene (e.g., coding for a therapeutic product or cytotoxin). 5′ and 3′ sequences (including, UTRs and introns) can be used to modulate or regulate stability, transcription, and translation of nucleic acids, including the sequence to which is attached in nature, as well as heterologous nucleic acids.

[0020] Constructs

[0021] A polynucleotide of the present invention can comprise additional polynucleotide sequences, e.g., sequences to enhance expression, detection, uptake, cataloging, tagging, etc. A polynucleotide can include only coding sequence; a coding sequence and additional non-naturally occurring or heterologous coding sequence (e.g., sequences coding for leader, signal, secretory, targeting, enzymatic, fluorescent, antibiotic resistance, and other functional or diagnostic peptides); coding sequences and non-coding sequences, e.g., untranslated sequences at either a 5′ or 3′ end, or dispersed in the coding sequence, e.g., introns.

[0022] A polynucleotide according to the present invention also can comprise an expression control sequence operably linked to a polynucleotide as described above. The phrase “expression control sequence” means a polynucleotide sequence that regulates expression of a polypeptide coded for by a polynucleotide to which it is functionally (“operably”) linked. Expression can be regulated at the level of the mRNA or polypeptide. Thus, the expression control sequence includes mRNA-related elements and protein-related elements. Such elements include promoters, enhancers (viral or cellular), ribosome binding sequences, transcriptional terminators, etc. An expression control sequence is operably linked to a nucleotide coding sequence when the expression control sequence is positioned in such a manner to effect or achieve expression of the coding sequence. For example, when a promoter is operably linked 5′ to a coding sequence, expression of the coding sequence is driven by the promoter. Expression control sequences can include an initiation codon and additional nucleotides to place a partial nucleotide sequence of the present invention in-frame in order to produce a polypeptide (e.g., pET vectors from Promega have been designed to permit a molecule to be inserted into all three reading frames to identify the one that results in polypeptide expression). Expression control sequences can be heterologous or endogenous to the normal gene.

[0023] A polynucleotide of the present invention can also comprise nucleic acid vector sequences, e.g., for cloning, expression, amplification, selection, etc. Any effective vector can be used. A vector is, e.g., a polynucleotide molecule which can replicate autonomously in a host cell, e.g., containing an origin of replication. Vectors can be useful to perform manipulations, to propagate, and/or obtain large quantities of the recombinant molecule in a desired host. A skilled worker can select a vector depending on the purpose desired, e.g., to propagate the recombinant molecule in bacteria, yeast, insect, or mammalian cells. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, Phagescript, phiX174, pBK Phagemid, pNH8A, pNH16a, pNH18Z, pNH46A (Stratagene); Bluescript KS+II (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR54 0, pRIT5 (Pharmacia). Eukaryotic: PWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene), pSVK3, PBPV, PMSG, pSVL (Pharmacia), pCR2.1/TOPO, pCRII/TOPO, pCR4/TOPO, pTrcHisB, pCMV6-XL4, etc. However, any other vector, e.g., plasmids, viruses, or parts thereof, may be used as long as they are replicable and viable in the desired host. The vector can also comprise sequences which enable it to replicate in the host whose genome is to be modified.

[0024] Hybridization

[0025] Polynucleotide hybridization, as discussed in more detail below, is useful in a variety of applications, including, in gene detection methods, for identifying mutations, for making mutations, to identify homologs in the same and different species, to identify related members of the same gene family, in diagnostic and prognostic assays, in therapeutic applications (e.g., where an antisense polynucleotide is used to inhibit expression), etc.

[0026] The ability of two single-stranded polynucleotide preparations to hybridize together is a measure of their nucleotide sequence complementarity, e.g., base-pairing between nucleotides, such as A-T, G-C, etc. The invention thus also relates to polynucleotides, and their complements, which hybridize to a polynucleotide comprising a nucleotide sequence as set forth in SEQ ID NO 1 and genomic sequences thereof. A nucleotide sequence hybridizing to the latter sequence will have a complementary polynucleotide strand, or act as a template for one in the presence of a polymerase (i.e., an appropriate polynucleotide synthesizing enzyme). The present invention includes both strands of polynucleotide, e.g., a sense strand and an anti-sense strand.

[0027] Hybridization conditions can be chosen to select polynucleotides which have a desired amount of nucleotide complementarity with the nucleotide sequences set forth in SEQ ID NO 1 and genomic sequences thereof. A polynucleotide capable of hybridizing to such sequence, preferably, possesses, e.g., about 70%, 75%, 80%, 85%, 87%, 90%, 92%, 95%, 97%, 99%, or 100% complementarity, between the sequences. The present invention particularly relates to polynucleotide sequences which hybridize to the nucleotide sequences set forth in SEQ ID NO 1 or genomic sequences thereof, under low or high stringency conditions. These conditions can be used, e.g., to select corresponding homologs in non-human species.

[0028] Polynucleotides which hybridize to polynucleotides of the present invention can be selected in various ways. Filter-type blots (i.e., matrices containing polynucleotide, such as nitrocellulose), glass chips, and other matrices and substrates comprising polynucleotides (short or long) of interest, can be incubated in a prehybridization solution (e.g., 6×SSC, 0.5% SDS, 100 μg/ml denatured salmon sperm DNA, 5× Denhardt's solution, and 50% formamide), at 22-68° C., overnight, and then hybridized with a detectable polynucleotide probe under conditions appropriate to achieve the desired stringency. In general, when high homology or sequence identity is desired, a high temperature can be used (e.g., 65° C). As the homology drops, lower washing temperatures are used. For salt concentrations, the lower the salt concentration, the higher the stringency. The length of the probe is another consideration. Very short probes (e.g., less than 100 base pairs) are washed at lower temperatures, even if the homology is high. With short probes, formamide can be omitted. See, e.g., Current Protocols in Molecular Biology, Chapter 6, Screening of Recombinant Libraries; Sambrook et al., Molecular Cloning, 1989, Chapter 9.

[0029] For instance, high stringency conditions can be achieved by incubating the blot overnight (e.g., at least 12 hours) with a long polynucleotide probe in a hybridization solution containing, e.g., about 5×SSC, 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 50% formamide, at 42° C. Blots can be washed at high stringency conditions that allow, e.g., for less than 5% bp mismatch (e.g., wash twice in 0.1% SSC and 0.1% SDS for 30 min at 65° C.), i.e., selecting sequences having 95% or greater sequence identity.

[0030] Other non-limiting examples of high stringency conditions includes a final wash at 65° C. in aqueous buffer containing 30 mM NaCl and 0.5% SDS. Another example of high stringent conditions is hybridization in 7% SDS, 0.5 M NaPO₄, pH 7, 1 mM EDTA at 50° C., e.g., overnight, followed by one or more washes with a 1% SDS solution at 42° C. Whereas high stringency washes can allow for less than 5% mismatch, reduced or low stringency conditions can permit up to 20% nucleotide mismatch. Hybridization at low stringency can be accomplished as above, but using lower formamide conditions, lower temperatures and/or lower salt concentrations, as well as longer periods of incubation time.

[0031] Hybridization can also be based on a calculation of melting temperature (Tm) of the hybrid formed between the probe and its target, as described in Sambrook et al. Generally, the temperature Tm at which a short oligonucleotide (containing 18 nucleotides or fewer) will melt from its target sequence is given by the following equation: Tm=(number of A's and T's)×2° C.+(number of C's and G's)×4° C. For longer molecules, Tm=81.5+16.6 log₁₀[Na⁺]+0.41(% GC)−600/N where [Na⁺] is the molar concentration of sodium ions, % GC is the percentage of GC base pairs in the probe, and N is the length. Hybridization can be carried out at several degrees below this temperature to ensure that the probe and target can hybridize. Mismatches can be allowed for by lowering the temperature even further.

[0032] Stringent conditions can be selected to isolate sequences, and their complements, which have, e.g., at least about 90%, 95%, or 97%, nucleotide complementarity between the probe (e.g., a short polynucleotide of SEQ ID NO 1 or genomic sequences thereof) and a target polynucleotide.

[0033] Other homologs of polynucleotides of the present invention can be obtained from mammalian and non-mammalian sources according to various methods. For example, hybridization with a polynucleotide can be employed to select homologs, e.g., as described in Sambrook et al., Molecular Cloning, Chapter 11, 1989. Such homologs can have varying amounts of nucleotide and amino acid sequence identity and similarity to such polynucleotides of the present invention. Mammalian organisms include, e.g., mice, rats, monkeys, pigs, cows, etc. Non-mammalian organisms include, e.g., vertebrates, invertebrates, zebra fish, chicken, Drosophila, C. elegans, Xenopus, yeast such as S. pombe, S. cerevisiae, roundworms, prokaryotes, plants, Arabidopsis, artemia, viruses, etc.

[0034] Alignment

[0035] Alignments can be accomplished by using any effective algorithm. For pairwise alignments of DNA sequences, the methods described by Wilbur-Lipman (e.g., Wilbur and Lipman, Proc. Natl. Acad. Sci., 80:726-730, 1983) or Martinez/Needleman-Wunsch (e.g., Martinez, Nucleic Acid Res., 11:4629-4634, 1983) can be used. For instance, if the Martinez/Needleman-Wunsch DNA alignment is applied, the minimum match can be set at 9, gap penalty at 1.10, and gap length penalty at 0.33. The results can be calculated as a similarity index, equal to the sum of the matching residues divided by the sum of all residues and gap characters, and then multiplied by 100 to express as a percent. Similarity index for related genes at the nucleotide level in accordance with the present invention can be greater than 70%, 80%, 85%, 90%, 95%, 99%, or more. Pairs of protein sequences can be aligned by the Lipman-Pearson method (e.g., Lipman and Pearson, Science, 227:1435-1441, 1985) with k-tuple set at 2, gap penalty set at 4, and gap length penalty set at 12. Results can be expressed as percent similarity index, where related genes at the amino acid level in accordance with the present invention can be greater than 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more. Various commercial and free sources of alignment programs are available, e.g., MegAlign by DNA Star, BLAST (National Center for Biotechnology Information), BCM (Baylor College of Medicine) Launcher, etc. BLAST can be used to calculate amino acid sequence identity, amino acid sequence homology, and nucleotide sequence identity. These calculations can be made along the entire length of each of the target sequences which are to be compared.

[0036] Percent sequence identity can also be determined by other conventional methods, e.g., as described in Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992.

[0037] Specific Polynucleotide Probes

[0038] A polynucleotide of the present invention can comprise any continuous nucleotide sequence of SEQ ID NO 1, sequences which share sequence identity thereto, or complements thereof. The term “probe” refers to any substance that can be used to detect, identify, isolate, etc., another substance. A polynucleotide probe is comprised of nucleic acid can be used to detect, identify, etc., other nucleic acids, such as DNA and RNA.

[0039] These polynucleotides can be of any desired size that is effective to achieve the specificity desired. For example, a probe can be from about 7 or 8 nucleotides to several thousand nucleotides, depending upon its use and purpose. For instance, a probe used as a primer PCR can be shorter than a probe used in an ordered array of polynucleotide probes. Probe sizes vary, and the invention is not limited in any way by their size, e.g., probes can be from about 7-2000 nucleotides, 7-1000, 8-700, 8-600, 8-500, 8-400, 8-300, 8-150, 8-100, 8-75, 7-50, 10-25, 14-16, at least about 8, at least about 10, at least about 15, at least about 25, etc. The polynucleotides can have non-naturally-occurring nucleotides, e.g., inosine, AZT, 3TC, etc. The polynucleotides can have 100% sequence identity or complementarity to a sequence of SEQ ID NO 1, or it can have mismatches or nucleotide substitutions, e.g., 1, 2, 3, 4, or 5 substitutions. The probes can be single-stranded or double-stranded.

[0040] In accordance with the present invention, a polynucleotide can be present in a kit, where the kit includes, e.g., one or more polynucleotides, a desired buffer (e.g., phosphate, tris, etc.), detection compositions, RNA or cDNA from different tissues to be used as controls, libraries, etc. The polynucleotide can be labeled or unlabeled, with radioactive or non-radioactive labels as known in the art. Kits can comprise one or more pairs of polynucleotides for amplifying nucleic acids specific for human kidins220Pc, e.g., comprising a forward and reverse primer effective in PCR. These include both sense and anti-sense orientations. For instance, in PCR-based methods (such as RT-PCR), a pair of primers are typically used, one having a sense sequence and the other having an antisense sequence.

[0041] Another aspect of the present invention is a nucleotide sequence that is specific to, or for, a selective polynucleotide. The phrases “specific for” or “specific to” a polynucleotide have a functional meaning that the polynucleotide can be used to identify the presence of one or more target genes in a sample and distinguish them from non-target genes. It is specific in the sense that it can be used to detect polynucleotides above background noise (“non-specific binding”). A specific sequence is a defined order of nucleotides (or amino acid sequences, if it is a polypeptide sequence) which occurs in the polynucleotide, e.g., in the nucleotide sequences of SEQ ID NO 1, and which is characteristic of that target sequence, and substantially no non-target sequences. A probe or mixture of probes can comprise a sequence or sequences that are specific to a plurality of target sequences, e.g., where the sequence is a consensus sequence, a functional domain, etc., e.g., capable of recognizing a family of related genes. Such sequences can be used as probes in any of the methods described herein or incorporated by reference. Both sense and antisense nucleotide sequences are included. A specific polynucleotide according to the present invention can be determined routinely.

[0042] A polynucleotide comprising a specific sequence can be used as a hybridization probe to identify the presence of, e.g., human or mouse polynucleotide, in a sample comprising a mixture of polynucleotides, e.g., on a Northern blot. Hybridization can be performed under high stringent conditions (see, above) to select polynucleotides (and their complements which can contain the coding sequence) having at least 90%, 95%, 99%, etc., identity (i.e., complementarity) to the probe, but less stringent conditions can also be used. A specific polynucleotide sequence can also be fused in-frame, at either its 5′ or 3′ end, to various nucleotide sequences as mentioned throughout the patent, including coding sequences for enzymes, detectable markers, GFP, etc, expression control sequences, etc.

[0043] A polynucleotide probe, especially one that is specific to a polynucleotide of the present invention, can be used in gene detection and hybridization methods as already described. Probes which are specific for polynucleotides of the present invention can also be prepared using involve transcription-based systems, e.g., incorporating an RNA polymerase promoter into a selective polynucleotide of the present invention, and then transcribing anti-sense RNA using the polynucleotide as a template. See, e.g., U.S. Pat. No. 5,545,522.

[0044] Polynucleotide Composition

[0045] A polynucleotide according to the present invention can comprise, e.g., DNA, RNA, synthetic polynucleotide, peptide polynucleotide, modified nucleotides, dsDNA, ssDNA, ssRNA, dsRNA, and mixtures thereof. A polynucleotide can be single- or double-stranded, triplex, DNA:RNA, duplexes, comprise hairpins, and other secondary structures, etc. Nucleotides comprising a polynucleotide can be joined via various known linkages, e.g., ester, sulfamate, sulfamide, phosphorothioate, phosphoramidate, methylphosphonate, carbamate, etc., depending on the desired purpose, e.g., resistance to nucleases, such as RNAse H, improved in vivo stability, etc. See, e.g., U.S. Pat. No. 5,378,825. Any desired nucleotide or nucleotide analog can be incorporated, e.g., 6-mercaptoguanine, 8-oxo-guanine, etc.

[0046] Various modifications can be made to the polynucleotides, such as attaching detectable markers (avidin, biotin, radioactive elements, fluorescent tags and dyes, energy transfer labels, energy-emitting labels, binding partners, etc.) or moieties which improve hybridization, detection, and/or stability. The polynucleotides can also be attached to solid supports, e.g., nitrocellulose, magnetic or paramagnetic microspheres (e.g., as described in U.S. Pat. No. 5,411,863; U.S. Pat. No. 5,543,289; for instance, comprising ferromagnetic, supermagnetic, paramagnetic, superparamagnetic, iron oxide and polysaccharide), nylon, agarose, diazotized cellulose, latex solid microspheres, polyacrylamides, etc., according to a desired method. See, e.g., U.S. Pat. Nos. 5,470,967, 5,476,925, and 5,478,893.

[0047] Polynucleotide according to the present invention can be labeled according to any desired method. The polynucleotide can be labeled using radioactive tracers such as ³²P, ³⁵S, ³H, or ¹⁴C, to mention some commonly used tracers. The radioactive labeling can be carried out according to any method, such as, for example, terminal labeling at the 3′ or 5′ end using a radiolabeled nucleotide, polynucleotide kinase (with or without dephosphorylation with a phosphatase) or a ligase (depending on the end to be labeled). A non-radioactive labeling can also be used, combining a polynucleotide of the present invention with residues having immunological properties (antigens, haptens), a specific affinity for certain reagents (ligands), properties enabling detectable enzyme reactions to be completed (enzymes or coenzymes, enzyme substrates, or other substances involved in an enzymatic reaction), or characteristic physical properties, such as fluorescence or the emission or absorption of light at a desired wavelength, etc.

[0048] Nucleic Acid Detection Methods

[0049] Another aspect of the present invention relates to methods and processes for detecting human kidins220Pc. Detection methods have a variety of applications, including for diagnostic, prognostic, forensic, and research applications. To accomplish gene detection, a polynucleotide in accordance with the present invention can be used as a “probe.” The term “probe” or “polynucleotide probe” has its customary meaning in the art, e.g., a polynucleotide which is effective to identify (e.g., by hybridization), when used in an appropriate process, the presence of a target polynucleotide to which it is designed. Identification can involve simply determining presence or absence, or it can be quantitative, e.g., in assessing amounts of a gene or gene transcript present in a sample. Probes can be useful in a variety of ways, such as for diagnostic purposes, to identify homologs, and to detect, quantitate, or isolate a polynucleotide of the present invention in a test sample.

[0050] Assays can be utilized which permit quantification and/or presence/absence detection of a target nucleic acid in a sample. Assays can be performed at the single-cell level, or in a sample comprising many cells, where the assay is “averaging” expression over the entire collection of cells and tissue present in the sample. Any suitable assay format can be used, including, but not limited to, e.g., Southern blot analysis, Northern blot analysis, polymerase chain reaction (“PCR”) (e.g., Saiki et al., Science, 241:53, 1988; U.S. Pat. Nos. 4,683,195, 4,683,202, and 6,040,166; PCR Protocols: A Guide to Methods and Applications, Inis et al., eds., Academic Press, New York, 1990), reverse transcriptase polymerase chain reaction (“RT-PCR”), anchored PCR, rapid amplification of cDNA ends (“RACE”) (e.g., Schaefer in Gene Cloning and Analysis: Current Innovations, Pages 99-115, 1997), ligase chain reaction (“LCR”) (EP 320 308), one-sided PCR (Ohara et al., Proc. Natl Acad. Sci., 86:5673-5677, 1989), indexing methods (e.g., U.S. Pat. No. 5,508,169), in situ hybridization, differential display (e.g., Liang et al., Nucl Acid. Res., 21:3269-3275, 1993; U.S. Pat. Nos. 5,262,311, 5,599,672 and 5,965,409; WO97/18454; Prashar and Weissman, Proc. Natl Acad. Sci., 93:659-663, and U.S. Pat. Nos. 6,010,850 and 5,712,126; Welsh et al., Nucleic Acid Res., 20:4965-4970, 1992, and U.S. Pat. No. 5,487,985) and other RNA fingerprinting techniques, nucleic acid sequence based amplification (“NASBA”) and other transcription based amplification systems (e.g., U.S. Pat. Nos. 5,409,818 and 5,554,527; WO 88/10315), polynucleotide arrays (e.g., U.S. Pat. Nos. 5,143,854, 5,424,186; 5,700,637, 5,874,219, and 6,054,270; PCT WO 92/10092; PCT WO 90/15070), Qbeta Replicase (PCT/US87/00880), Strand Displacement Amplification (“SDA”), Repair Chain Reaction (“RCR”), nuclease protection assays, subtraction-based methods, Rapid-Scan™, etc. Additional useful methods include, but are not limited to, e.g., template-based amplification methods, competitive PCR (e.g., U.S. Pat. No. 5,747,251), redox-based assays (e.g., U.S. Pat. No. 5,871,918), Taqman-based assays (e.g., Holland et al., Proc. Natl. Acad, Sci., 88:7276-7280, 1991; U.S. Pat. Nos. 5,210,015 and 5,994,063), real-time fluorescence-based monitoring (e.g., U.S. Pat. No. 5,928,907), molecular energy transfer labels (e.g., U.S. Pat. Nos. 5,348,853, 5,532,129, 5,565,322, 6,030,787, and 6,117,635; Tyagi and Kramer, Nature Biotech., 14:303-309, 1996). Any method suitable for single cell analysis of gene or protein expression can be used, including in situ hybridization, immunocytochemistry, MACS, FACS, flow cytometry, etc. For single cell assays, expression products can be measured using antibodies, PCR, or other types of nucleic acid amplification (e.g., Brady et al., Methods Mol. & Cell. Biol. 2, 17-25, 1990; Eberwine et al., 1992, Proc. Natl. Acad. Sci., 89, 3010-3014, 1992; U.S. Pat. No. 5,723,290). These and other methods can be carried out conventionally, e.g., as described in the mentioned publications.

[0051] Many of such methods may require that the polynucleotide is labeled, or comprises a particular nucleotide type useful for detection. The present invention includes such modified polynucleotides that are necessary to carry out such methods. Thus, polynucleotides can be DNA, RNA, DNA:RNA hybrids, PNA, etc., and can comprise any modification or substituent which is effective to achieve detection.

[0052] Detection can be desirable for a variety of different purposes, including research, diagnostic, prognostic, and forensic. For diagnostic purposes, it may be desirable to identify the presence or quantity of a polynucleotide sequence in a sample, where the sample is obtained from tissue, cells, body fluids, etc. In a preferred method as described in more detail below, the present invention relates to a method of detecting a polynucleotide comprising, contacting a target polynucleotide in a test sample with a polynucleotide probe under conditions effective to achieve hybridization between the target and probe; and detecting hybridization.

[0053] Any test sample in which it is desired to identify a polynucleotide or polypeptide thereof can be used, including, e.g., blood, urine, saliva, stool (for extracting nucleic acid, see, e.g., U.S. Pat. No. 6,177,251), swabs comprising tissue, biopsied tissue, tissue sections, cultured cells, etc.

[0054] Detection can be accomplished in combination with polynucleotide probes for other genes, e.g., genes which are expressed in other disease states, tissues, cells, such as brain, heart, kidney, spleen, thymus, liver, stomach, small intestine, colon, muscle, lung, testis, placenta, pituitary, thyroid, skin, adrenal gland, pancreas, salivary gland, uterus, ovary, prostate gland, peripheral blood cells (T-cells, lymphocytes, etc.), embryo, normal breast fat, adult and embryonic stem cells, specific cell-types, such as endothelial, epithelial, myocytes, adipose, luminal epithelial, basoepithelial, myoepithelial, stromal cells, etc.

[0055] Polynucleotides can be used in wide range of methods and compositions, including for detecting, diagnosing, staging, grading, assessing, prognosticating, etc. diseases and disorders associated with human kidins220Pc, for monitoring or assessing therapeutic and/or preventative measures, in ordered arrays, etc. Any method of detecting genes and polynucleotides of SEQ ID NO 1 can be used; certainly, the present invention is not to be limited how such methods are implemented.

[0056] Along these lines, the present invention relates to methods of detecting human kidins220Pc in a sample comprising nucleic acid. Such methods can comprise one or more the following steps in any effective order, e.g., contacting said sample with a polynucleotide probe under conditions effective for said probe to hybridize specifically to nucleic acid in said sample, and detecting the presence or absence of probe hybridized to nucleic acid in said sample, wherein said probe is a polynucleotide which is SEQ ID NO 1, a polynucleotide having, e.g., about 70%, 80%, 85%, 90%, 95%, 99%, or more sequence identity thereto, effective or specific fragments thereof, or complements thereto. The detection method can be applied to any sample, e.g., cultured primary, secondary, or established cell lines, tissue biopsy, blood, urine, stool, cerebral spinal fluid, and other bodily fluids, for any purpose.

[0057] Contacting the sample with probe can be carried out by any effective means in any effective environment. It can be accomplished in a solid, liquid, frozen, gaseous, amorphous, solidified, coagulated, colloid, etc., mixtures thereof, matrix. For instance, a probe in an aqueous medium can be contacted with a sample which is also in an aqueous medium, or which is affixed to a solid matrix, or vice-versa.

[0058] Generally, as used throughout the specification, the term “effective conditions” means, e.g., the particular milieu in which the desired effect is achieved. Such a milieu, includes, e.g., appropriate buffers, oxidizing agents, reducing agents, pH, co-factors, temperature, ion concentrations, suitable age and/or stage of cell (such as, in particular part of the cell cycle, or at a particular stage where particular genes are being expressed) where cells are being used, culture conditions (including substrate, oxygen, carbon dioxide, etc.). When hybridization is the chosen means of achieving detection, the probe and sample can be combined such that the resulting conditions are functional for said probe to hybridize specifically to nucleic acid in said sample.

[0059] The phrase “hybridize specifically” indicates that the hybridization between single-stranded polynucleotides is based on nucleotide sequence complementarity. The effective conditions are selected such that the probe hybridizes to a preselected and/or definite target nucleic acid in the sample. For instance, if detection of a polynucleotide set forth in SEQ ID NO 1 is desired, a probe can be selected which can hybridize to such target gene under high stringent conditions, without significant hybridization to other genes in the sample. To detect homologs of a polynucleotide set forth in SEQ ID NO 1, the effective hybridization conditions can be less stringent, and/or the probe can comprise codon degeneracy, such that a homolog is detected in the sample.

[0060] As already mentioned, the methods can be carried out by any effective process, e.g., by Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, in situ hybridization, etc., as indicated above. When PCR based techniques are used, two or more probes are generally used. One probe can be specific for a defined sequence which is characteristic of a selective polynucleotide, but the other probe can be specific for the selective polynucleotide, or specific for a more general sequence, e.g., a sequence such as polyA which is characteristic of mRNA, a sequence which is specific for a promoter, ribosome binding site, or other transcriptional features, a consensus sequence (e.g., representing a functional domain). For the former aspects, 5′ and 3′ probes (e.g., polyA, Kozak, etc.) are preferred which are capable of specifically hybridizing to the ends of transcripts. When PCR is utilized, the probes can also be referred to as “primers” in that they can prime a DNA polymerase reaction.

[0061] In addition to testing for the presence or absence of polynucleotides, the present invention also relates to determining the amounts at which polynucleotides of the present invention are expressed in sample and determining the differential expression of such polynucleotides in samples. Such methods can involve substantially the same steps as described above for presence/absence detection, e.g., contacting with probe, hybridizing, and detecting hybridized probe, but using more quantitative methods and/or comparisons to standards.

[0062] The amount of hybridization between the probe and target can be determined by any suitable methods, e.g., PCR, RT-PCR, RACE PCR, Northern blot, polynucleotide microarrays, Rapid-Scan, etc., and includes both quantitative and qualitative measurements. For further details, see the hybridization methods described above and below. Determining by such hybridization whether the target is differentially expressed (e.g., up-regulated or down-regulated) in the sample can also be accomplished by any effective means. For instance, the target's expression pattern in the sample can be compared to its pattern in a known standard, such as in a normal tissue, or it can be compared to another gene in the same sample. When a second sample is utilized for the comparison, it can be a sample of normal tissue that is known not to contain diseased cells. The comparison can be performed on samples which contain the same amount of RNA (such as polyadenylated RNA or total RNA), or, on RNA extracted from the same amounts of starting tissue. Such a second sample can also be referred to as a control or standard. Hybridization can also be compared to a second target in the same tissue sample. Experiments can be performed that determine a ratio between the target nucleic acid and a second nucleic acid (a standard or control), e.g., in a normal tissue. When the ratio between the target and control are substantially the same in a normal and sample, the sample is determined or diagnosed not to contain cells. However, if the ratio is different between the normal and sample tissues, the sample is determined to contain cancer cells. The approaches can be combined, and one or more second samples, or second targets can be used. Any second target nucleic acid can be used as a comparison, including “housekeeping” genes, such as beta-actin, alcohol dehydrogenase, or any other gene whose expression does not vary depending upon the disease status of the cell.

[0063] Methods of Identifying Polymorphisms, Mutations, etc., of Human kidins220Pc

[0064] Polynucleotides of the present invention can also be utilized to identify mutant alleles, SNPs, gene rearrangements and modifications, and other polymorphisms of the wild-type gene. Mutant alleles, polymorphisms, SNPs, etc., can be identified and isolated from cancers that are known, or suspected to have, a genetic component. Identification of such genes can be carried out routinely (see, above for more guidance), e.g., using PCR, hybridization techniques, direct sequencing, mismatch reactions (see, e.g., above), RFLP analysis, SSCP (e.g., Orita et al., Proc. Natl. Acad. Sci., 86:2766, 1992), etc., where a polynucleotide having a sequence selected from SEQ ID NO 1 is used as a probe. The selected mutant alleles, SNPs, polymorphisms, etc., can be used diagnostically to determine whether a subject has, or is susceptible to a disorder associated with human kidins220Pc, as well as to design therapies and predict the outcome of the disorder. Methods involve, e.g., diagnosing a disorder associated with human kidins220Pc or determining susceptibility to a disorder, comprising, detecting the presence of a mutation in a gene represented by a polynucleotide selected from SEQ ID NO 1. The detecting can be carried out by any effective method, e.g., obtaining cells from a subject, determining the gene sequence or structure of a target gene (using, e.g., mRNA, cDNA, genomic DNA, etc), comparing the sequence or structure of the target gene to the structure of the normal gene, whereby a difference in sequence or structure indicates a mutation in the gene in the subject. Polynucleotides can also be used to test for mutations, SNPs, polymorphisms, etc., e.g., using mismatch DNA repair technology as described in U.S. Pat. No. 5,683,877; U.S. Pat. No. 5,656,430; Wu et al., Proc. Natl. Acad. Sci., 89:8779-8783, 1992.

[0065] The present invention also relates to methods of detecting polymorphisms in human kidins220Pc, comprising, e.g., comparing the structure of: genomic DNA comprising all or part of human kidins220Pc, mRNA comprising all or part of human kidins220Pc, cDNA comprising all or part of human kidins220Pc, or a polypeptide comprising all or part of human kidins220Pc, with the structure of human kidins220Pc set forth in SEQ ID NO 1 or 2. The methods can be carried out on a sample from any source, e.g., cells, tissues, body fluids, blood, urine, stool, hair, egg, sperm,cerebral spinal fluid, etc.

[0066] These methods can be implemented in many different ways. For example, “comparing the structure” steps include, but are not limited to, comparing restriction maps, nucleotide sequences, amino acid sequences, RFLPs, Dnase sites, DNA methylation fingerprints (e.g., U.S. Pat. No. 6,214,556), protein cleavage sites, molecular weights, electrophoretic mobilities, charges, ion mobility, etc., between a standard human kidins220Pc and a test human kidins220Pc. The term “structure” can refer to any physical characteristics or configurations which can be used to distinguish between nucleic acids and polypeptides. The methods and instruments used to accomplish the comparing step depends upon the physical characteristics which are to be compared. Thus, various techniques are contemplated, including, e.g., sequencing machines (both amino acid and polynucleotide), electrophoresis, mass spectrometer (U.S. Pat. Nos. 6,093,541, 6,002,127), liquid chromatography, HPLC, etc.

[0067] To carry out such methods, “all or part” of the gene or polypeptide can be compared. For example, if nucleotide sequencing is utilized, the entire gene can be sequenced, including promoter, introns, and exons, or only parts of it can be sequenced and compared, e.g., exon 1, exon 2, etc.

[0068] Mutagenesis

[0069] Mutated polynucleotide sequences of the present invention are useful for various purposes, e.g., to create mutations of the polypeptides they encode, to identify functional regions of genomic DNA, to produce probes for screening libraries, etc. Mutagenesis can be carried out routinely according to any effective method, e.g., oligonucleotide-directed (Smith, M., Ann. Rev. Genet. 19:423-463, 1985), degenerate oligonucleotide-directed (Hill et al., Method Enzymology, 155:558-568, 1987), region-specific (Myers et al., Science, 229:242-246, 1985; Derbyshire et al., Gene, 46:145, 1986; Ner et al., DNA, 7:127, 1988), linker-scanning (McKnight and Kingsbury, Science, 217:316-324, 1982), directed using PCR, recursive ensemble mutagenesis (Arkin and Yourvan, Proc. Natl Acad. Sci., 89:7811-7815, 1992), random mutagenesis (e.g., U.S. Pat. Nos. 5,096,815; 5,198,346; and 5,223,409), site-directed mutagenesis (e.g., Walder et al., Gene, 42:133, 1986; Bauer et al., Gene, 37:73, 1985; Craik, Bio Techniques, January 1985, 12-19; Smith et al., Genetic Engineering: Principles and Methods, Plenum Press, 1981), phage display (e.g., Lowman et al., Biochem. 30:10832-10837, 1991; Ladner et al., U.S. Pat. No. 5,223,409; Huse, WIPO Publication WO 92/06204), etc. Desired sequences can also be produced by the assembly of target sequences using mutually priming oligonucleotides (Uhlmann, Gene, 71:29-40, 1988). For directed mutagenesis methods, analysis of the three-dimensional structure of the human kidins220Pc polypeptide can be used to guide and facilitate making mutants which effect polypeptide activity. Sites of substrate-enzyme interaction or other biological activities can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al., Science 255:306-312, 1992; Smith et al., J. Mol. Biol. 224:899-904, 1992; Wlodaver et al., FEBS Lett. 309:59-64, 1992.

[0070] In addition, libraries of human kidins220Pc and fragments thereof can be used for screening and selection of human kidins220Pc variants. For instance, a library of coding sequences can be generated by treating a double-stranded DNA with a nuclease under conditions where the nicking occurs, e.g., only once per molecule, denaturing the double-stranded DNA, renaturing it to for double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single-stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting DNAs into an expression vecore. By this method, xpression libraries can be made comprising “mutagenized” human kidins220Pc. The entire coding sequence or parts thereof can be used.

[0071] Polynucleotide Expression, Polypeptides Produced Thereby, and Specific-Binding Partners Thereto.

[0072] A polynucleotide according to the present invention can be expressed in a variety of different systems, in vitro and in vivo, according to the desired purpose. For example, a polynucleotide can be inserted into an expression vector, introduced into a desired host, and cultured under conditions effective to achieve expression of a polypeptide coded for by the polynucleotide, to search for specific binding partners. Effective conditions include any culture conditions which are suitable for achieving production of the polypeptide by the host cell, including effective temperatures, pH, medium, additives to the media in which the host cell is cultured (e.g., additives which amplify or induce expression such as butyrate, or methotrexate if the coding polynucleotide is adjacent to a dhfr gene), cycloheximide, cell densities, culture dishes, etc. A polynucleotide can be introduced into the cell by any effective method including, e.g., naked DNA, calcium phosphate precipitation, electroporation, injection, DEAE-Dextran mediated transfection, fusion with liposomes, association with agents which enhance its uptake into cells, viral transfection. A cell into which a polynucleotide of the present invention has been introduced is a transformed host cell. The polynucleotide can be extrachromosomal or integrated into a chromosome(s) of the host cell. It can be stable or transient. An expression vector is selected for its compatibility with the host cell. Host cells include, mammalian cells, e.g., COS, CV1, BHK, CHO, HeLa, LTK, NIH 3T3, PC-3 (CRL-1435), LNCaP (CRL-1740), CA-HPV-10 (CRL-2220), PZ-HPV-7 (CRL-2221), MDA-PCa 2b (CRL-2422), 22Rv1 (CRL2505), NCI-H660 (CRL-5813), HS 804.Sk (CRL-7535), LNCaP-FGF (CRL-10995), RWPE-1 (CRL-11609), RWPE-2 (CRL-11610), PWR-1E (CRL 11611), rat MAT-Ly-LuB-2 (CRL-2376), and other prostate cells, CNS neural stem cells (e.g., U.S. Pat. No. 6,103,530), IMR-32, A172 (ATCC CRL-1620), T98G (ATCC CRL-1690), CCF-STTG1 (ATCC CRL-1718), DBTRG-05MG (ATCC CRL-2020), PFSK-1 (ATCC CRL-2060), SK—N-AS and other SK cell lines (ATCC CRL-2137), CHP-212 (ATCC CRL-2273), RG2 (ATCC CRL-2433), HCN-2 (ATCC CRL-10742), U-87 MG and other U MG cell lines (ATCC HTB-14), D283 Med (ATCC HTB-185), PC12, Neuro-2a (ATCC CCL-131), insect cells, such as Sf9 (S. frugipeda) and Drosophila, bacteria, such as E. coli, Streptococcus, bacillus, yeast, such as Sacharomyces, S. cerevisiae, fungal cells, plant cells, embryonic or adult stem cells (e.g., mammalian, such as mouse or human).

[0073] Expression control sequences are similarly selected for host compatibility and a desired purpose, e.g., high copy number, high amounts, induction, amplification, controlled expression. Other sequences which can be employed include enhancers such as from SV40, CMV, RSV, inducible promoters, cell-type specific elements, or sequences which allow selective or specific cell expression. Promoters that can be used to drive its expression, include, e.g., the endogenous promoter, MMTV, SV40, trp, lac, tac, or T7 promoters for bacterial hosts; or alpha factor, alcohol oxidase, or PGH promoters for yeast. RNA promoters can be used to produced RNA transcripts, such as T7 or SP6. See, e.g., Melton et al., Polynucleotide Res., 12(18):7035-7056, 1984; Dunn and Studier. J. Mol. Bio., 166:477-435, 1984; U.S. Pat. No. 5,891,636; Studier et al., Gene Expression Technology, Methods in Enzymology, 85:60-89, 1987. In addition, as discussed above, translational signals (including in-frame insertions) can be included.

[0074] When a polynucleotide is expressed as a heterologous gene in a transfected cell line, the gene is introduced into a cell as described above, under effective conditions in which the gene is expressed. The term “heterologous” means that the gene has been introduced into the cell line by the “hand-of-man.” Introduction of a gene into a cell line is discussed above. The transfected (or transformed) cell expressing the gene can be lysed or the cell line can be used intact.

[0075] For expression and other purposes, a polynucleotide can contain codons found in a naturally-occurring gene, transcript, or cDNA, for example, e.g., as set forth in SEQ ID NO 1, or it can contain degenerate codons coding for the same amino acid sequences. For instance, it may be desirable to change the codons in the sequence to optimize the sequence for expression in a desired host. See, e.g., U.S. Pat. Nos. 5,567,600 and 5,567,862.

[0076] A polypeptide according to the present invention can be recovered from natural sources, transformed host cells (culture medium or cells) according to the usual methods, including, detergent extraction (e.g., non-ionic detergent, Triton X-100, CHAPS, octylglucoside, Igepal CA-630), ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography, lectin chromatography, gel electrophoresis. Protein refolding steps can be used, as necessary, in completing the configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for purification steps. Another approach is express the polypeptide recombinantly with an affinity tag (Flag epitope, HA epitope, myc epitope, 6×His, maltose binding protein, chitinase, etc) and then purify by anti-tag antibody-conjugated affinity chromatography.

[0077] The present invention also relates to polypeptides of human kidins220Pc, e.g., an isolated human kidins220Pc polypeptide comprising or having the amino acid sequence set forth in SEQ ID NO 2, an isolated human kidins220Pc polypeptide comprising an amino acid sequence having 99% or more amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO 2 along its entire length, and optionally having one or more of human kidins220Pc activities, such as protein anchoring activity (e.g., anchoring proteins to the cytoplasmic side of the membrane), kinase substrate activity (e.g., kidins220 is a substrate for protein kinase D), signal transduction regulatory activity (e.g., mediates signal transduction), protein binding activity (e.g., both the SAM domain and the ankyrin repeats (“ANK”) are involved in protein-protein interactions, and mediate protein binding to other proteins and modified residues), immunogenic activity (e.g., capable of eliciting an immune response).

[0078] Protein anchoring and binding activity can be measured routinely, e.g., using protein-protein binding assays (e.g., filtration assays, chromatography, etc.), yeast two-hybrid system., protein arrays, FRET (fluorescence resonance energy transfer) assays, and other ways of detecting protein-protein interactions. Protein binding includes binding to modified residues, e.g., phosphorylated tyrosines and serines.

[0079] Fragments specific to human kidins220Pc can also used, e.g., to produce antibodies or other immune responses, as competitors to protein kinase D activity. These fragments can be referred to as being “specific for” human kidins220Pc. The latter phrase, as already defined, indicates that the peptides are characteristic of human kidins220Pc, and that the defined sequences are substantially absent from all other protein types. Such polypeptides can be of any size which is necessary to confer specificity, e.g., 5, 8, 10, 12, 15, 20, etc. Especially preferred are polypeptides which comprise the following amino acid residues: polypeptides comprising amino acid residue 136 (SEQ ID NO 2), 1-1138 (SEQ ID NO 2), 1139-1715 (SEQ ID NO 2), 1138-1771 (SEQ ID NO 4), 1138-1194 (SEQ ID NO 4), 1177-1194 (SEQ ID NO 4), 1138-1184 (SEQ ID NO 3), 1138-1176 (SEQ ID NO 3), 1177-1184 (SEQ ID NO 3). Other peptides of interest, include those which are displayed on the cell-surface, e.g., between the transmembrane domains, such as 519-524 and 682-687 (SEQ ID NO 2).

[0080] The present invention also relates to antibodies, and other specific-binding partners, which are specific for polypeptides encoded by polynucleotides of the present invention, e.g., human kidins220Pc. Antibodies, e.g., polyclonal, monoclonal, recombinant, chimeric, humanized, single-chain, Fab, and fragments thereof, can be prepared according to any desired method. See, also, screening recombinant immunoglobulin libraries (e.g., Orlandi et al., Proc. Natl. Acad. Sci., 86:3833-3837, 1989; Huse et al., Science, 256:1275-1281, 1989); in vitro stimulation of lymphocyte populations; Winter and Milstein, Nature, 349: 293-299, 1991. The antibodies can be IgM, IgG, subtypes, IgG2a, IgG1, etc. Antibodies, and immune responses, can also be generated by administering naked DNA See, e.g., U.S. Pat. Nos. 5,703,055; 5,589,466; 5,580,859. Antibodies can be used from any source, including, goat, rabbit, mouse, chicken (e.g., IgY; see, Duan, W0/029444 for methods of making antibodies in avian hosts, and harvesting the antibodies from the eggs). An antibody specific for a polypeptide means that the antibody recognizes a defined sequence of amino acids within or including the polypeptide. Other specific binding partners include, e.g., aptamers and PNA. antibodies can be prepared against specific epitopes or domains of human kidins220Pc or variants shown in FIG. 1, such as polypeptides comprising amino acid residue 136 (SEQ ID NO 2), 1-1138 (SEQ ID NO 2), 1139-1715 (SEQ ID NO 2), 1138-1771 (SEQ ID NO 4), 1138-1194 (SEQ ID NO 4), 1177-1194 (SEQ ID NO 4), 1138-1184 (SEQ ID NO 3), 1138-1176 (SEQ ID NO 3), 1177-1184 (SEQ ID NO 3).

[0081] The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green et al., Production of Polyclonal Antisera, in IMMUNOCHEMICAL PROTOCOLS (Manson, ed.), pages 1-5 (Humana Press 1992); Coligan et al., Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters, in CURRENT PROTOCOLS IN IMMUNOLOGY, section 2.4.1 (1992). The preparation of monoclonal antibodies likewise is conventional. See, for example, Kohler & Milstein, Nature 256:495 (1975); Coligan et al., sections 2.5.1-2.6.7; and Harlow et al., ANTIBODIES: A LABORATORY MANUAL, page 726 (Cold Spring Harbor Pub. 1988).

[0082] Antibodies can also be humanized, e.g., where they are to be used therapeutically. Humanized monoclonal antibodies are produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi et al., Proc. Nat'l Acad. Sci. USA 86:3833 (1989), which is hereby incorporated in its entirety by reference. Techniques for producing humanized monoclonal antibodies are described, for example, in U.S. Pat. No. 6,054,297, Jones et al., Nature 321: 522 (1986); Riechmann et al., Nature 332: 323 (1988); Verhoeyen et al., Science 239: 1534 (1988); Carter et al., Proc. Nat'l Acad. Sci. USA 89: 4285 (1992); Sandhu, Crit. Rev. Biotech. 12: 437 (1992); and Singer et al., J. Immunol. 150: 2844 (1993).

[0083] Antibodies of the invention also may be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas et al., METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, VOL. 2, page 119 (1991); Winter et al., Ann. Rev. Immunol. 12: 433 (1994). Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained commercially, for example, from STRATAGENE Cloning Systems (La Jolla, Calif.).

[0084] In addition, antibodies of the present invention may be derived from a human monoclonal antibody. Such antibodies are obtained from transgenic mice that have been “engineered” to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens and can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, e.g., in Green et al., Nature Genet. 7:13 (1994); Lonberg et al., Nature 368:856 (1994); and Taylor et al., Int. Immunol. 6:579 (1994).

[0085] Antibody fragments of the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli of nucleic acid encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab′).sub.2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab′ monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab′ fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. No. 4,036,945 and U.S. Pat. No. 4,331,647, and references contained therein. These patents are hereby incorporated in their entireties by reference. See also Nisoiihoffet al., Arch. Biochem. Biophys. 89:230 (1960); Porter, Biochem. J. 73:119 (1959); Edelman etal, METHODS IN ENZYMOLOGY, VOL. 1, page 422 (Academic Press 1967); and Coligan et al. at sections 2.8.1-2.8.10 and 2.10.1-2.10.4.

[0086] Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques can also be used. For example, Fv fragments comprise an association of V.sub.H and V.sub.L chains. This association may be noncovalent, as described in Inbar et al., Proc. Nat'l Acad. Sci. USA 69:2659 (1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. See, e.g., Sandhu, supra. Preferably, the Fv fragments comprise V.sub.H and V.sub.L chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising nucleic acid sequences encoding the V.sub.H and V.sub.L domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow et al., METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, VOL. 2, page 97 (1991); Bird et al., Science 242:423-426 (1988); Ladneret al., U.S. Pat. No. 4,946,778; Pack et al., Bio/Technology 11: 1271-77 (1993); and Sandhu, supra.

[0087] Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides (“minimal recognition units”) can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick et al., METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, VOL. 2, page 106 (1991).

[0088] The term “antibody” as used herein includes intact molecules as well as fragments thereof, such as Fab, F(ab′)2, and Fv which are capable of binding to an epitopic determinant present in Bin1 polypeptide. Such antibody fragments retain some ability to selectively bind with its antigen or receptor. The term “epitope” refers to an antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Antibodies can be prepared against specific epitopes or polypeptide domains.

[0089] Antibodies which bind to human kidins220Pc polypeptides of the present invention can be prepared using an intact polypeptide or fragments containing small peptides of interest as the immunizing antigen. For example, it may be desirable to produce antibodies that specifically bind to the N- or C-terminal domains of human kidins220Pc. The polypeptide or peptide used to immunize an animal which is derived from translated cDNA or chemically synthesized which can be conjugated to a carrier protein, if desired. Such commonly used carriers which are chemically coupled to the immunizing peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid.

[0090] Polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound. Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan, et al., Unit 9, Current Protocols in Immunology, Wiley Interscience, 1994, incorporated by reference).

[0091] Anti-idiotype technology can also be used to produce invention monoclonal antibodies which mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the “image” of the epitope bound by the first monoclonal antibody.

[0092] Methods of Detecting Polypeptides

[0093] Polypeptides coded for by human kidins220Pc of the present invention can be detected, visualized, determined, quantitated, etc. according to any effective method. useful methods include, e.g., but are not limited to, immunoassays, RIA (radioimmunassay), ELISA, (enzyme-linked-immunosorbent assay), immunoflourescence, flow cytometry, histology, electron microscopy, light microscopy, in situ assays, immunoprecipitation, Western blot, and others.

[0094] Immunoassays may be carried in liquid or on biological support. For instance, a sample (e.g., blood, stool, urine, cells, tissue,cerebral spinal fluid, body fluids, etc.) can be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support that is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled human kidins220Pc specific antibody. The solid phase support can then be washed with a buffer a second time to remove unbound antibody. The amount of bound label on solid support may then be detected by conventional means.

[0095] A “solid phase support or carrier” includes any support capable of binding an antigen, antibody, or other specific binding partner. Supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, and magnetite. A support material can have any structural or physical configuration. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads.

[0096] One of the many ways in which gene peptide-specific antibody can be detectably labeled is by linking it to an enzyme and using it in an enzyme immunoassay (EIA). See, e.g., Voller, A., “The Enzyme Linked Immunosorbent Assay (ELISA),” 1978, Diagnostic Horizons 2, 1-7, Microbiological Associates Quarterly Publication, Walkersville, Md.); Voller, A. et al., 1978, J. Clin. Pathol. 31, 507-520; Butler, J. E., 1981, Meth. Enzymol. 73, 482-523; Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, Fla. The enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes that can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, .alpha.-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta.-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by calorimetric methods that employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

[0097] Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect human kidins220Pc peptides through the use of a radioimmunoassay (RIA). See, e.g., Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986. The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

[0098] It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine. The antibody can also be detectably labeled using fluorescence emitting metals such as those in the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

[0099] The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

[0100] Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

[0101] Diagnostic

[0102] The present invention also relates to methods and compositions for diagnosing a prostate cancer, neurological disorders, etc., or determining susceptibility to such disorders, using polynucleotides, polypeptides, and specific-binding partners of the present invention to detect, assess, determine, etc., human kidins220Pc. In such methods, the gene can serve as a marker for the disorder, e.g., where the gene, when mutant, is a direct cause of the disorder; where the gene is affected by another gene(s) which is directly responsible for the disorder, e.g., when the gene is part of the same signaling pathway as the directly responsible gene; and, where the gene is chromosomally linked to the gene(s) directly responsible for the disorder, and segregates with it. Many other situations are possible. To detect, assess, determine, etc., a probe specific for the gene can be employed as described above and below. Any method of detecting and/or assessing the gene can be used, including detecting expression of the gene using polynucleotides, antibodies, or other specific-binding partners.

[0103] The present invention relates to methods of diagnosing a disorder associated with human kidins220Pc, or determining a subject's susceptibility to such disorder, comprising, e.g., assessing the expression of kidins220Pc in a tissue sample comprising tissue or cells suspected of having the disorder (e.g., where the sample comprises prostate tissue). The phrase “diagnosing” indicates that it is determined whether the sample has the disorder. A “disorder” means, e.g., any abnormal condition as in a disease or malady. “Determining a subject's susceptibility to a disease or disorder” indicates that the subject is assessed for whether s/he is predisposed to get such a disease or disorder, where the predisposition is indicated by abnormal expression of the gene (e.g., gene mutation, gene expression pattern is not normal, etc.). Predisposition or susceptibility to a disease may result when a such disease is influenced by epigenetic, environmental, etc., factors. This includes prenatal screening where samples from the fetus or embryo (e.g., via amniocentesis or CV sampling) are analyzed for the expression of the gene.

[0104] Human kidins220Pc can be used to treat and/or diagnose any disorder or condition associated with kidins220Pc, including, but not limited to, prostate cancer, spinal cord injury, polio, spina bifada, Friedreich's Ataxia, back injuries, ruptured disk, spinal stenosis, pinched nerves, and other conditions in which the spinal nerves are damaged, and which could benefit from neurite outgrowth.

[0105] By the phrase “assessing expression of kidins220Pc,” it is meant that the functional status of the gene is evaluated. This includes, but is not limited to, measuring expression levels of said gene, determining the genomic structure of said gene, determining the mRNA structure of transcripts from said gene, or measuring the expression levels of polypeptide coded for by said gene. Thus, the term “assessing expression” includes evaluating the all aspects of the transcriptional and translational machinery of the gene. For instance, if a promoter defect causes, or is suspected of causing, the disorder, then a sample can be evaluated (i.e., “assessed”) by looking (e.g., sequencing or restriction mapping) at the promoter sequence in the gene, by detecting transcription products (e.g., RNA), by detecting translation product (e.g., polypeptide). Any measure of whether the gene is functional can be used, including, polypeptide, polynucleotide, and functional assays for the gene's biological activity.

[0106] In making the assessment, it can be useful to compare the results to a normal gene, e.g., a gene which is not associated with the disorder. The nature of the comparison can be determined routinely, depending upon how the assessing is accomplished. If, for example, the mRNA levels of a sample is detected, then the mRNA levels of a normal can serve as a comparison, or a gene which is known not to be affected by the disorder. Methods of detecting mRNA are well known, and discussed above, e.g., but not limited to, Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, etc. Similarly, if polypeptide production is used to evaluate the gene, then the polypeptide in a normal tissue sample can be used as a comparison, or, polypeptide from a different gene whose expression is known not to be affected by the disorder. These are only examples of how such a method could be carried out.

[0107] Assessing the effects of therapeutic and preventative interventions (e.g., administration of a drug, chemotherapy, radiation, etc.) on prostate cancers is a major effort in drug discovery, clinical medicine, and pharmacogenomics. The evaluation of therapeutic and preventative measures, whether experimental or already in clinical use, has broad applicability, e.g., in clinical trials, for monitoring the status of a patient, for analyzing and assessing animal models, and in any scenario involving cancer treatment and prevention. Analyzing the expression profiles of polynucleotides of the present invention can be utilized as a parameter by which interventions are judged and measured. Treatment of a disorder can change the expression profile in some manner which is prognostic or indicative of the drug's effect on it. Changes in the profile can indicate, e.g., drug toxicity, return to a normal level, etc. Accordingly, the present invention also relates to methods of monitoring or assessing a therapeutic or preventative measure (e.g., chemotherapy, radiation, anti-neoplastic drugs, antibodies, etc.) in a subject having prostate cancer, or, susceptible to it, comprising, e.g., detecting the expression levels of human kidins220Pc. A subject can be a cell-based assay system, non-human animal model, human patient, etc. Detecting can be accomplished as described for the methods above and below. By “therapeutic or preventative intervention,” it is meant, e.g., a drug administered to a patient, surgery, radiation, chemotherapy, and other measures taken to prevent, treat, or diagnose a disorder.

[0108] Expression can be assessed in any sample comprising any tissue or cell type, body fluid, etc., as discussed for other methods of the present invention, including cells from prostate can be used, or cells derived from prostate. By the phrase “cells derived from prostate,” it is meant that the derived cells originate from prostate, e.g., when metastasis from a primary tumor site has occurred, when a progenitor-type or pluripotent cell gives rise to other cells, etc.

[0109] The present invention also relates to methods of measuring protein kinase activity, such as protein kinase D (“PKD”), based on the property of human kidins220Pc, or fragments thereof, to serve as kinase substrates. See, e.g., Iglesias et al., J. Biol. Chem., 275:40048-40056, 2000. Assays can be used to determine whether kinase activity is present or absent in a sample, to determine whether a particular agent is a modulator of kinase activity, to identify proteins and genes which modulate kinase activity, to identify genes and proteins which comprise the kinase signaling pathway, etc. Kinase activity can be determined according to any suitable method, including, but not limited to, methods of detecting phosphorylation of kidins220Pc, or fragments thereof, using radioactive ATP, antibodies that bind to phosphorylated amino acids, etc. Assays can be carried out in any environment, including, e.g., in whole cells (e.g., the cells have been transfected with a gene coding for human kidins220Pc) in lysates, in vivo, in vitro, etc.

[0110] Kinase assays typically comprise the kinase enzyme, substrates, buffers, and components of a detection system. A typical kinase assay involves a reaction of a protein kinase sample with a peptide substrate and a gamma-labeled ATP, such as 32P-ATP. The resulting labeled phosphoprotein is then separated from the gamma-labeled ATP. Separation and detection of the phosphoprotein can be achieved through any suitable method. When a radioactive label is utilized, the labeled phosphoprotein can be separated from the unreacted gamma-32P-ATP using an affinity membrane or gel electrophoresis, and then visualized on the gel using autoradiography.

[0111] Non-radioactive methods can also be used. Methods can utilize an antibody which recognizes the phosphorylated substrate, e.g., an anti-phosphoserine or anti-phosphothreonine antibody. For instance, kinase enzyme can incubated with a substrate in the presence of ATP and kinase buffer under conditions which are effective for the enzyme to phosphorylate the substrate. The reaction mixture can be separated, e.g., electrophoretically, and then phosphorylation of the substrate can be measured by Western blotting using an anti-phosphoserine or anti-phosphothreonine antibody. The antibody can be labeled with a detectable label, e.g., an enzyme, such as HRP, avidin or biotin, chemiluminescent reagents, etc. Other methods can utilize ELISA formats, affinity membrane separation, fluorescence polarization assays, luminescent assays, etc. Kinase assays are available commercially, e.g., Cell Signaling Corporation (e.g., p44/42 MAP Kinase Assay Kit), AUSA Universal Protein Kinase Assay Kit, ProMega (e.g., PepTag assays), SpinZyme calorimetric assays from Pierce, Calbiochem's ELISA-based kinase assays, Upstate Biotechnology's ELISA-based kits using chemiluminescent DuoLuX substrate from Vector Laboratories, PanVera's fluorescent polarization kits, etc. For kinase assays, see also, e.g., Kemp et al., “Design and use of peptide substrates for protein kinases,” Methods in Enzymol., 200:121-34, 1991; Wang et al., “Identification of the major site of rat prolactin phosphorylation as serine 177,” J. Biol. Chem., 271:2462-9, 1996; Yasuda et al., “A synthetic peptide substrate for selective assay of protein kinase C,” Biochem. Biophys. Res. Comm., 166:1220-7, 1990; Gonzalez et al., “Use of the synthetic peptide neurogranin(28-43) as a selective protein kinase C substrate in assays of tissue homogenates,” Anal. Biochem., 215:184-9, 1993; Parker et al., “Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays,” J. Biomol. Screen., 5:77-88, April 2000. See, also., U.S. Pat. Nos. 6,203,994, 6,074,861, 6,066,462, 6,004,757, and 5,741,689.

[0112] The present invention relates to methods of detecting protein kinase D activity in a sample, comprising one or more of the following steps, e.g., contacting a human kidins220Pc with a sample comprising a protein kinase D under conditions effective for said kinase to phosphorylate said kidins220Pc polypeptide, and detecting phosphorylation of said kidins220Pc polypeptide, whereby said kinase activity is detected. The present invention also relates to methods of determining the presence of a protein kinase D activity, comprising one or more of the following steps, e.g., contacting a human kidins220Pc polypeptide with a sample in which the presence of protein kinase D is to be determined, wherein said contacting is under conditions effective for said kinase to phosphorylate said kidins220Pc polypeptide, and detecting phosphorylation of said kidins220Pc polypeptide, whereby the presence of said kinase activity is determined.

[0113] The present invention also relates to methods of using human kidins220Pc binding partners, such as antibodies, to deliver active agents to prostate or neuronal tissue for a variety of different purposes, including, e.g., for diagnostic, therapeutic (e.g., to treat prostate cancer), and research purposes. Methods can involve delivering or administering an active agent to tissues, comprising, e.g., administering to a subject in need thereof, an effective amount of an active agent coupled to a binding partner specific for human human kidins220Pc polypeptide, wherein said binding partner is effective to deliver said active agent specifically to said tissue, such as prostate.

[0114] Any type of active agent can be used in combination with human kidins220Pc, including, therapeutic, cytotoxic, cytostatic, chemotherapeutic, anti-neoplastic, anti-proliferative, anti-biotic, etc., agents. A chemotherapeutic agent can be, e.g., DNA-interactive agent, alkylating agent, antimetabolite, tubulin-interactive agent, hormonal agent, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, paclitaxel, cytoxan, 2-methoxy-carbonyl-aminobenzimidazole, Plicamycin, Methotrexate, Fluorouracil, Fluorodeoxyuridin, CB3717, Azacitidine, Floxuridine, Mercapyopurine, 6-Thioguanine, Pentostatin, Cytarabine, Fludarabine, etc. Agents can also be contrast agents useful in imaging technology, e.g., X-ray, CT, CAT, MRI, ultrasound, PET, SPECT, and scintographic. An active agent can be associated in any manner with a human kidins220Pc binding partner which is effective to achieve its delivery specifically to the target. Specific delivery or targeting indicates that the agent is provided to, e.g., the prostate, without being substantially provided to other tissues. This is useful especially where an agent is toxic, and specific targeting to the prostate enables the majority of the toxicity to be aimed at it, with as small as possible effect on other tissues in the body. The association of the active agent and the binding partner (“coupling) can be direct, e.g., through chemical bonds between the binding partner and the agent, or, via a linking agent, or the association can be less direct, e.g., where the active agent is in a liposome, or other carrier, and the binding partner is associated with the liposome surface. In such case, the binding partner can be oriented in such a way that it is able to bind to human kidins220Pc on the cell surface. Methods for delivery of DNA via a cell-surface receptor is described, e.g., in U.S. Pat. No. 6,339,139.

[0115] Identifying Agent Methods

[0116] The present invention also relates to methods of identifying agents, and the agents themselves, which modulate human kidins220Pc. These agents can be used to modulate the biological activity of the polypeptide encoded for the gene, or the gene, itself. Agents which regulate the gene or its product are useful in variety of different environments, including as medicinal agents to treat or prevent disorders associated with human kidins220Pc and as research reagents to modify the function of tissues and cell.

[0117] Methods of identifying agents generally comprise steps in which an agent is placed in contact with the gene, transcription product, translation product, or other target, and then a determination is performed to assess whether the agent “modulates” the target. The specific method utilized will depend upon a number of factors, including, e.g., the target (i.e., is it the gene or polypeptide encoded by it), the environment (e.g., in vitro or in vivo), the composition of the agent, etc.

[0118] For modulating the expression of human kidins220Pc gene, a method can comprise, in any effective order, one or more of the following steps, e.g., contacting a human kidins220Pc gene (e.g., in a cell population) with a test agent under conditions effective for said test agent to modulate the expression of human kidins220Pc, and determining whether said test agent modulates said human kidins220Pc. An agent can modulate expression of human kidins220Pc at any level, including transcription, translation, and/or perdurance of the nucleic acid (e.g., degradation, stability, etc.) in the cell.

[0119] For modulating the biological activity of human kidins220Pc polypeptides, a method can comprise, in any effective order, one or more of the following steps, e.g., contacting a human kidins220Pe polypeptide (e.g., in a cell, lysate, or isolated) with a test agent under conditions effective for said test agent to modulate the biological activity of said polypeptide, and determining whether said test agent modulates said biological activity.

[0120] Contacting human kidins220Pc with the test agent can be accomplished by any suitable method and/or means that places the agent in a position to functionally control expression or biological activity of human kidins220Pc present in the sample. Functional control indicates that the agent can exert its physiological effect on human kidins220Pc through whatever mechanism it works. The choice of the method and/or means can depend upon the nature of the agent and the condition and type of environment in which the human kidins220Pc is presented, e.g., lysate, isolated, or in a cell population (such as, in vivo, in vitro, organ explants, etc.). For instance, if the cell population is an in vitro cell culture, the agent can be contacted with the cells by adding it directly into the culture medium. If the agent cannot dissolve readily in an aqueous medium, it can be incorporated into liposomes, or another lipophilic carrier, and then administered to the cell culture. Contact can also be facilitated by incorporation of agent with carriers and delivery molecules and complexes, by injection, by infusion, etc.

[0121] After the agent has been administered in such a way that it can gain access to human kidins220Pc, it can be determined whether the test agent modulates human kidins220Pc expression or biological activity. Modulation can be of any type, quality, or quantity, e.g., increase, facilitate, enhance, up-regulate, stimulate, activate, amplify, augment, induce, decrease, down-regulate, diminish, lessen, reduce, etc. The modulatory quantity can also encompass any value, e.g., 1%, 5%, 10%, 50%, 75%, 1-fold, 2-fold, 5-fold, 10-fold, 100-fold fold, etc. To modulate human kidins220Pc expression means, e.g., that the test agent has an effect on its expression, e.g., to effect the amount of transcription, to effect RNA splicing, to effect translation of the RNA into polypeptide, to effect RNA or polypeptide stability, to effect polyadenylation or other processing of the RNA, to effect post-transcriptional or post-translational processing, etc. To modulate biological activity means, e.g., that a functional activity of the polypeptide is changed in comparison to its normal activity in the absence of the agent. This effect includes, increase, decrease, block, inhibit, enhance, etc. Biological activities of human kidins220Pc include, e.g., protein anchoring activity (e.g., anchoring proteins to the cytoplasmic side of the membrane), kinase substrate activity (e.g., kidins220 is a substrate for protein kinase D), protein binding activity (e.g., both the SAM domain and the ankyrin repeats (“ANK”) are involved in protein-protein interactions), immunogenic activity (e.g., capable of eliciting an immune response), etc.

[0122] A test agent can be of any molecular composition, e.g., chemical compounds, biomolecules, such as polypeptides, lipids, nucleic acids (e.g., antisense to a polynucleotide sequence selected from SEQ ID NO 1), carbohydrates, antibodies, ribozymes, double-stranded RNA, aptamers, etc. For example, if a polypeptide to be modulated is a cell-surface molecule, a test agent can be an antibody that specifically recognizes it and, e.g., causes the polypeptide to be internalized, leading to its down regulation on the surface of the cell. Such an effect does not have to be permanent, but can require the presence of the antibody to continue the down-regulatory effect. Antibodies can also be used to modulate the biological activity a polypeptide in a lysate or other cell-free form. Antisense human kidins220Pc can also be used as test agents to modulate gene expression.

[0123] Therapeutics

[0124] Selective polynucleotides, polypeptides, and specific-binding partners thereto, can be utilized in therapeutic applications, especially to treat diseases and conditions of prostate. Useful methods include, but are not limited to, immunotherapy (e.g., using specific-binding partners to polypeptides), vaccination (e.g., using a selective polypeptide or a naked DNA encoding such polypeptide), protein or polypeptide replacement therapy, gene therapy (e.g., germ-line correction, antisense), etc.

[0125] Various immunotherapeutic approaches can be used. For instance, unlabeled antibody that specifically recognizes a tissue-specific antigen can be used to stimulate the body to destroy or attack the cancer, to cause down-regulation, to produce complement-mediated lysis, to inhibit cell growth, etc., of target cells which display the antigen, e.g., analogously to how c-erbB-2 antibodies are used to treat breast cancer. In addition, antibody can be labeled or conjugated to enhance its deleterious effect, e.g., with radionuclides and other energy emitting entitities, toxins, such as ricin, exotoxin A (ETA), and diphtheria, cytotoxic or cytostatic agents, immunomodulators, chemotherapeutic agents, etc. See, e.g., U.S. Pat. No. 6,107,090.

[0126] An antibody or other specific-binding partner can be conjugated to a second molecule, such as a cytotoxic agent, and used for targeting the second molecule to a tissue-antigen positive cell (Vitetta, E. S. et al., 1993, Immunotoxin therapy, in DeVita, Jr., V. T. et al., eds, Cancer: Principles and Practice of Oncology, 4th ed., J. B. Lippincott Co., Philadelphia, 2624-2636). Examples of cytotoxic agents include, but are not limited to, antimetabolites, alkylating agents, anthracyclines, antibiotics, anti-mitotic agents, radioisotopes and chemotherapeutic agents. Further examples of cytotoxic agents include, but are not limited to ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, 1-dehydrotestosterone, diptheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, elongation factor-2 and glucocorticoid. Techniques for conjugating therapeutic agents to antibodies are well.

[0127] In addition to immunotherapy, polynucleotides and polypeptides can be used as targets for non-immunotherapeutic applications, e.g., using compounds which interfere with function, expression (e.g., antisense as a therapeutic agent), assembly, etc. RNA interference can be used in vivtro and in vivo to silence human kidins220Pc when its expression contributes to a disease (but also for other purposes, e.g., to identify the gene's function to change a developmental pathway of a cell, etc.). See, e.g., Sharp and Zamore, Science, 287:2431-2433, 2001; Grishok et al., Science, 287:2494, 2001.

[0128] Delivery of therapeutic agents can be achieved according to any effective method, including, liposomes, viruses, plasmid vectors, bacterial delivery systems, orally, systemically, etc. Therapeutic agents of the present invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosal, inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, etc. They can be administered alone, or in combination with any ingredient(s), active or inactive.

[0129] In addition to therapeutics, per se, the present invention also relates to methods of treating a disease showing altered expression of human kidins220Pc, comprising, e.g., administering to a subject in need thereof a therapeutic agent which is effective for regulating expression of said human kidins220Pc and/or which is effective in treating said disease. The term “treating” is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder. Diseases or disorders which can be treated in accordance with the present invention include, but are not limited to prostate cancer, spinal cord injury, spinal cord injury, polio, spina bifada, Friedreich's Ataxia, back injuries, ruptured disk, spinal stenosis, pinched nerves, and other conditions in which the spinal nerves are damaged, and which could benefit from neurite outgrowth.

[0130] By the phrase “altered expression,” it is meant that the disease is associated with a mutation in the gene, or any modification to the gene (or corresponding product) which affects its normal function. Thus, expression of human kidins220Pc refers to, e.g., transcription, translation, splicing, stability of the mRNA or protein product, activity of the gene product, differential expression, etc.

[0131] Any agent which “treats” the disease can be used. Such an agent can be one which regulates the expression of the human kidins220Pc. Expression refers to the same acts already mentioned, e.g. transcription, translation, splicing, stability of the mRNA or protein product, activity of the gene product, differential expression, etc. For instance, if the condition was a result of a complete deficiency of the gene product, administration of gene product to a patient would be said to treat the disease and regulate the gene's expression. Many other possible situations are possible, e.g., where the gene is aberrantly expressed, and the therapeutic agent regulates the aberrant expression by restoring its normal expression pattern.

[0132] Antisense

[0133] Antisense polynucleotide (e.g., RNA) can also be prepared from a polynucleotide according to the present invention, preferably an anti-sense to a sequence of SEQ ID NO 1. Antisense polynucleotide can be used in various ways, such as to regulate or modulate expression of the polypeptides they encode, e.g., inhibit their expression, for in situ hybridization, for therapeutic purposes, for making targeted mutations (in vivo, triplex, etc.) etc. For guidance on administering and designing anti-sense, see, e.g., U.S. Pat. Nos. 6,200,960, 6,200,807, 6,197,584, 6,190,869, 6,190,661, 6,187,587, 6,168,950, 6,153,595, 6,150,162, 6,133,246, 6,117,847, 6,096,722, 6,087,343, 6,040,296, 6,005,095, 5,998,383, 5,994,230, 5,891,725, 5,885,970, and 5,840,708. An antisense polynucleotides can be operably linked to an expression control sequence. A total length of about 35 bp can be used in cell culture with cationic liposomes to facilitate cellular uptake, but for in vivo use, preferably shorter oligonucleotides are administered, e.g. 25 nucleotides.

[0134] Antisense polynucleotides can comprise modified, nonnaturally-occurring nucleotides and linkages between the nucleotides (e.g., modification of the phosphate-sugar backbone; methyl phosphonate, phosphorothioate, or phosphorodithioate linkages; and 2′-O-methyl ribose sugar units), e.g., to enhance in vivo or in vitro stability, to confer nuclease resistance, to modulate uptake, to modulate cellular distribution and compartmentalization, etc. Any effective nucleotide or modification can be used, including those already mentioned, as known in the art, etc., e.g., disclosed in U.S. Pat. Nos. 6,133,438; 6,127,533; 6,124,445; 6,121,437; 5,218,103 (e.g., nucleoside thiophosphoramidites); 4,973,679; Sproat et al., “2′-O-Methyloligoribonucleotides: synthesis and applications,” Oligonucleotides and Analogs A Practical Approach, Eckstein (ed.), IRL Press, Oxford, 1991, 49-86; Iribarren et al., “2′O-Alkyl Oligoribonucleotides as Antisense Probes,” Proc. Natl. Acad. Sci. USA, 1990, 87, 7747-7751; Cotton et al., “2′-O-methyl, 2′-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event,” Nucl. Acids Res., 1991, 19, 2629-2635.

[0135] Arrays

[0136] The present invention also relates to an ordered array of polynucleotide probes and specific-binding partners (e.g., antibodies) for detecting the expression of human kidins220Pc in a sample, comprising, one or more polynucleotide probes or specific binding partners associated with a solid support, wherein each probe is specific for human kidins220Pc, and the probes comprise a nucleotide sequence of SEQ ID NO 1 which is specific for said gene, a nucleotide sequence having sequence identity to SEQ ID NO 1 which is specific for said gene or polynucleotide, or complements thereto, or a specific-binding partner which is specific for human kidins220Pc.

[0137] The phrase “ordered array” indicates that the probes are arranged in an identifiable or position-addressable pattern, e.g., such as the arrays disclosed in U.S. Pat. Nos. 6,156,501, 6,077,673, 6,054,270, 5,723,320, 5,700,637, WO0991971 1, WO00023803. The probes are associated with the solid support in any effective way. For instance, the probes can be bound to the solid support, either by polymerizing the probes on the substrate, or by attaching a probe to the substrate. Association can be, covalent, electrostatic, noncovalent, hydrophobic, hydrophilic, noncovalent, coordination, adsorbed, absorbed, polar, etc. When fibers or hollow filaments are utilized for the array, the probes can fill the hollow orifice, be absorbed into the solid filament, be attached to the surface of the orifice, etc. Probes can be of any effective size, sequence identity, composition, etc., as already discussed. Ordered arrays can further comprise polynucleotide probes or specific-binding partners which are specific for other genes, including genes specific for prostate, neurons, etc.

[0138] Transgenic Animals

[0139] The present invention also relates to transgenic animals comprising human kidins220Pc genes. Such genes, as discussed in more detail below, include, but are not limited to, functionally-disrupted genes, mutated genes, ectopically or selectively-expressed genes, inducible or regulatable genes, etc. These transgenic animals can be produced according to any suitable technique or method, including homologous recombination, mutagenesis (e.g., ENU, Rathkolb et al., Exp. Physiol., 85(6):635-644, 2000), and the tetracycline-regulated gene expression system (e.g., U.S. Pat. No. 6,242,667). The term “gene” as used herein includes any part of a gene, i.e., regulatory sequences, promoters, enhancers, exons, introns, coding sequences, etc. The human kidins220Pc nucleic acid present in the construct or transgene can be naturally-occurring wild-type, polymorphic, or mutated.

[0140] Along these lines, polynucleotides of the present invention can be used to create transgenic animals, e.g. a non-human animal, comprising at least one cell whose genome comprises a functional disruption of human kidins220Pc. By the phrases “functional disruption” or “functionally disrupted,” it is meant that the gene does not express a biologically-active product. It can be substantially deficient in at least one functional activity coded for by the gene. Expression of a polypeptide can be substantially absent, i.e., essentially undetectable amounts are made. However, polypeptide can also be made, but which is deficient in activity, e.g., where only an amino-terminal portion of the gene product is produced.

[0141] The transgenic animal can comprise one or more cells. When substantially all its cells contain the engineered gene, it can be referred to as a transgenic animal “whose genome comprises” the engineered gene. This indicates that the endogenous gene loci of the animal has been modified and substantially all cells contain such modification.

[0142] Functional disruption of the gene can be accomplished in any effective way, including, e.g., introduction of a stop codon into any part of the coding sequence such that the resulting polypeptide is biologically inactive (e.g., because it lacks a catalytic domain, a ligand binding domain, etc.), introduction of a mutation into a promoter or other regulatory sequence that is effective to turn it off, or reduce transcription of the gene, insertion of an exogenous sequence into the gene which inactivates it (e.g., which disrupts the production of a biologically-active polypeptide or which disrupts the promoter or other transcriptional machinery), deletion of sequences from the human kidins220Pc gene, etc. Examples of transgenic animals having functionally disrupted genes are well known, e.g., as described in U.S. Pat. Nos. 6,239,326, 6,225,525, 6,207,878, 6,194,633, 6,187,992, 6,180,849, 6,177,610, 6,100,445, 6,087,555, 6,080,910, 6,069,297, 6,060,642, 6,028,244, 6,013,858, 5,981,830, 5,866,760, 5,859,314, 5,850,004, 5,817,912, 5,789,654, 5,777,195, and 5,569,824. A transgenic animal which comprises the functional disruption can also be referred to as a “knock-out” animal, since the biological activity of its human kidins220Pc genes has been “knocked-out.” Knock-outs can be homozygous or heterozygous.

[0143] For creating functional disrupted genes, and other gene mutations, homologous recombination technology is of special interest since it allows specific regions of the genome to be targeted. Using homologous recombination methods, genes can be specifically-inactivated, specific mutations can be introduced, and exogenous sequences can be introduced at specific sites. These methods are well known in the art, e.g., as described in the patents above. See, also, Robertson, Biol. Reproduc., 44(2):238-245, 1991. Generally, the genetic engineering is performed in an embryonic stem (ES) cell, or other pluripotent cell line (e.g., adult stem cells, EG cells), and that genetically-modified cell (or nucleus) is used to create a whole organism. Nuclear transfer can be used in combination with homologous recombination technologies.

[0144] For example, the human kidins220Pc locus can be disrupted in mouse ES cells using a positive-negative selection method (e.g., Mansour et al., Nature, 336:348-352, 1988). In this method, a targeting vector can be constructed which comprises a part of the gene to be targeted. A selectable marker, such as neomycin resistance genes, can be inserted into a human kidins220Pc exon present in the targeting vector, disrupting it. When the vector recombines with the ES cell genome, it disrupts the function of the gene. The presence in the cell of the vector can be determined by expression of neomycin resistance. See, e.g., U.S. Pat. No. 6,239,326. Cells having at least one functionally disrupted gene can be used to make chimeric and germline animals, e.g., animals having somatic and/or germ cells comprising the engineered gene. Homozygous knock-out animals can be obtained from breeding heterozygous knock-out animals. See, e.g., U.S. Pat. No. 6,225,525.

[0145] A transgenic animal, or animal cell, lacking one or more functional human kidins220Pc genes can be useful in a variety of applications, including, as an animal model for prostate cancer, neuronal development (e.g., by disrupting neurite outgrowth), etc., for drug screening assays (e.g., for agents that modulate PKD—by assaying for agents that modulate phosphorylation of kidins220Pc), as a source of tissues deficient in human kidins220Pc activity, and any of the utilities mentioned in any issued U.S. Patent on transgenic animals, including, U.S. Pat. Nos. 6,239,326, 6,225,525, 6,207,878, 6,194,633, 6,187,992, 6,180,849, 6,177,610, 6,100,445, 6,087,555, 6,080,910, 6,069,297, 6,060,642, 6,028,244, 6,013,858, 5,981,830, 5,866,760, 5,859,314, 5,850,004, 5,817,912, 5,789,654, 5,777,195, and 5,569,824.

[0146] The present invention also relates to non-human, transgenic animal whose genome comprises recombinant human kidins220Pc nucleic acid operatively linked to an expression control sequence effective to express said coding sequence, e.g., in prostate or neurons. Such a transgenic animal can also be referred to as a “knock-in” animal since an exogenous gene has been introduced, stably, into its genome. Since kidins220Pc is up-regulated in prostate cancer, knock-in mouse displaying increased expression of the kidins220Pc protein, can display increased susceptibility to prostate cancer.

[0147] A recombinant human kidins220Pc nucleic acid refers to a gene which has been introduced into a target host cell and optionally modified, such as cells derived from animals, plants, bacteria, yeast, etc. A recombinant human kidins220Pc includes completely synthetic nucleic acid sequences, semi-synthetic nucleic acid sequences, sequences derived from natural sources, and chimeras thereof. “Operable linkage” has the meaning used through the specification, i.e., placed in a functional relationship with another nucleic acid. When a gene is operably linked to an expression control sequence, as explained above, it indicates that the gene (e.g., coding sequence) is joined to the expression control sequence (e.g., promoter) in such a way that facilitates transcription and translation of the coding sequence. As described above, the phrase “genome” indicates that the genome of the cell has been modified. In this case, the recombinant human kidins220Pc has been stably integrated into the genome of the animal. The human kidins220Pc nucleic acid in operable linkage with the expression control sequence can also be referred to as a construct or transgene.

[0148] Any expression control sequence can be used depending on the purpose. For instance, if selective expression is desired, then expression control sequences which limit its expression can be selected. These include, e.g., tissue or cell-specific promoters, introns, enhancers, etc. For various methods of cell and tissue-specific expression, see, e.g., U.S. Pat. Nos. 6,215,040, 6,210,736, and 6,153,427. These also include the endogenous promoter, i.e., the coding sequence can be operably linked to its own promoter. Inducible and regulatable promoters can also be utilized.

[0149] The present invention also relates to a transgenic animal which contains a functionally disrupted and a transgene stably integrated into the animals genome. Such an animal can be constructed using combinations any of the above- and below-mentioned methods. Such animals have any of the aforementioned uses, including permitting the knock-out of the normal gene and its replacement with a mutated gene. Such a transgene can be integrated at the endogenous gene locus so that the functional disruption and “knock-in” are carried out in the same step.

[0150] In addition to the methods mentioned above, transgenic animals can be prepared according to known methods, including, e.g., by pronuclear injection of recombinant genes into pronuclei of 1-cell embryos, incorporating an artificial yeast chromosome into embryonic stem cells, gene targeting methods, embryonic stem cell methodology, cloning methods, nuclear transfer methods. See, also, e.g., U.S. Pat. Nos. 4,736,866; 4,873,191; 4,873,316; 5,082,779; 5,304,489; 5,174,986; 5,175,384; 5,175,385; 5,221,778; Gordon et al., Proc. Natl. Acad. Sci., 77:7380-7384, 1980; Palmiter et al., Cell, 41:343-345, 1985; Palmiter et al., Ann. Rev. Genet., 20:465-499, 1986; Askew et al., Mol. Cell. Bio., 13:4115-4124, 1993; Games et al. Nature, 373:523-527, 1995; Valancius and Smithies, Mol. Cell. Bio., 11:1402-1408, 1991; Stacey et al., Mol. Cell. Bio., 14:1009-1016, 1994; Hasty et al., Nature, 350:243-246, 1995; Rubinstein et al., Nucl. Acid Res., 21:2613-2617,1993; Cibelli et al., Science, 280:1256-1258, 1998. For guidance on recombinase excision systems, see, e.g., U.S. Pat. Nos. 5,626,159, 5,527,695, and 5,434,066. See also, Orban, P. C., et al., “Tissue- and Site-Specific DNA Recombination in Transgenic Mice,” Proc. Natl. Acad. Sci. USA, 89:6861-6865 (1992); O'Gorman, S., et al., “Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells,” Science, 251:1351-1355 (1991); Sauer, B., et al., “Cre-stimulated recombination at loxP-Containing DNA sequences placed into the mammalian genome,” Polynucleotides Research, 17(1):147-161 (1989); Gagneten, S. et al. (1997) Nucl. Acids Res. 25:3326-3331; Xiao and Weaver (1997) Nucl. Acids Res. 25:2985-2991; Agah, R. et al. (1997) J. Clin. Invest. 100:169-179; Barlow, C. et al. (1997) Nucl. Acids Res. 25:2543-2545; Araki, K. et al. (1997) Nucl. Acids Res. 25:868-872; Mortensen, R. N. et al. (1992) Mol. Cell. Biol. 12:2391-2395 (G418 escalation method); Lakhlani, P. P. et al. (1997) Proc. Natl. Acad. Sci. USA 94:9950-9955 (“hit and run”); Westphal and Leder (1997) Curr. Biol. 7:530-533 (transposon-generated “knock-out” and “knock-in”); Templeton, N. S. et al. (1997) Gene Ther. 4:700-709 (methods for efficient gene targeting, allowing for a high frequency of homologous recombination events, e.g., without selectable markers); PCT International Publication WO 93/22443 (functionally-disrupted).

[0151] A polynucleotide according to the present invention can be introduced into any non-human animal, including a non-human mammal, mouse (Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1986), pig (Hammer et al., Nature, 315:343-345, 1985), sheep (Hammer et al., Nature, 315:343-345, 1985), cattle, rat, or primate. See also, e.g., Church, 1987, Trends in Biotech. 5:13-19; Clark et al., Trends in Biotech. 5:20-24, 1987); and DePamphilis et al., BioTechniques, 6:662-680, 1988. Transgenic animals can be produced by the methods described in U.S. Pat. No. 5,994,618, and utilized for any of the utilities described therein.

[0152] Database

[0153] The present invention also relates to electronic forms of polynucleotides, polypeptides, etc., of the present invention, including computer-readable medium (e.g., magnetic, optical, etc., stored in any suitable format, such as flat files or hierarchical files) which comprise such sequences, or fragments thereof, e-commerce-related means, etc. Along these lines, the present invention relates to methods of retrieving gene sequences from a computer-readable medium, comprising, one or more of the following steps in any effective order, e.g., selecting a cell or gene expression profile, e.g., a profile that specifies that said gene is up-regulated in prostate cancer, and retrieving said differentially expressed gene sequences, where the gene sequences consist of the genes represented by SEQ ID NO 1 or NO2.

[0154] A “gene expression profile” means the list of tissues, cells, etc., in which a defined gene is expressed (i.e, transcribed and/or translated). A “cell expression profile” means the genes which are expressed in the particular cell type. The profile can be a list of the tissues in which the gene is expressed, but can include additional information as well, including level of expression (e.g., a quantity as compared or normalized to a control gene), and information on temporal (e.g., at what point in the cell-cycle or developmental program) and spatial expression. By the phrase “selecting a gene or cell expression profile,” it is meant that a user decides what type of gene or cell expression pattern he is interested in retrieving. Any pattern of expression preferences may be selected. The selecting can be performed by any effective method. In general, “selecting” refers to the process in which a user forms a query that is used to search a database of gene expression profiles. The step of retrieving involves searching for results in a database that correspond to the query set forth in the selecting step. Any suitable algorithm can be utilized to perform the search query, including algorithms that look for matches, or that perform optimization between query and data. The database is information that has been stored in an appropriate storage medium, having a suitable computer-readable format. Once results are retrieved, they can be displayed in any suitable format, such as HTML.

[0155] For instance, the user may be interested in identifying genes that are up-regulated in prostate cancer. He may not care whether expression occur in other tissues. A query is formed by the user to retrieve the set of genes from the database having the desired gene or cell expression profile. Once the query is inputted into the system, a search algorithm is used to interrogate the database, and retrieve results.

[0156] Advertising, Licensing, etc., Methods

[0157] The present invention also relates to methods of advertising, licensing, selling, purchasing, brokering, etc., genes, polynucleotides, specific-binding partners, antibodies, etc., of the present invention. Methods can comprises, e.g., displaying a human kidins220Pc gene, human kidins220Pc polypeptide, or antibody specific for human kidins220Pc in a printed or computer-readable medium (e.g., on the Web or Internet), accepting an offer to purchase said gene, polypeptide, or antibody.

[0158] Other

[0159] A polynucleotide, probe, polypeptide, antibody, specific-binding partner, etc., according to the present invention can be isolated. The term “isolated” means that the material is in a form in which it is not found in its original environment or in nature, e.g., more concentrated, more purified, separated from component, etc. An isolated polynucleotide includes, e.g., a polynucleotide having the sequenced separated from the chromosomal DNA found in a living animal, e.g., as the complete gene, a transcript, or a cDNA. This polynucleotide can be part of a vector or inserted into a chromosome (by specific gene-targeting or by random integration at a position other than its normal position) and still be isolated in that it is not in a form that is found in its natural environment. A polynucleotide, polypeptide, etc., of the present invention can also be substantially purified. By substantially purified, it is meant that polynucleotide or polypeptide is separated and is essentially free from other polynucleotides or polypeptides, i.e., the polynucleotide or polypeptide is the primary and active constituent. A polynucleotide can also be a recombinant molecule. By “recombinant,” it is meant that the polynucleotide is an arrangement or form which does not occur in nature. For instance, a recombinant molecule comprising a promoter sequence would not encompass the naturally-occurring gene, but would include the promoter operably linked to a coding sequence not associated with it in nature, e.g., a reporter gene, or a truncation of the normal coding sequence.

[0160] The term “marker” is used herein to indicate a means for detecting or labeling a target. A marker can be a polynucleotide (usually referred to as a “probe”), polypeptide (e.g., an antibody conjugated to a detectable label), PNA, or any effective material.

[0161] The topic headings set forth above are meant as guidance where certain information can be found in the application, but are not intended to be the only source in the application where information on such topic can be found. Reference materials

[0162] For other aspects of the polynucleotides, reference is made to standard textbooks of molecular biology. See, e.g., Hames et al., Polynucleotide Hybridization, IL Press, 1985; Davis et al., Basic Methods in Molecular Biology, Elsevir Sciences Publishing, Inc., New York, 1986; Sambrook et al., Molecular Cloning, CSH Press, 1989; Howe, Gene Cloning and Manipulation, Cambridge University Press, 1995; Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 1994-1998.

[0163] The preceding preferred specific embodiments are merely illustrative, and not limiting the remainder of the disclosure in any way whatsoever. The entire disclosure of all applications, patents and publications, cited above and in the figures are hereby incorporated by reference in their entirety.

1 11 1 7103 DNA Homo sapiens CDS (147)..(5294) 1 gccgccgggt gtggtgaggg cgacgcgctt gcagtcgccg tctcttgctt ccccgtcctc 60 tgacatcgcc tgcagccgag cgggcccgtt ccgccggagc tgaggaccag gtattcaaat 120 aaagttaatt gcagctttct gtgaaa atg tca gtt ttg ata tca cag agc gtc 173 Met Ser Val Leu Ile Ser Gln Ser Val 1 5 ata aat tat gta gag gaa gaa aac att cct gct ctg aaa gct ctt ctt 221 Ile Asn Tyr Val Glu Glu Glu Asn Ile Pro Ala Leu Lys Ala Leu Leu 10 15 20 25 gaa aaa tgc aaa gat gta gat gag aga aat gag tgt ggc cag act cca 269 Glu Lys Cys Lys Asp Val Asp Glu Arg Asn Glu Cys Gly Gln Thr Pro 30 35 40 ctg atg ata gct gcc gaa caa ggc aat ctg gaa ata gtg aag gaa tta 317 Leu Met Ile Ala Ala Glu Gln Gly Asn Leu Glu Ile Val Lys Glu Leu 45 50 55 att aag aat gga gct aac tgc aat ctg gaa gat ttg gat aat tgg aca 365 Ile Lys Asn Gly Ala Asn Cys Asn Leu Glu Asp Leu Asp Asn Trp Thr 60 65 70 gca ctt ata tct gca tcg aaa gaa ggg cat gtg cac atc gta gag gaa 413 Ala Leu Ile Ser Ala Ser Lys Glu Gly His Val His Ile Val Glu Glu 75 80 85 cta ctg aaa tgt ggg gtt aac ttg gag cac cgt gat atg gga gga tgg 461 Leu Leu Lys Cys Gly Val Asn Leu Glu His Arg Asp Met Gly Gly Trp 90 95 100 105 aca gct ctt atg tgg gca tgt tac aaa ggc cgt act gac gta gta gag 509 Thr Ala Leu Met Trp Ala Cys Tyr Lys Gly Arg Thr Asp Val Val Glu 110 115 120 ttg ctt ctt tct cat ggt gcc aat cca agt gtc act ggt ctg cag tac 557 Leu Leu Leu Ser His Gly Ala Asn Pro Ser Val Thr Gly Leu Gln Tyr 125 130 135 agt gtt tac cca atc att tgg gca gca ggg aga ggc cat gca gat ata 605 Ser Val Tyr Pro Ile Ile Trp Ala Ala Gly Arg Gly His Ala Asp Ile 140 145 150 gtt cat ctt tta ctg caa aat ggt gct aaa gtc aac tgc tct gat aag 653 Val His Leu Leu Leu Gln Asn Gly Ala Lys Val Asn Cys Ser Asp Lys 155 160 165 tat gga acc acc cct tta gtt tgg gct gca cga aag ggt cat ttg gaa 701 Tyr Gly Thr Thr Pro Leu Val Trp Ala Ala Arg Lys Gly His Leu Glu 170 175 180 185 tgt gtg aaa cat tta ttg gcc atg gga gct gat gtg gat caa gaa gga 749 Cys Val Lys His Leu Leu Ala Met Gly Ala Asp Val Asp Gln Glu Gly 190 195 200 gct aat tca atg act gca ctt att gtg gca gtg aaa gga ggt tac aca 797 Ala Asn Ser Met Thr Ala Leu Ile Val Ala Val Lys Gly Gly Tyr Thr 205 210 215 cag tca gta aaa gaa att ttg aag agg aat cca aat gta aac tta aca 845 Gln Ser Val Lys Glu Ile Leu Lys Arg Asn Pro Asn Val Asn Leu Thr 220 225 230 gat aaa gat gga aat aca gct ttg atg att gca tca aag gag gga cat 893 Asp Lys Asp Gly Asn Thr Ala Leu Met Ile Ala Ser Lys Glu Gly His 235 240 245 acg gag att gtg cag gat ctg ctc gac gct gga aca tat gtg aac ata 941 Thr Glu Ile Val Gln Asp Leu Leu Asp Ala Gly Thr Tyr Val Asn Ile 250 255 260 265 cct gac agg agt ggg gat act gtg ttg att ggc gct gtc aga ggt ggt 989 Pro Asp Arg Ser Gly Asp Thr Val Leu Ile Gly Ala Val Arg Gly Gly 270 275 280 cat gtt gaa att gtt cga gcg ctt ctc caa aaa tat gct gat ata gac 1037 His Val Glu Ile Val Arg Ala Leu Leu Gln Lys Tyr Ala Asp Ile Asp 285 290 295 att aga gga cag gat aat aaa act gct ttg tat tgg gct gtt gag aaa 1085 Ile Arg Gly Gln Asp Asn Lys Thr Ala Leu Tyr Trp Ala Val Glu Lys 300 305 310 gga aat gca aca atg gtg aga gat atc tta cag tgc aat cct gac act 1133 Gly Asn Ala Thr Met Val Arg Asp Ile Leu Gln Cys Asn Pro Asp Thr 315 320 325 gaa ata tgc aca aag gat ggt gaa acg cca ctt ata aag gct acc aag 1181 Glu Ile Cys Thr Lys Asp Gly Glu Thr Pro Leu Ile Lys Ala Thr Lys 330 335 340 345 atg aga aac att gaa gtg gtg gag ctg ctg cta gat aaa ggt gct aaa 1229 Met Arg Asn Ile Glu Val Val Glu Leu Leu Leu Asp Lys Gly Ala Lys 350 355 360 gtg tct gct gta gat aag aaa gga gat act ccc ttg cat att gct att 1277 Val Ser Ala Val Asp Lys Lys Gly Asp Thr Pro Leu His Ile Ala Ile 365 370 375 cgt gga agg agc cgg aaa ctg gca gaa ctg ctt tta aga aat ccc aaa 1325 Arg Gly Arg Ser Arg Lys Leu Ala Glu Leu Leu Leu Arg Asn Pro Lys 380 385 390 gat ggg cga tta ctt tat agg ccc aac aaa gca ggc gag act cct tat 1373 Asp Gly Arg Leu Leu Tyr Arg Pro Asn Lys Ala Gly Glu Thr Pro Tyr 395 400 405 aat att gac tgt agc cat cag aag agt att tta act caa ata ttt gga 1421 Asn Ile Asp Cys Ser His Gln Lys Ser Ile Leu Thr Gln Ile Phe Gly 410 415 420 425 gcc aga cac ttg tct cct act gaa aca gac ggt gac atg ctt gga tat 1469 Ala Arg His Leu Ser Pro Thr Glu Thr Asp Gly Asp Met Leu Gly Tyr 430 435 440 gat tta tat agc agt gcc ctg gca gat att ctc agt gag cct acc atg 1517 Asp Leu Tyr Ser Ser Ala Leu Ala Asp Ile Leu Ser Glu Pro Thr Met 445 450 455 cag cca ccc att tgt gtg ggg tta tat gca cag tgg gga agt ggg aaa 1565 Gln Pro Pro Ile Cys Val Gly Leu Tyr Ala Gln Trp Gly Ser Gly Lys 460 465 470 tct ttc tta ctc aag aaa cta gaa gac gaa atg aaa acc ttc gcc gga 1613 Ser Phe Leu Leu Lys Lys Leu Glu Asp Glu Met Lys Thr Phe Ala Gly 475 480 485 caa cag att gag cct ctc ttt cag ttc tca tgg ctc ata gtg ttt ctt 1661 Gln Gln Ile Glu Pro Leu Phe Gln Phe Ser Trp Leu Ile Val Phe Leu 490 495 500 505 acc ctg cta ctt tgt gga ggg ctt ggt tta ttg ttt gcc ttc acg gtc 1709 Thr Leu Leu Leu Cys Gly Gly Leu Gly Leu Leu Phe Ala Phe Thr Val 510 515 520 cac cca aat ctt gga ata gca gtg tca ctg agc ttc ttg gct ctc tta 1757 His Pro Asn Leu Gly Ile Ala Val Ser Leu Ser Phe Leu Ala Leu Leu 525 530 535 tat ata ttc ttt att gtc att tac ttt ggt gga cga aga gaa gga gag 1805 Tyr Ile Phe Phe Ile Val Ile Tyr Phe Gly Gly Arg Arg Glu Gly Glu 540 545 550 agt tgg aat tgg gcc tgg gtc ctc agc act aga ttg gca aga cat att 1853 Ser Trp Asn Trp Ala Trp Val Leu Ser Thr Arg Leu Ala Arg His Ile 555 560 565 gga tat ttg gaa ctc ctc ctt aaa ttg atg ttt gtg aat cca cct gag 1901 Gly Tyr Leu Glu Leu Leu Leu Lys Leu Met Phe Val Asn Pro Pro Glu 570 575 580 585 ttg cca gag cag act act aaa gct tta cct gtg agg ttt ttg ttt aca 1949 Leu Pro Glu Gln Thr Thr Lys Ala Leu Pro Val Arg Phe Leu Phe Thr 590 595 600 gat tac aat aga ctg tcc agt gta ggt gga gaa act tct ctg gct gaa 1997 Asp Tyr Asn Arg Leu Ser Ser Val Gly Gly Glu Thr Ser Leu Ala Glu 605 610 615 atg att gca acc ctc tcg gat gct tgt gaa aga gag ttt ggc ttt ttg 2045 Met Ile Ala Thr Leu Ser Asp Ala Cys Glu Arg Glu Phe Gly Phe Leu 620 625 630 gca acc agg ctt ttt cga gta ttc aag act gaa gat act cag ggt aaa 2093 Ala Thr Arg Leu Phe Arg Val Phe Lys Thr Glu Asp Thr Gln Gly Lys 635 640 645 aag aaa tgg aaa aaa aca tgt tgt ctc cca tct ttt gtc atc ttc ctt 2141 Lys Lys Trp Lys Lys Thr Cys Cys Leu Pro Ser Phe Val Ile Phe Leu 650 655 660 665 ttt atc att ggc tgc att ata tct gga att act ctt ctg gct ata ttt 2189 Phe Ile Ile Gly Cys Ile Ile Ser Gly Ile Thr Leu Leu Ala Ile Phe 670 675 680 aga gtt gac cca aag cat ctg act gta aat gct gtc ctc ata tca atc 2237 Arg Val Asp Pro Lys His Leu Thr Val Asn Ala Val Leu Ile Ser Ile 685 690 695 gca tct gta gtg gga ttg gcc ttt gtg ttg aac tgt cgt aca tgg tgg 2285 Ala Ser Val Val Gly Leu Ala Phe Val Leu Asn Cys Arg Thr Trp Trp 700 705 710 caa gtg ctg gac tcg ctc ctg aat tcc caa aga aaa cgc ctc cat aat 2333 Gln Val Leu Asp Ser Leu Leu Asn Ser Gln Arg Lys Arg Leu His Asn 715 720 725 gca gcc tcc aaa ctg cac aaa ttg aaa agt gaa gga ttc atg aaa gtt 2381 Ala Ala Ser Lys Leu His Lys Leu Lys Ser Glu Gly Phe Met Lys Val 730 735 740 745 ctt aaa tgt gaa gtg gaa ttg atg gcc agg atg gca aaa acc att gac 2429 Leu Lys Cys Glu Val Glu Leu Met Ala Arg Met Ala Lys Thr Ile Asp 750 755 760 agc ttc act cag aat cag aca agg ctg gtg gtc atc atc gat gga tta 2477 Ser Phe Thr Gln Asn Gln Thr Arg Leu Val Val Ile Ile Asp Gly Leu 765 770 775 gat gcc tgt gag cag gac aaa gtc ctt cag atg ctg gac act gtc cga 2525 Asp Ala Cys Glu Gln Asp Lys Val Leu Gln Met Leu Asp Thr Val Arg 780 785 790 gtt ctg ttt tca aaa ggc ccg ttc att gcc att ttt gca agt gat cca 2573 Val Leu Phe Ser Lys Gly Pro Phe Ile Ala Ile Phe Ala Ser Asp Pro 795 800 805 cat att atc ata aag gca att aac cag aac ctc aat agt gtg ctt cgg 2621 His Ile Ile Ile Lys Ala Ile Asn Gln Asn Leu Asn Ser Val Leu Arg 810 815 820 825 gat tca aat ata aat ggc cat gac tac atg cgc aac ata gtc cac ttg 2669 Asp Ser Asn Ile Asn Gly His Asp Tyr Met Arg Asn Ile Val His Leu 830 835 840 cct gtg ttc ctt aat agt cgt gga cta agc aat gca aga aaa ttt ctc 2717 Pro Val Phe Leu Asn Ser Arg Gly Leu Ser Asn Ala Arg Lys Phe Leu 845 850 855 gta act tca gca aca aat gga gac gtt cca tgc tca gat act aca ggg 2765 Val Thr Ser Ala Thr Asn Gly Asp Val Pro Cys Ser Asp Thr Thr Gly 860 865 870 ata cag gaa gat gct gac aga aga gtt tca cag aac agc ctt ggg gag 2813 Ile Gln Glu Asp Ala Asp Arg Arg Val Ser Gln Asn Ser Leu Gly Glu 875 880 885 atg aca aaa ctt ggt agc aag aca gcc ctc aat aga cgg gac act tac 2861 Met Thr Lys Leu Gly Ser Lys Thr Ala Leu Asn Arg Arg Asp Thr Tyr 890 895 900 905 cga aga agg cag atg cag agg acc atc act cgc cag atg tcc ttt gat 2909 Arg Arg Arg Gln Met Gln Arg Thr Ile Thr Arg Gln Met Ser Phe Asp 910 915 920 ctt aca aaa ctg ctg gtt acc gag gac tgg ttc agt gac atc agt ccc 2957 Leu Thr Lys Leu Leu Val Thr Glu Asp Trp Phe Ser Asp Ile Ser Pro 925 930 935 cag acc atg aga aga tta ctt aat att gtt tct gtg aca gga cga tta 3005 Gln Thr Met Arg Arg Leu Leu Asn Ile Val Ser Val Thr Gly Arg Leu 940 945 950 ctg aga gcc aat cag att agt ttc aac tgg gac agg ctt gct agc tgg 3053 Leu Arg Ala Asn Gln Ile Ser Phe Asn Trp Asp Arg Leu Ala Ser Trp 955 960 965 atc aac ctt act gag cag tgg cca tac cgg act tca tgg ctc ata tta 3101 Ile Asn Leu Thr Glu Gln Trp Pro Tyr Arg Thr Ser Trp Leu Ile Leu 970 975 980 985 tat ttg gaa gag act gaa ggt att cca gat caa atg aca tta aaa acc 3149 Tyr Leu Glu Glu Thr Glu Gly Ile Pro Asp Gln Met Thr Leu Lys Thr 990 995 1000 atc tac gaa aga ata tca aag aat att cca aca act aag gat gtt 3194 Ile Tyr Glu Arg Ile Ser Lys Asn Ile Pro Thr Thr Lys Asp Val 1005 1010 1015 gag cca ctt ctt gaa att gat gga gat ata aga aat ttt gaa gtg 3239 Glu Pro Leu Leu Glu Ile Asp Gly Asp Ile Arg Asn Phe Glu Val 1020 1025 1030 ttt ttg tct tca agg acc cca gtt ctt gtg gct cga gat gta aaa 3284 Phe Leu Ser Ser Arg Thr Pro Val Leu Val Ala Arg Asp Val Lys 1035 1040 1045 gtc ttt ttg cca tgc act gta aac cta gat ccc aaa cta cgg gaa 3329 Val Phe Leu Pro Cys Thr Val Asn Leu Asp Pro Lys Leu Arg Glu 1050 1055 1060 att att gca gat gtt cgt gct gcc aga gag cag atc agt att gga 3374 Ile Ile Ala Asp Val Arg Ala Ala Arg Glu Gln Ile Ser Ile Gly 1065 1070 1075 gga ctg gcg tac ccc ccg ctc cct cta cat gag ggt cct cct agg 3419 Gly Leu Ala Tyr Pro Pro Leu Pro Leu His Glu Gly Pro Pro Arg 1080 1085 1090 gcg cca tca ggg tac agc cag ccc cca tcc gtg tgc tct tcc acg 3464 Ala Pro Ser Gly Tyr Ser Gln Pro Pro Ser Val Cys Ser Ser Thr 1095 1100 1105 tcc ttc aat ggg ccc ttc gca ggt gga gtg gtg tca cca cag cct 3509 Ser Phe Asn Gly Pro Phe Ala Gly Gly Val Val Ser Pro Gln Pro 1110 1115 1120 cac agc agc tat tac agc ggc atg acg ggc cct cag cat ccc ttc 3554 His Ser Ser Tyr Tyr Ser Gly Met Thr Gly Pro Gln His Pro Phe 1125 1130 1135 tac aac agg ggg tca ggc cca gcc cca ggc cca gtg gta tta ctg 3599 Tyr Asn Arg Gly Ser Gly Pro Ala Pro Gly Pro Val Val Leu Leu 1140 1145 1150 aat tca ctg aat gtg gat gca gta tgt gag aag ctg aaa caa ata 3644 Asn Ser Leu Asn Val Asp Ala Val Cys Glu Lys Leu Lys Gln Ile 1155 1160 1165 gaa ggg ctg gac cag agt atg ctg cct cag tat tgt acc acg atc 3689 Glu Gly Leu Asp Gln Ser Met Leu Pro Gln Tyr Cys Thr Thr Ile 1170 1175 1180 aaa aag gca aac ata aat ggc cgt gtg tta gct cag tgt aac att 3734 Lys Lys Ala Asn Ile Asn Gly Arg Val Leu Ala Gln Cys Asn Ile 1185 1190 1195 gat gag ctg aag aaa gag atg aat atg aat ttt gga gac tgg cac 3779 Asp Glu Leu Lys Lys Glu Met Asn Met Asn Phe Gly Asp Trp His 1200 1205 1210 ctt ttc aga agc aca gta cta gaa atg aga aac gca gaa agc cac 3824 Leu Phe Arg Ser Thr Val Leu Glu Met Arg Asn Ala Glu Ser His 1215 1220 1225 gtg gtc cct gaa gac cca cgt ttc ctc agt gag agc agc agt ggc 3869 Val Val Pro Glu Asp Pro Arg Phe Leu Ser Glu Ser Ser Ser Gly 1230 1235 1240 cca gcc ccg cac ggt gag cct gct cgc cgc gct tcc cac aac gag 3914 Pro Ala Pro His Gly Glu Pro Ala Arg Arg Ala Ser His Asn Glu 1245 1250 1255 ctg cct cac acc gag ctc tcc agc cag acg ccc tac aca ctc aac 3959 Leu Pro His Thr Glu Leu Ser Ser Gln Thr Pro Tyr Thr Leu Asn 1260 1265 1270 ttc agc ttc gaa gag ctg aac acg ctt ggc ctg gat gaa ggt gcc 4004 Phe Ser Phe Glu Glu Leu Asn Thr Leu Gly Leu Asp Glu Gly Ala 1275 1280 1285 cct cgt cac agt aat cta agt tgg cag tca caa act cgc aga acc 4049 Pro Arg His Ser Asn Leu Ser Trp Gln Ser Gln Thr Arg Arg Thr 1290 1295 1300 cca agt ctt tcg agt ctc aat tcc cag gat tcc agt att gaa att 4094 Pro Ser Leu Ser Ser Leu Asn Ser Gln Asp Ser Ser Ile Glu Ile 1305 1310 1315 tca aag ctt act gat aag gtg cag gcc gag tat aga gat gcc tat 4139 Ser Lys Leu Thr Asp Lys Val Gln Ala Glu Tyr Arg Asp Ala Tyr 1320 1325 1330 aga gaa tac att gct cag atg tcc cag tta gaa ggg ggc ccc ggg 4184 Arg Glu Tyr Ile Ala Gln Met Ser Gln Leu Glu Gly Gly Pro Gly 1335 1340 1345 tct aca acc att agt ggc aga tct tct cca cat agc aca tat tac 4229 Ser Thr Thr Ile Ser Gly Arg Ser Ser Pro His Ser Thr Tyr Tyr 1350 1355 1360 atg ggt cag agt tca tca ggg ggc tct att cat tca aac cta gag 4274 Met Gly Gln Ser Ser Ser Gly Gly Ser Ile His Ser Asn Leu Glu 1365 1370 1375 caa gaa aag ggg aag gat agt gaa cca aag ccc gat gat ggg agg 4319 Gln Glu Lys Gly Lys Asp Ser Glu Pro Lys Pro Asp Asp Gly Arg 1380 1385 1390 aag tcc ttt cta atg aag agg gga gat gtt atc gat tat tca tca 4364 Lys Ser Phe Leu Met Lys Arg Gly Asp Val Ile Asp Tyr Ser Ser 1395 1400 1405 tca ggg gtt tcc acc aac gat gct tcc ccc ctg gat cct atc act 4409 Ser Gly Val Ser Thr Asn Asp Ala Ser Pro Leu Asp Pro Ile Thr 1410 1415 1420 gaa gaa gat gaa aaa tca gat cag tca ggc agt aag ctt ctc cca 4454 Glu Glu Asp Glu Lys Ser Asp Gln Ser Gly Ser Lys Leu Leu Pro 1425 1430 1435 ggc aag aaa tct tcc gaa agg tca agc ctc ttc cag aca gat ttg 4499 Gly Lys Lys Ser Ser Glu Arg Ser Ser Leu Phe Gln Thr Asp Leu 1440 1445 1450 aag ctt aag gga agt ggg ctg cgc tat caa aaa ctc cca agt gac 4544 Lys Leu Lys Gly Ser Gly Leu Arg Tyr Gln Lys Leu Pro Ser Asp 1455 1460 1465 gag gat gaa tct ggc aca gaa gaa tca gat aac act cca ctg ctc 4589 Glu Asp Glu Ser Gly Thr Glu Glu Ser Asp Asn Thr Pro Leu Leu 1470 1475 1480 aaa gat gac aaa gac aga aaa gcc gaa ggg aaa gta gag aga gtg 4634 Lys Asp Asp Lys Asp Arg Lys Ala Glu Gly Lys Val Glu Arg Val 1485 1490 1495 ccg aag tct cca gaa cac agt gct gag ccg atc aga acc ttc att 4679 Pro Lys Ser Pro Glu His Ser Ala Glu Pro Ile Arg Thr Phe Ile 1500 1505 1510 aaa gcc aaa gag tat tta tcg gat gcg ctc ctt gac aaa aag gat 4724 Lys Ala Lys Glu Tyr Leu Ser Asp Ala Leu Leu Asp Lys Lys Asp 1515 1520 1525 tca tcg gat tca gga gtg aga tcc agt gaa agt tct ccc aat cac 4769 Ser Ser Asp Ser Gly Val Arg Ser Ser Glu Ser Ser Pro Asn His 1530 1535 1540 tct ctg cac aat gaa gtg gcg gat gac tcc cag ctt gaa aag gca 4814 Ser Leu His Asn Glu Val Ala Asp Asp Ser Gln Leu Glu Lys Ala 1545 1550 1555 aat ctc ata gag ctg gaa gat gac agt cac agc gga aag cgg gga 4859 Asn Leu Ile Glu Leu Glu Asp Asp Ser His Ser Gly Lys Arg Gly 1560 1565 1570 atc cca cat agc ctg agt ggc ctg caa gat cca att ata gct cgg 4904 Ile Pro His Ser Leu Ser Gly Leu Gln Asp Pro Ile Ile Ala Arg 1575 1580 1585 atg tcc att tgt tca gaa gac aag aaa agc cct tcc gaa tgc agc 4949 Met Ser Ile Cys Ser Glu Asp Lys Lys Ser Pro Ser Glu Cys Ser 1590 1595 1600 ttg ata gcc agc agc cct gaa gaa aac tgg cct gca tgc cag aaa 4994 Leu Ile Ala Ser Ser Pro Glu Glu Asn Trp Pro Ala Cys Gln Lys 1605 1610 1615 gcc tac aac ctg aac cga act ccc agc acc gtg act ctg aac aac 5039 Ala Tyr Asn Leu Asn Arg Thr Pro Ser Thr Val Thr Leu Asn Asn 1620 1625 1630 aat agt gct cca gcc aac aga gcc aat caa aat ttc gat gag atg 5084 Asn Ser Ala Pro Ala Asn Arg Ala Asn Gln Asn Phe Asp Glu Met 1635 1640 1645 gag gga att agg gag act tct caa gtc att ttg agg cct agt tcc 5129 Glu Gly Ile Arg Glu Thr Ser Gln Val Ile Leu Arg Pro Ser Ser 1650 1655 1660 agt ccc aac cca acc act att cag aat gag aat cta aaa agc atg 5174 Ser Pro Asn Pro Thr Thr Ile Gln Asn Glu Asn Leu Lys Ser Met 1665 1670 1675 aca cat aag cga agc caa cgt tca agt tac aca agg ctc tcc aaa 5219 Thr His Lys Arg Ser Gln Arg Ser Ser Tyr Thr Arg Leu Ser Lys 1680 1685 1690 gat cct ccg gag ctc cat gca gca gcc tct tct gag agc aca ggc 5264 Asp Pro Pro Glu Leu His Ala Ala Ala Ser Ser Glu Ser Thr Gly 1695 1700 1705 ttt gga gaa gaa aga gaa agc att ctt tga gaaaaacaag caaaggagaa 5314 Phe Gly Glu Glu Arg Glu Ser Ile Leu 1710 1715 gagtgttact gtacccttat gacagaattg tcctggattt tgactccatc cacgcccatc 5374 acctttctac attttgctga cagataacta accgatgatg aggccgaggt aaaagagaca 5434 tctgcagtgt gacagaaggg agcatgagaa gcatggctca ccagccagcc tctgtggtct 5494 ttgtaattag aagcttcaga actcactaat actactgtac ctttcattgg cgcattaccc 5554 cataaaactt tttgagacga ggtgagatct gagtataaag ataggtcaga agtattttaa 5614 agggcttaat gtgccaaaaa gaaaaaaagc tagagaccct ttttgcaaac atttggtgac 5674 cacacatttg agggaagacg tggcgttagg tgaagcagaa gcaaaccctg ctcttagggg 5734 ctcacctagg tgagtgcaca gcctgtgacg ctacagggag aggctgagta aaccgagatc 5794 cagcgttctg tatggcaggg gtattgctta tcacagaggt tctgaagagt aggaagtaca 5854 taatgaagag ggctttaaaa attgccaaca aagtgagtca ccagggctgg cagtagtgtg 5914 acggggctgt cctgagctgt taggagagta gatgcgggga gggctggtga cctccgtggg 5974 tttatatgtc ggaaactctt ctctccaaat cccaggcctg gcttccagca ccatccagct 6034 gtgcccaaga agccaccctg gtctgttctc caactctttt aaatggtgcc caacttttct 6094 aagtgagctt agcaatgaga agaaaaaaaa acatgaattc tttttctgga aaatcaggga 6154 gacatgggta ataataggta ctaataaata tttatagatg agtgaatgag gaaataatta 6214 catcaaaaag gtcagtgaca attgataaat gacaaggaaa tatttaatta ggtaaaacta 6274 aatcattgct ctctatacta ggatagactt tatctacttc atctgttcct aagtcagcat 6334 gttagttctg gggaaggatc ataagaaagg aaatactttt taaaaaaaaa tttggaaaca 6394 tgtaacaaag caagggtaaa atatatatat atatctatat aagtgctgtg actgtaaaag 6454 tgtactttcc attaattatt agccgagtta agagaatggt cacattgaag tactgtgtgg 6514 actagaaatg taccctgtca tcatgcaatg aaatattgtt atcgttttaa catagctcat 6574 ttatgtagaa tgaattctgg tggtttaccc caagtcacag ttaggacggt agatggtgag 6634 atcgcagatg cgctattatc tagattcagt gttacatttt cgatgtttat cactcagtgg 6694 gtttttatta atatgctgat taagttattt actgggccag tcattgtgct aaatagttgc 6754 tcttttgtgt ttcattgcct tgatgtttga gtgtaatcta gcattttaat acagtgttta 6814 ttttgcatga tctttaacaa atgttttaag caattttaaa aaggcaggat gttattgaca 6874 ttatacactg aagtcttaac attttaacat ttatagtgct tatttgcaaa attgtataat 6934 taggaattat ttcagagaca atgttttctt tttcaggtga gtagttgccg cgtaatatca 6994 ttggagtaca ttctttatac tgtttgtgaa attaatacta gcatattaag tgtacaaata 7054 gatttagaaa acaataaaaa attgcatgct aaaaaaaaaa aaaaaaaaa 7103 2 1715 PRT Homo sapiens 2 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Ile Ala Ala Glu Gln 35 40 45 Gly Asn Leu Glu Ile Val Lys Glu Leu Ile Lys Asn Gly Ala Asn Cys 50 55 60 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 Glu Gly His Val His Ile Val Glu Glu Leu Leu Lys Cys Gly Val Asn 85 90 95 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 Asn Pro Ser Val Thr Gly Leu Gln Tyr Ser Val Tyr Pro Ile Ile Trp 130 135 140 Ala Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn 145 150 155 160 Gly Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val 165 170 175 Trp Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala 180 185 190 Met Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu 195 200 205 Ile Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu 210 215 220 Lys Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala 225 230 235 240 Leu Met Ile Ala Ser Lys Glu Gly His Thr Glu Ile Val Gln Asp Leu 245 250 255 Leu Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr 260 265 270 Val Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala 275 280 285 Leu Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys 290 295 300 Thr Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg 305 310 315 320 Asp Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly 325 330 335 Glu Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val 340 345 350 Glu Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys 355 360 365 Gly Asp Thr Pro Leu His Ile Ala Ile Arg Gly Arg Ser Arg Lys Leu 370 375 380 Ala Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg 385 390 395 400 Pro Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln 405 410 415 Lys Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr 420 425 430 Glu Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu 435 440 445 Ala Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly 450 455 460 Leu Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu 465 470 475 480 Glu Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Ile Glu Pro Leu Phe 485 490 495 Gln Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly 500 505 510 Leu Gly Leu Leu Phe Ala Phe Thr Val His Pro Asn Leu Gly Ile Ala 515 520 525 Val Ser Leu Ser Phe Leu Ala Leu Leu Tyr Ile Phe Phe Ile Val Ile 530 535 540 Tyr Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Val 545 550 555 560 Leu Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Leu 565 570 575 Lys Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys 580 585 590 Ala Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser 595 600 605 Val Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp 610 615 620 Ala Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val 625 630 635 640 Phe Lys Thr Glu Asp Thr Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys 645 650 655 Cys Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Ile Gly Cys Ile Ile 660 665 670 Ser Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu 675 680 685 Thr Val Asn Ala Val Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala 690 695 700 Phe Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu 705 710 715 720 Asn Ser Gln Arg Lys Arg Leu His Asn Ala Ala Ser Lys Leu His Lys 725 730 735 Leu Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu 740 745 750 Met Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr 755 760 765 Arg Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys 770 775 780 Val Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro 785 790 795 800 Phe Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile 805 810 815 Asn Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His 820 825 830 Asp Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg 835 840 845 Gly Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly 850 855 860 Asp Val Pro Cys Ser Asp Thr Thr Gly Ile Gln Glu Asp Ala Asp Arg 865 870 875 880 Arg Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys 885 890 895 Thr Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg 900 905 910 Thr Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr 915 920 925 Glu Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu 930 935 940 Asn Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Ser 945 950 955 960 Phe Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp 965 970 975 Pro Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly 980 985 990 Ile Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg Ile Ser Lys 995 1000 1005 Asn Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp 1010 1015 1020 Gly Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro 1025 1030 1035 Val Leu Val Ala Arg Asp Val Lys Val Phe Leu Pro Cys Thr Val 1040 1045 1050 Asn Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala 1055 1060 1065 Ala Arg Glu Gln Ile Ser Ile Gly Gly Leu Ala Tyr Pro Pro Leu 1070 1075 1080 Pro Leu His Glu Gly Pro Pro Arg Ala Pro Ser Gly Tyr Ser Gln 1085 1090 1095 Pro Pro Ser Val Cys Ser Ser Thr Ser Phe Asn Gly Pro Phe Ala 1100 1105 1110 Gly Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly 1115 1120 1125 Met Thr Gly Pro Gln His Pro Phe Tyr Asn Arg Gly Ser Gly Pro 1130 1135 1140 Ala Pro Gly Pro Val Val Leu Leu Asn Ser Leu Asn Val Asp Ala 1145 1150 1155 Val Cys Glu Lys Leu Lys Gln Ile Glu Gly Leu Asp Gln Ser Met 1160 1165 1170 Leu Pro Gln Tyr Cys Thr Thr Ile Lys Lys Ala Asn Ile Asn Gly 1175 1180 1185 Arg Val Leu Ala Gln Cys Asn Ile Asp Glu Leu Lys Lys Glu Met 1190 1195 1200 Asn Met Asn Phe Gly Asp Trp His Leu Phe Arg Ser Thr Val Leu 1205 1210 1215 Glu Met Arg Asn Ala Glu Ser His Val Val Pro Glu Asp Pro Arg 1220 1225 1230 Phe Leu Ser Glu Ser Ser Ser Gly Pro Ala Pro His Gly Glu Pro 1235 1240 1245 Ala Arg Arg Ala Ser His Asn Glu Leu Pro His Thr Glu Leu Ser 1250 1255 1260 Ser Gln Thr Pro Tyr Thr Leu Asn Phe Ser Phe Glu Glu Leu Asn 1265 1270 1275 Thr Leu Gly Leu Asp Glu Gly Ala Pro Arg His Ser Asn Leu Ser 1280 1285 1290 Trp Gln Ser Gln Thr Arg Arg Thr Pro Ser Leu Ser Ser Leu Asn 1295 1300 1305 Ser Gln Asp Ser Ser Ile Glu Ile Ser Lys Leu Thr Asp Lys Val 1310 1315 1320 Gln Ala Glu Tyr Arg Asp Ala Tyr Arg Glu Tyr Ile Ala Gln Met 1325 1330 1335 Ser Gln Leu Glu Gly Gly Pro Gly Ser Thr Thr Ile Ser Gly Arg 1340 1345 1350 Ser Ser Pro His Ser Thr Tyr Tyr Met Gly Gln Ser Ser Ser Gly 1355 1360 1365 Gly Ser Ile His Ser Asn Leu Glu Gln Glu Lys Gly Lys Asp Ser 1370 1375 1380 Glu Pro Lys Pro Asp Asp Gly Arg Lys Ser Phe Leu Met Lys Arg 1385 1390 1395 Gly Asp Val Ile Asp Tyr Ser Ser Ser Gly Val Ser Thr Asn Asp 1400 1405 1410 Ala Ser Pro Leu Asp Pro Ile Thr Glu Glu Asp Glu Lys Ser Asp 1415 1420 1425 Gln Ser Gly Ser Lys Leu Leu Pro Gly Lys Lys Ser Ser Glu Arg 1430 1435 1440 Ser Ser Leu Phe Gln Thr Asp Leu Lys Leu Lys Gly Ser Gly Leu 1445 1450 1455 Arg Tyr Gln Lys Leu Pro Ser Asp Glu Asp Glu Ser Gly Thr Glu 1460 1465 1470 Glu Ser Asp Asn Thr Pro Leu Leu Lys Asp Asp Lys Asp Arg Lys 1475 1480 1485 Ala Glu Gly Lys Val Glu Arg Val Pro Lys Ser Pro Glu His Ser 1490 1495 1500 Ala Glu Pro Ile Arg Thr Phe Ile Lys Ala Lys Glu Tyr Leu Ser 1505 1510 1515 Asp Ala Leu Leu Asp Lys Lys Asp Ser Ser Asp Ser Gly Val Arg 1520 1525 1530 Ser Ser Glu Ser Ser Pro Asn His Ser Leu His Asn Glu Val Ala 1535 1540 1545 Asp Asp Ser Gln Leu Glu Lys Ala Asn Leu Ile Glu Leu Glu Asp 1550 1555 1560 Asp Ser His Ser Gly Lys Arg Gly Ile Pro His Ser Leu Ser Gly 1565 1570 1575 Leu Gln Asp Pro Ile Ile Ala Arg Met Ser Ile Cys Ser Glu Asp 1580 1585 1590 Lys Lys Ser Pro Ser Glu Cys Ser Leu Ile Ala Ser Ser Pro Glu 1595 1600 1605 Glu Asn Trp Pro Ala Cys Gln Lys Ala Tyr Asn Leu Asn Arg Thr 1610 1615 1620 Pro Ser Thr Val Thr Leu Asn Asn Asn Ser Ala Pro Ala Asn Arg 1625 1630 1635 Ala Asn Gln Asn Phe Asp Glu Met Glu Gly Ile Arg Glu Thr Ser 1640 1645 1650 Gln Val Ile Leu Arg Pro Ser Ser Ser Pro Asn Pro Thr Thr Ile 1655 1660 1665 Gln Asn Glu Asn Leu Lys Ser Met Thr His Lys Arg Ser Gln Arg 1670 1675 1680 Ser Ser Tyr Thr Arg Leu Ser Lys Asp Pro Pro Glu Leu His Ala 1685 1690 1695 Ala Ala Ser Ser Glu Ser Thr Gly Phe Gly Glu Glu Arg Glu Ser 1700 1705 1710 Ile Leu 1715 3 1184 PRT Homo sapiens 3 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Ile Ala Ala Glu Gln 35 40 45 Gly Asn Leu Glu Ile Val Lys Glu Leu Ile Lys Asn Gly Ala Asn Cys 50 55 60 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 Glu Gly His Val His Ile Val Glu Glu Leu Leu Lys Cys Gly Val Asn 85 90 95 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 Asn Pro Ser Val Thr Gly Leu Tyr Ser Val Tyr Pro Ile Ile Trp Ala 130 135 140 Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn Gly 145 150 155 160 Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp 165 170 175 Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala Met 180 185 190 Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu Ile 195 200 205 Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys 210 215 220 Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala Leu 225 230 235 240 Met Ile Ala Ser Lys Glu Gly His Thr Glu Ile Val Gln Asp Leu Leu 245 250 255 Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr Val 260 265 270 Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala Leu 275 280 285 Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys Thr 290 295 300 Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg Asp 305 310 315 320 Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly Glu 325 330 335 Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val Glu 340 345 350 Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys Gly 355 360 365 Asp Thr Pro Leu His Ile Ala Ile Arg Gly Arg Ser Arg Lys Leu Ala 370 375 380 Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro 385 390 395 400 Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln Lys 405 410 415 Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr Glu 420 425 430 Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala 435 440 445 Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly Leu 450 455 460 Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu Glu 465 470 475 480 Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Ile Glu Pro Leu Phe Gln 485 490 495 Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly Leu 500 505 510 Gly Leu Leu Phe Ala Phe Thr Val His Pro Asn Leu Gly Ile Ala Val 515 520 525 Ser Leu Ser Phe Leu Ala Leu Leu Tyr Ile Phe Phe Ile Val Ile Tyr 530 535 540 Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Val Leu 545 550 555 560 Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Leu Lys 565 570 575 Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys Ala 580 585 590 Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser Val 595 600 605 Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp Ala 610 615 620 Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val Phe 625 630 635 640 Lys Thr Glu Asp Thr Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys 645 650 655 Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Ile Gly Cys Ile Ile Ser 660 665 670 Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu Thr 675 680 685 Val Asn Ala Val Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala Phe 690 695 700 Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu Asn 705 710 715 720 Ser Gln Arg Lys Arg Leu His Asn Ala Ala Ser Lys Leu His Lys Leu 725 730 735 Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu Met 740 745 750 Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr Arg 755 760 765 Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys Val 770 775 780 Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro Phe 785 790 795 800 Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile Asn 805 810 815 Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His Asp 820 825 830 Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg Gly 835 840 845 Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly Asp 850 855 860 Val Pro Cys Ser Asp Thr Thr Gly Ile Gln Glu Asp Ala Asp Arg Arg 865 870 875 880 Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys Thr 885 890 895 Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr 900 905 910 Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr Glu 915 920 925 Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu Asn 930 935 940 Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Ser Phe 945 950 955 960 Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp Pro 965 970 975 Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly Ile 980 985 990 Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg Ile Ser Lys Asn 995 1000 1005 Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp Gly 1010 1015 1020 Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro Val 1025 1030 1035 Leu Val Ala Arg Asp Val Lys Val Phe Leu Pro Cys Thr Val Asn 1040 1045 1050 Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala Ala 1055 1060 1065 Arg Glu Gln Ile Ser Ile Gly Gly Leu Ala Tyr Pro Pro Leu Pro 1070 1075 1080 Leu His Glu Gly Pro Pro Arg Ala Pro Ser Gly Tyr Ser Gln Pro 1085 1090 1095 Pro Ser Val Cys Ser Ser Thr Ser Phe Asn Gly Pro Phe Ala Gly 1100 1105 1110 Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly Met 1115 1120 1125 Thr Gly Pro Gln His Pro Phe Tyr Asn Arg Pro Phe Phe Ala Pro 1130 1135 1140 Tyr Leu Tyr Thr Pro Arg Tyr Tyr Pro Gly Gly Ser Gln His Leu 1145 1150 1155 Ile Ser Arg Pro Ser Val Lys Thr Ser Leu Pro Arg Asp Gln Asn 1160 1165 1170 Asn Gly Leu Val Ser Tyr Gln Gly Gly Cys Cys 1175 1180 4 1771 PRT Homo sapiens 4 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Ile Ala Ala Glu Gln 35 40 45 Gly Asn Leu Glu Ile Val Lys Glu Leu Ile Lys Asn Gly Ala Asn Cys 50 55 60 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 Glu Gly His Val His Ile Val Glu Glu Leu Leu Lys Cys Gly Val Asn 85 90 95 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 Asn Pro Ser Val Thr Gly Leu Tyr Ser Val Tyr Pro Ile Ile Trp Ala 130 135 140 Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn Gly 145 150 155 160 Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp 165 170 175 Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala Met 180 185 190 Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu Ile 195 200 205 Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys 210 215 220 Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala Leu 225 230 235 240 Met Ile Ala Ser Lys Glu Gly His Thr Glu Ile Val Gln Asp Leu Leu 245 250 255 Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr Val 260 265 270 Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala Leu 275 280 285 Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys Thr 290 295 300 Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg Asp 305 310 315 320 Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly Glu 325 330 335 Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val Glu 340 345 350 Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys Gly 355 360 365 Asp Thr Pro Leu His Ile Ala Ile Arg Gly Arg Ser Arg Lys Leu Ala 370 375 380 Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro 385 390 395 400 Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln Lys 405 410 415 Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr Glu 420 425 430 Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala 435 440 445 Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly Leu 450 455 460 Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu Glu 465 470 475 480 Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Ile Glu Pro Leu Phe Gln 485 490 495 Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly Leu 500 505 510 Gly Leu Leu Phe Ala Phe Thr Val His Pro Asn Leu Gly Ile Ala Val 515 520 525 Ser Leu Ser Phe Leu Ala Leu Leu Tyr Ile Phe Phe Ile Val Ile Tyr 530 535 540 Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Val Leu 545 550 555 560 Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Leu Lys 565 570 575 Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys Ala 580 585 590 Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser Val 595 600 605 Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp Ala 610 615 620 Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val Phe 625 630 635 640 Lys Thr Glu Asp Thr Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys 645 650 655 Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Ile Gly Cys Ile Ile Ser 660 665 670 Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu Thr 675 680 685 Val Asn Ala Val Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala Phe 690 695 700 Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu Asn 705 710 715 720 Ser Gln Arg Lys Arg Leu His Asn Ala Ala Ser Lys Leu His Lys Leu 725 730 735 Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu Met 740 745 750 Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr Arg 755 760 765 Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys Val 770 775 780 Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro Phe 785 790 795 800 Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile Asn 805 810 815 Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His Asp 820 825 830 Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg Gly 835 840 845 Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly Asp 850 855 860 Val Pro Cys Ser Asp Thr Thr Gly Ile Gln Glu Asp Ala Asp Arg Arg 865 870 875 880 Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys Thr 885 890 895 Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr 900 905 910 Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr Glu 915 920 925 Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu Asn 930 935 940 Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Ser Phe 945 950 955 960 Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp Pro 965 970 975 Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly Ile 980 985 990 Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg Ile Ser Lys Asn 995 1000 1005 Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp Gly 1010 1015 1020 Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro Val 1025 1030 1035 Leu Val Ala Arg Asp Val Lys Val Phe Leu Pro Cys Thr Val Asn 1040 1045 1050 Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala Ala 1055 1060 1065 Arg Glu Gln Ile Ser Ile Gly Gly Leu Ala Tyr Pro Pro Leu Pro 1070 1075 1080 Leu His Glu Gly Pro Pro Arg Ala Pro Ser Gly Tyr Ser Gln Pro 1085 1090 1095 Pro Ser Val Cys Ser Ser Thr Ser Phe Asn Gly Pro Phe Ala Gly 1100 1105 1110 Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly Met 1115 1120 1125 Thr Gly Pro Gln His Pro Phe Tyr Asn Arg Pro Phe Phe Ala Pro 1130 1135 1140 Tyr Leu Tyr Thr Pro Arg Tyr Tyr Pro Gly Gly Ser Gln His Leu 1145 1150 1155 Ile Ser Arg Pro Ser Val Lys Thr Ser Leu Pro Arg Asp Gln Asn 1160 1165 1170 Asn Gly Leu Glu Val Ile Lys Glu Asp Ala Ala Glu Gly Leu Ser 1175 1180 1185 Ser Pro Thr Asp Ser Ser Arg Gly Ser Gly Pro Ala Pro Gly Pro 1190 1195 1200 Val Val Leu Leu Asn Ser Leu Asn Val Asp Ala Val Cys Glu Lys 1205 1210 1215 Leu Lys Gln Ile Glu Gly Leu Asp Gln Ser Met Leu Pro Gln Tyr 1220 1225 1230 Cys Thr Thr Ile Lys Lys Ala Asn Ile Asn Gly Arg Val Leu Ala 1235 1240 1245 Gln Cys Asn Ile Asp Glu Leu Lys Lys Glu Met Asn Met Asn Phe 1250 1255 1260 Gly Asp Trp His Leu Phe Arg Ser Thr Val Leu Glu Met Arg Asn 1265 1270 1275 Ala Glu Ser His Val Val Pro Glu Asp Pro Arg Phe Leu Ser Glu 1280 1285 1290 Ser Ser Ser Gly Pro Ala Pro His Gly Glu Pro Ala Arg Arg Ala 1295 1300 1305 Ser His Asn Glu Leu Pro His Thr Glu Leu Ser Ser Gln Thr Pro 1310 1315 1320 Tyr Thr Leu Asn Phe Ser Phe Glu Glu Leu Asn Thr Leu Gly Leu 1325 1330 1335 Asp Glu Gly Ala Pro Arg His Ser Asn Leu Ser Trp Gln Ser Gln 1340 1345 1350 Thr Arg Arg Thr Pro Ser Leu Ser Ser Leu Asn Ser Gln Asp Ser 1355 1360 1365 Ser Ile Glu Ile Ser Lys Leu Thr Asp Lys Val Gln Ala Glu Tyr 1370 1375 1380 Arg Asp Ala Tyr Arg Glu Tyr Ile Ala Gln Met Ser Gln Leu Glu 1385 1390 1395 Gly Gly Pro Gly Ser Thr Thr Ile Ser Gly Arg Ser Ser Pro His 1400 1405 1410 Ser Thr Tyr Tyr Met Gly Gln Ser Ser Ser Gly Gly Ser Ile His 1415 1420 1425 Ser Asn Leu Glu Gln Glu Lys Gly Lys Asp Ser Glu Pro Lys Pro 1430 1435 1440 Asp Asp Gly Arg Lys Ser Phe Leu Met Lys Arg Gly Asp Val Ile 1445 1450 1455 Asp Tyr Ser Ser Ser Gly Val Ser Thr Asn Asp Ala Ser Pro Leu 1460 1465 1470 Asp Pro Ile Thr Glu Glu Asp Glu Lys Ser Asp Gln Ser Gly Ser 1475 1480 1485 Lys Leu Leu Pro Gly Lys Lys Ser Ser Glu Arg Ser Ser Leu Phe 1490 1495 1500 Gln Thr Asp Leu Lys Leu Lys Gly Ser Gly Leu Arg Tyr Gln Lys 1505 1510 1515 Leu Pro Ser Asp Glu Asp Glu Ser Gly Thr Glu Glu Ser Asp Asn 1520 1525 1530 Thr Pro Leu Leu Lys Asp Asp Lys Asp Arg Lys Ala Glu Gly Lys 1535 1540 1545 Val Glu Arg Val Pro Lys Ser Pro Glu His Ser Ala Glu Pro Ile 1550 1555 1560 Arg Thr Phe Ile Lys Ala Lys Glu Tyr Leu Ser Asp Ala Leu Leu 1565 1570 1575 Asp Lys Lys Asp Ser Ser Asp Ser Gly Val Arg Ser Ser Glu Ser 1580 1585 1590 Ser Pro Asn His Ser Leu His Asn Glu Val Ala Asp Asp Ser Gln 1595 1600 1605 Leu Glu Lys Ala Asn Leu Ile Glu Leu Glu Asp Asp Ser His Ser 1610 1615 1620 Gly Lys Arg Gly Ile Pro His Ser Leu Ser Gly Leu Gln Asp Pro 1625 1630 1635 Ile Ile Ala Arg Met Ser Ile Cys Ser Glu Asp Lys Lys Ser Pro 1640 1645 1650 Ser Glu Cys Ser Leu Ile Ala Ser Ser Pro Glu Glu Asn Trp Pro 1655 1660 1665 Ala Cys Gln Lys Ala Tyr Asn Leu Asn Arg Thr Pro Ser Thr Val 1670 1675 1680 Thr Leu Asn Asn Asn Ser Ala Pro Ala Asn Arg Ala Asn Gln Asn 1685 1690 1695 Phe Asp Glu Met Glu Gly Ile Arg Glu Thr Ser Gln Val Ile Leu 1700 1705 1710 Arg Pro Ser Ser Ser Pro Asn Pro Thr Thr Ile Gln Asn Glu Asn 1715 1720 1725 Leu Lys Ser Met Thr His Lys Arg Ser Gln Arg Ser Ser Tyr Thr 1730 1735 1740 Arg Leu Ser Lys Asp Pro Pro Glu Leu His Ala Ala Ala Ser Ser 1745 1750 1755 Glu Ser Thr Gly Phe Gly Glu Glu Arg Glu Ser Ile Leu 1760 1765 1770 5 6 PRT Homo sapiens 5 Leu Gln Leu Ser Val Lys 1 5 6 1715 PRT Rattus norvegicus 6 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Leu Ala Ala Glu Gln 35 40 45 Gly Asn Val Glu Ile Val Lys Glu Leu Leu Lys Asn Gly Ala Asn Cys 50 55 60 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 Glu Gly His Ile His Ile Val Glu Glu Leu Leu Lys Ser Gly Ala Ser 85 90 95 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 Asn Pro Ser Val Thr Gly Leu Gln Tyr Ser Val Tyr Pro Ile Ile Trp 130 135 140 Ala Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn 145 150 155 160 Gly Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val 165 170 175 Trp Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala 180 185 190 Met Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu 195 200 205 Ile Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu 210 215 220 Lys Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala 225 230 235 240 Leu Met Ile Ala Ser Lys Glu Gly His Ile Glu Ile Val Gln Asp Leu 245 250 255 Leu Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr 260 265 270 Val Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala 275 280 285 Leu Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys 290 295 300 Thr Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg 305 310 315 320 Asp Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly 325 330 335 Glu Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val 340 345 350 Glu Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys 355 360 365 Gly Asp Thr Pro Leu His Val Ala Ile Arg Gly Arg Ser Arg Arg Leu 370 375 380 Ala Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg 385 390 395 400 Pro Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln 405 410 415 Lys Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr 420 425 430 Glu Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu 435 440 445 Ala Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly 450 455 460 Leu Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu 465 470 475 480 Glu Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Thr Glu Pro Leu Phe 485 490 495 Gln Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly 500 505 510 Leu Gly Leu Val Phe Ala Phe Pro Val Asp Thr Asn Leu Ala Ile Ala 515 520 525 Ile Ser Leu Ser Phe Leu Ala Leu Ile Tyr Ile Phe Phe Ile Val Ile 530 535 540 Tyr Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Ala 545 550 555 560 Leu Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Phe 565 570 575 Lys Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys 580 585 590 Ala Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser 595 600 605 Val Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp 610 615 620 Ala Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val 625 630 635 640 Phe Arg Thr Glu Glu Ser Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys 645 650 655 Cys Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Val Gly Cys Ile Ile 660 665 670 Ala Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu 675 680 685 Thr Val Asn Ala Ile Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala 690 695 700 Phe Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu 705 710 715 720 Asn Ser Gln Arg Lys Arg Leu His Ser Ala Ala Ser Lys Leu His Lys 725 730 735 Leu Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu 740 745 750 Met Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr 755 760 765 Arg Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys 770 775 780 Val Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro 785 790 795 800 Phe Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile 805 810 815 Asn Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His 820 825 830 Asp Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg 835 840 845 Gly Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly 850 855 860 Asp Ile Thr Cys Ser Asp Thr Thr Gly Thr Gln Glu Asp Thr Asp Arg 865 870 875 880 Arg Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys 885 890 895 Thr Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg 900 905 910 Thr Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr 915 920 925 Glu Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu 930 935 940 Asn Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Thr 945 950 955 960 Phe Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp 965 970 975 Pro Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly 980 985 990 Leu Pro Asp Gln Met Thr Leu Lys Thr Met Tyr Glu Arg Ile Ser Lys 995 1000 1005 Asn Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp 1010 1015 1020 Gly Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro 1025 1030 1035 Val Leu Val Ala Arg Asp Val Lys Thr Phe Leu Pro Cys Thr Val 1040 1045 1050 Asn Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala 1055 1060 1065 Ala Arg Glu Gln Ile Asn Ile Gly Gly Leu Ala Tyr Pro Pro Leu 1070 1075 1080 Pro Leu His Glu Gly Pro Pro Arg Pro Pro Ser Gly Tyr Ser Gln 1085 1090 1095 Pro Ala Ser Val Cys Ser Ser Ala Ser Phe Asn Gly Pro Phe Pro 1100 1105 1110 Gly Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly 1115 1120 1125 Leu Ser Gly Pro Gln His Pro Phe Tyr Asn Arg Ala Ala Val Pro 1130 1135 1140 Ala Thr Gly Ser Ser Leu Leu Leu Ser Ser Met Thr Val Asp Val 1145 1150 1155 Val Cys Glu Lys Leu Arg Gln Ile Glu Gly Leu Asp Gln Asn Met 1160 1165 1170 Met Pro Gln Tyr Cys Thr Thr Ile Lys Lys Ala Asn Ile Asn Gly 1175 1180 1185 Arg Val Leu Ser Gln Cys Asn Ile Asp Glu Leu Lys Lys Glu Met 1190 1195 1200 Ala Met Asn Phe Gly Asp Trp His Leu Phe Arg Ser Met Val Leu 1205 1210 1215 Glu Met Arg Ser Val Glu Ser Gln Val Val Pro Glu Asp Pro Arg 1220 1225 1230 Phe Leu Asn Glu Asn Ser Ser Ala Pro Val Pro His Gly Glu Ser 1235 1240 1245 Ala Arg Arg Ser Ser His Thr Glu Leu Pro Leu Thr Glu Leu Ser 1250 1255 1260 Ser Gln Thr Pro Tyr Thr Leu Asn Phe Ser Phe Glu Glu Leu Asn 1265 1270 1275 Thr Leu Gly Leu Asp Glu Gly Ala Pro Arg His Ser Asn Leu Ser 1280 1285 1290 Trp Gln Ser Gln Thr Arg Arg Thr Pro Ser Leu Ser Ser Leu Asn 1295 1300 1305 Ser Gln Asp Ser Ser Ile Glu Ile Ser Lys Leu Thr Asp Lys Val 1310 1315 1320 Gln Ala Glu Tyr Arg Asp Ala Tyr Arg Glu Tyr Ile Ala Gln Met 1325 1330 1335 Ser Gln Leu Glu Gly Gly Thr Gly Ser Ser Thr Ile Ser Gly Arg 1340 1345 1350 Ser Ser Pro His Ser Thr Tyr Tyr Ile Gly Gln Ser Ser Ser Gly 1355 1360 1365 Gly Ser Ile His Ser Thr Leu Glu Gln Glu Arg Gly Lys Glu Gly 1370 1375 1380 Glu Leu Lys Gln Glu Asp Gly Arg Lys Ser Phe Leu Met Lys Arg 1385 1390 1395 Gly Asp Val Ile Asp Tyr Ser Ser Ser Gly Val Ser Thr Asn Glu 1400 1405 1410 Ala Ser Pro Leu Asp Pro Ile Thr Glu Glu Asp Glu Lys Ser Asp 1415 1420 1425 Gln Ser Gly Ser Lys Leu Leu Pro Gly Lys Lys Ser Ser Glu Arg 1430 1435 1440 Pro Ser Leu Phe Gln Thr Asp Leu Lys Leu Lys Gly Gly Gly Leu 1445 1450 1455 Arg Tyr Gln Lys Leu Pro Ser Asp Glu Asp Glu Ser Gly Thr Gly 1460 1465 1470 Arg Val Gln Ile Thr Pro His Cys Ser Lys Met Ile Arg Thr Lys 1475 1480 1485 Arg Leu Lys Ala Lys Gln Arg Glu Cys Ala Ser Pro Gln Glu His 1490 1495 1500 Ser Ala Glu Pro Ile Arg Thr Phe Ile Lys Ala Lys Glu Tyr Leu 1505 1510 1515 Ser Asp Ala Leu Leu Asp Lys Lys Asp Ser Ser Asp Ser Gly Val 1520 1525 1530 Arg Ser Asn Glu Ser Ser Pro Asn His Ser Leu His Asn Glu Ala 1535 1540 1545 Ala Asp Asp Ser Gln Leu Glu Lys Ala Asn Leu Ile Glu Leu Glu 1550 1555 1560 Asp Glu Gly His Ser Gly Lys Arg Gly Met Pro His Ser Leu Ser 1565 1570 1575 Gly Leu Gln Asp Pro Ile Ile Ala Arg Met Ser Ile Cys Ser Glu 1580 1585 1590 Asp Lys Lys Ser Pro Ser Glu Cys Ser Leu Ile Ala Ser Ser Pro 1595 1600 1605 Glu Glu Ser Trp Pro Ala Cys Gln Lys Ala Tyr Asn Leu Asn Arg 1610 1615 1620 Thr Pro Ser Thr Val Thr Leu Asn Asn Asn Thr Ala Pro Thr Asn 1625 1630 1635 Arg Ala Asn Gln Asn Phe Asp Glu Ile Glu Gly Ile Arg Glu Thr 1640 1645 1650 Ser Gln Val Ile Leu Arg Pro Gly Pro Ser Pro Asn Pro Thr Ala 1655 1660 1665 Val Gln Asn Glu Asn Leu Lys Ser Met Ala His Lys Arg Ser Gln 1670 1675 1680 Arg Ser Ser Tyr Thr Arg Leu Ser Lys Asp Ala Ser Glu Leu His 1685 1690 1695 Ala Ala Ser Ser Glu Ser Thr Gly Phe Gly Glu Glu Arg Glu Ser 1700 1705 1710 Ile Leu 1715 7 1762 PRT Rattus norvegicus 7 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Leu Ala Ala Glu Gln 35 40 45 Gly Asn Val Glu Ile Val Lys Glu Leu Leu Lys Asn Gly Ala Asn Cys 50 55 60 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 Glu Gly His Ile His Ile Val Glu Glu Leu Leu Lys Ser Gly Ala Ser 85 90 95 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 Asn Pro Ser Val Thr Gly Leu Tyr Ser Val Tyr Pro Ile Ile Trp Ala 130 135 140 Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn Gly 145 150 155 160 Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp 165 170 175 Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala Met 180 185 190 Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu Ile 195 200 205 Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys 210 215 220 Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala Leu 225 230 235 240 Met Ile Ala Ser Lys Glu Gly His Ile Glu Ile Val Gln Asp Leu Leu 245 250 255 Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr Val 260 265 270 Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala Leu 275 280 285 Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys Thr 290 295 300 Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg Asp 305 310 315 320 Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly Glu 325 330 335 Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val Glu 340 345 350 Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys Gly 355 360 365 Asp Thr Pro Leu His Val Ala Ile Arg Gly Arg Ser Arg Arg Leu Ala 370 375 380 Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro 385 390 395 400 Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln Lys 405 410 415 Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr Glu 420 425 430 Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala 435 440 445 Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly Leu 450 455 460 Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu Glu 465 470 475 480 Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Thr Glu Pro Leu Phe Gln 485 490 495 Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly Leu 500 505 510 Gly Leu Val Phe Ala Phe Thr Val Asp Thr Asn Leu Ala Ile Ala Ile 515 520 525 Ser Leu Ser Phe Leu Ala Leu Ile Tyr Ile Phe Phe Ile Val Ile Tyr 530 535 540 Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Ala Leu 545 550 555 560 Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Phe Lys 565 570 575 Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys Ala 580 585 590 Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser Val 595 600 605 Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp Ala 610 615 620 Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val Phe 625 630 635 640 Arg Thr Glu Glu Ser Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys 645 650 655 Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Val Gly Cys Ile Ile Ala 660 665 670 Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu Thr 675 680 685 Val Asn Ala Ile Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala Phe 690 695 700 Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu Asn 705 710 715 720 Ser Gln Arg Lys Arg Leu His Ser Ala Ala Ser Lys Leu His Lys Leu 725 730 735 Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu Met 740 745 750 Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr Arg 755 760 765 Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys Val 770 775 780 Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro Phe 785 790 795 800 Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile Asn 805 810 815 Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His Asp 820 825 830 Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg Gly 835 840 845 Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly Asp 850 855 860 Ile Thr Cys Ser Asp Thr Thr Gly Thr Gln Glu Asp Thr Asp Arg Arg 865 870 875 880 Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys Thr 885 890 895 Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr 900 905 910 Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr Glu 915 920 925 Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu Asn 930 935 940 Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Thr Phe 945 950 955 960 Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp Pro 965 970 975 Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly Leu 980 985 990 Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg Ile Ser Lys Asn 995 1000 1005 Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp Gly 1010 1015 1020 Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro Val 1025 1030 1035 Leu Val Ala Arg Asp Val Lys Thr Phe Leu Pro Cys Thr Val Asn 1040 1045 1050 Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala Ala 1055 1060 1065 Arg Glu Gln Ile Asn Ile Gly Gly Leu Ala Tyr Pro Pro Leu Pro 1070 1075 1080 Leu His Glu Gly Pro Pro Arg Pro Pro Ser Gly Tyr Ser Gln Pro 1085 1090 1095 Ala Ser Val Cys Ser Ser Ala Ser Phe Asn Gly Pro Phe Pro Gly 1100 1105 1110 Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly Leu 1115 1120 1125 Ser Gly Pro Gln His Pro Phe Tyr Asn Arg Pro Phe Phe Ala Pro 1130 1135 1140 Tyr Leu Tyr Thr Pro Arg Tyr Tyr Pro Gly Gly Ser Gln His Leu 1145 1150 1155 Ile Ser Arg Ser Ser Val Lys Thr Ser Leu Pro Arg Asp Gln Asn 1160 1165 1170 Asn Gly Leu Pro Cys Asp Ser Gly Phe Asn Lys Gln Arg Gln Ala 1175 1180 1185 Ala Val Pro Ala Thr Gly Ser Ser Leu Leu Leu Ser Ser Met Thr 1190 1195 1200 Val Asp Val Val Cys Glu Lys Leu Arg Gln Ile Glu Gly Leu Asp 1205 1210 1215 Gln Ser Met Met Pro Gln Tyr Cys Thr Thr Ile Lys Lys Ala Asn 1220 1225 1230 Ile Asn Gly Arg Val Leu Ser Gln Cys Asn Ile Asp Glu Leu Lys 1235 1240 1245 Lys Glu Met Ala Met Asn Phe Gly Asp Trp His Leu Phe Arg Ser 1250 1255 1260 Met Val Leu Glu Met Arg Ser Val Glu Ser Gln Val Val Pro Glu 1265 1270 1275 Asp Pro Arg Phe Leu Asn Glu Asn Ser Ser Ala Pro Val Pro His 1280 1285 1290 Gly Glu Ser Ala Arg Arg Ser Ser His Thr Glu Leu Pro Leu Thr 1295 1300 1305 Glu Leu Ser Ser Gln Thr Pro Tyr Thr Leu Asn Phe Ser Phe Glu 1310 1315 1320 Glu Leu Asn Thr Leu Gly Leu Asp Glu Gly Ala Pro Arg His Ser 1325 1330 1335 Asn Leu Ser Trp Gln Ser Gln Thr Arg Arg Thr Pro Ser Leu Ser 1340 1345 1350 Ser Leu Asn Ser Gln Asp Ser Ser Ile Glu Ile Ser Lys Leu Thr 1355 1360 1365 Asp Lys Val Gln Ala Glu Tyr Arg Asp Ala Tyr Arg Glu Tyr Ile 1370 1375 1380 Ala Gln Met Ser Gln Leu Glu Gly Gly Thr Gly Ser Ser Thr Ile 1385 1390 1395 Ser Gly Arg Ser Ser Pro His Ser Thr Tyr Tyr Ile Gly Gln Ser 1400 1405 1410 Ser Ser Gly Gly Ser Ile His Ser Thr Leu Glu Gln Glu Arg Gly 1415 1420 1425 Lys Glu Gly Glu Leu Lys Gln Glu Asp Gly Arg Lys Ser Phe Leu 1430 1435 1440 Met Lys Arg Gly Asp Val Ile Asp Tyr Ser Ser Ser Gly Val Ser 1445 1450 1455 Thr Asn Glu Ala Ser Pro Leu Asp Pro Ile Thr Glu Glu Asp Glu 1460 1465 1470 Lys Ser Asp Gln Ser Gly Ser Lys Leu Leu Pro Gly Lys Lys Ser 1475 1480 1485 Ser Glu Arg Pro Ser Leu Phe Gln Thr Asp Leu Lys Leu Lys Gly 1490 1495 1500 Gly Gly Leu Arg Tyr Gln Lys Leu Pro Ser Asp Glu Asp Glu Ser 1505 1510 1515 Gly Thr Glu Glu Ser Asp Asn Thr Pro Leu Leu Lys Asp Asp Lys 1520 1525 1530 Asp Lys Lys Ala Glu Gly Lys Ala Glu Arg Val Cys Lys Ser Pro 1535 1540 1545 Glu His Ser Ala Glu Pro Ile Arg Thr Phe Ile Lys Ala Lys Glu 1550 1555 1560 Tyr Leu Ser Asp Ala Leu Leu Asp Lys Lys Asp Ser Ser Asp Ser 1565 1570 1575 Gly Val Arg Ser Asn Glu Ser Ser Pro Asn His Ser Leu His Asn 1580 1585 1590 Glu Ala Ala Asp Asp Ser Gln Leu Glu Lys Ala Asn Leu Ile Glu 1595 1600 1605 Leu Glu Asp Glu Gly His Ser Gly Lys Arg Gly Met Pro His Ser 1610 1615 1620 Leu Ser Gly Leu Gln Asp Pro Ile Ile Ala Arg Met Ser Ile Cys 1625 1630 1635 Ser Glu Asp Lys Lys Ser Pro Ser Glu Cys Ser Leu Ile Ala Ser 1640 1645 1650 Ser Pro Glu Glu Ser Trp Pro Ala Cys Gln Lys Ala Tyr Asn Leu 1655 1660 1665 Asn Arg Thr Pro Ser Thr Val Thr Leu Asn Asn Asn Thr Ala Pro 1670 1675 1680 Thr Asn Arg Ala Asn Gln Asn Phe Asp Glu Ile Glu Gly Ile Arg 1685 1690 1695 Glu Thr Ser Gln Val Ile Leu Arg Pro Gly Pro Ser Pro Asn Pro 1700 1705 1710 Thr Ala Val Gln Asn Glu Asn Leu Lys Ser Met Ala His Lys Arg 1715 1720 1725 Ser Gln Arg Ser Ser Tyr Thr Arg Leu Ser Lys Asp Ala Ser Glu 1730 1735 1740 Leu His Ala Ala Ser Ser Glu Ser Thr Gly Phe Gly Glu Glu Arg 1745 1750 1755 Glu Ser Ile Leu 1760 8 4140 DNA Homo sapiens CDS (158)..(3712) 8 ggaagaatat ggccgccggg tgtggtgagg gcgacgcgct tgcagtcgcc gtctcttgct 60 tccccgtcct ctgacatcgc ctgcagccga gcgggcccgt tccgccggag ctgaggacca 120 ggtattcaaa taaagttaat tgcagctttc tgtgaaa atg tca gtt ttg ata tca 175 Met Ser Val Leu Ile Ser 1 5 cag agc gtc ata aat tat gta gag gaa gaa aac att cct gct ctg aaa 223 Gln Ser Val Ile Asn Tyr Val Glu Glu Glu Asn Ile Pro Ala Leu Lys 10 15 20 gct ctt ctt gaa aaa tgc aaa gat gta gat gag aga aat gag tgt ggc 271 Ala Leu Leu Glu Lys Cys Lys Asp Val Asp Glu Arg Asn Glu Cys Gly 25 30 35 cag act cca ctg atg ata gct gcc gaa caa ggc aat ctg gaa ata gtg 319 Gln Thr Pro Leu Met Ile Ala Ala Glu Gln Gly Asn Leu Glu Ile Val 40 45 50 aag gaa tta att aag aat gga gct aac tgc aat ctg gaa gat ttg gat 367 Lys Glu Leu Ile Lys Asn Gly Ala Asn Cys Asn Leu Glu Asp Leu Asp 55 60 65 70 aat tgg aca gca ctt ata tct gca tcg aaa gaa ggg cat gtg cac atc 415 Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys Glu Gly His Val His Ile 75 80 85 gta gag gaa cta ctg aaa tgt ggg gtt aac ttg gag cac cgt gat atg 463 Val Glu Glu Leu Leu Lys Cys Gly Val Asn Leu Glu His Arg Asp Met 90 95 100 gga gga tgg aca gct ctt atg tgg gca tgt tac aaa ggc cgt act gac 511 Gly Gly Trp Thr Ala Leu Met Trp Ala Cys Tyr Lys Gly Arg Thr Asp 105 110 115 gta gta gag ttg ctt ctt tct cat ggt gcc aat cca agt gtc act ggt 559 Val Val Glu Leu Leu Leu Ser His Gly Ala Asn Pro Ser Val Thr Gly 120 125 130 ctg tac agt gtt tac cca atc att tgg gca gca ggg aga ggc cat gca 607 Leu Tyr Ser Val Tyr Pro Ile Ile Trp Ala Ala Gly Arg Gly His Ala 135 140 145 150 gat ata gtt cat ctt tta ctg caa aat ggt gct aaa gtc aac tgc tct 655 Asp Ile Val His Leu Leu Leu Gln Asn Gly Ala Lys Val Asn Cys Ser 155 160 165 gat aag tat gga acc acc cct tta gtt tgg gct gca cga aag ggt cat 703 Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp Ala Ala Arg Lys Gly His 170 175 180 ttg gaa tgt gtg aaa cat tta ttg gcc atg gga gct gat gtg gat caa 751 Leu Glu Cys Val Lys His Leu Leu Ala Met Gly Ala Asp Val Asp Gln 185 190 195 gaa gga gct aat tca atg act gca ctt att gtg gca gtg aaa gga ggt 799 Glu Gly Ala Asn Ser Met Thr Ala Leu Ile Val Ala Val Lys Gly Gly 200 205 210 tac aca cag tca gta aaa gaa att ttg aag agg aat cca aat gta aac 847 Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys Arg Asn Pro Asn Val Asn 215 220 225 230 tta aca gat aaa gat gga aat aca gct ttg atg att gca tca aag gag 895 Leu Thr Asp Lys Asp Gly Asn Thr Ala Leu Met Ile Ala Ser Lys Glu 235 240 245 gga cat acg gag att gtg cag gat ctg ctc gac gct gga aca tat gtg 943 Gly His Thr Glu Ile Val Gln Asp Leu Leu Asp Ala Gly Thr Tyr Val 250 255 260 aac ata cct gac agg agt ggg gat act gtg ttg att ggc gct gtc aga 991 Asn Ile Pro Asp Arg Ser Gly Asp Thr Val Leu Ile Gly Ala Val Arg 265 270 275 ggt ggt cat gtt gaa att gtt cga gcg ctt ctc caa aaa tat gct gat 1039 Gly Gly His Val Glu Ile Val Arg Ala Leu Leu Gln Lys Tyr Ala Asp 280 285 290 ata gac att aga gga cag gat aat aaa act gct ttg tat tgg gct gtt 1087 Ile Asp Ile Arg Gly Gln Asp Asn Lys Thr Ala Leu Tyr Trp Ala Val 295 300 305 310 gag aaa gga aat gca aca atg gtg aga gat atc tta cag tgc aat cct 1135 Glu Lys Gly Asn Ala Thr Met Val Arg Asp Ile Leu Gln Cys Asn Pro 315 320 325 gac act gaa ata tgc aca aag gat ggt gaa acg cca ctt ata aag gct 1183 Asp Thr Glu Ile Cys Thr Lys Asp Gly Glu Thr Pro Leu Ile Lys Ala 330 335 340 acc aag atg aga aac att gaa gtg gtg gag ctg ctg cta gat aaa ggt 1231 Thr Lys Met Arg Asn Ile Glu Val Val Glu Leu Leu Leu Asp Lys Gly 345 350 355 gct aaa gtg tct gct gta gat aag aaa gga gat act ccc ttg cat att 1279 Ala Lys Val Ser Ala Val Asp Lys Lys Gly Asp Thr Pro Leu His Ile 360 365 370 gct att cgt gga agg agc cgg aaa ctg gca gaa ctg ctt tta aga aat 1327 Ala Ile Arg Gly Arg Ser Arg Lys Leu Ala Glu Leu Leu Leu Arg Asn 375 380 385 390 ccc aaa gat ggg cga tta ctt tat agg ccc aac aaa gca ggc gag act 1375 Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro Asn Lys Ala Gly Glu Thr 395 400 405 cct tat aat att gac tgt agc cat cag aag agt att tta act caa ata 1423 Pro Tyr Asn Ile Asp Cys Ser His Gln Lys Ser Ile Leu Thr Gln Ile 410 415 420 ttt gga gcc aga cac ttg tct cct act gaa aca gac ggt gac atg ctt 1471 Phe Gly Ala Arg His Leu Ser Pro Thr Glu Thr Asp Gly Asp Met Leu 425 430 435 gga tat gat tta tat agc agt gcc ctg gca gat att ctc agt gag cct 1519 Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala Asp Ile Leu Ser Glu Pro 440 445 450 acc atg cag cca ccc att tgt gtg ggg tta tat gca cag tgg gga agt 1567 Thr Met Gln Pro Pro Ile Cys Val Gly Leu Tyr Ala Gln Trp Gly Ser 455 460 465 470 ggg aaa tct ttc tta ctc aag aaa cta gaa gac gaa atg aaa acc ttc 1615 Gly Lys Ser Phe Leu Leu Lys Lys Leu Glu Asp Glu Met Lys Thr Phe 475 480 485 gcc gga caa cag att gag cct ctc ttt cag ttc tca tgg ctc ata gtg 1663 Ala Gly Gln Gln Ile Glu Pro Leu Phe Gln Phe Ser Trp Leu Ile Val 490 495 500 ttt ctt acc ctg cta ctt tgt gga ggg ctt ggt tta ttg ttt gcc ttc 1711 Phe Leu Thr Leu Leu Leu Cys Gly Gly Leu Gly Leu Leu Phe Ala Phe 505 510 515 acg gtc cac cca aat ctt gga ata gca gtg tca ctg agc ttc ttg gct 1759 Thr Val His Pro Asn Leu Gly Ile Ala Val Ser Leu Ser Phe Leu Ala 520 525 530 ctc tta tat ata ttc ttt att gtc att tac ttt ggt gga cga aga gaa 1807 Leu Leu Tyr Ile Phe Phe Ile Val Ile Tyr Phe Gly Gly Arg Arg Glu 535 540 545 550 gga gag agt tgg aat tgg gcc tgg gtc ctc agc act aga ttg gca aga 1855 Gly Glu Ser Trp Asn Trp Ala Trp Val Leu Ser Thr Arg Leu Ala Arg 555 560 565 cat att gga tat ttg gaa ctc ctc ctt aaa ttg atg ttt gtg aat cca 1903 His Ile Gly Tyr Leu Glu Leu Leu Leu Lys Leu Met Phe Val Asn Pro 570 575 580 cct gag ttg cca gag cag act act aaa gct tta cct gtg agg ttt ttg 1951 Pro Glu Leu Pro Glu Gln Thr Thr Lys Ala Leu Pro Val Arg Phe Leu 585 590 595 ttt aca gat tac aat aga ctg tcc agt gta ggt gga gaa act tct ctg 1999 Phe Thr Asp Tyr Asn Arg Leu Ser Ser Val Gly Gly Glu Thr Ser Leu 600 605 610 gct gaa atg att gca acc ctc tcg gat gct tgt gaa aga gag ttt ggc 2047 Ala Glu Met Ile Ala Thr Leu Ser Asp Ala Cys Glu Arg Glu Phe Gly 615 620 625 630 ttt ttg gca acc agg ctt ttt cga gta ttc aag act gaa gat act cag 2095 Phe Leu Ala Thr Arg Leu Phe Arg Val Phe Lys Thr Glu Asp Thr Gln 635 640 645 ggt aaa aag aaa tgg aaa aaa aca tgt tgt ctc cca tct ttt gtc atc 2143 Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys Leu Pro Ser Phe Val Ile 650 655 660 ttc ctt ttt atc att ggc tgc att ata tct gga att act ctt ctg gct 2191 Phe Leu Phe Ile Ile Gly Cys Ile Ile Ser Gly Ile Thr Leu Leu Ala 665 670 675 ata ttt aga gtt gac cca aag cat ctg act gta aat gct gtc ctc ata 2239 Ile Phe Arg Val Asp Pro Lys His Leu Thr Val Asn Ala Val Leu Ile 680 685 690 tca atc gca tct gta gtg gga ttg gcc ttt gtg ttg aac tgt cgt aca 2287 Ser Ile Ala Ser Val Val Gly Leu Ala Phe Val Leu Asn Cys Arg Thr 695 700 705 710 tgg tgg caa gtg ctg gac tcg ctc ctg aat tcc caa aga aaa cgc ctc 2335 Trp Trp Gln Val Leu Asp Ser Leu Leu Asn Ser Gln Arg Lys Arg Leu 715 720 725 cat aat gca gcc tcc aaa ctg cac aaa ttg aaa agt gaa gga ttc atg 2383 His Asn Ala Ala Ser Lys Leu His Lys Leu Lys Ser Glu Gly Phe Met 730 735 740 aaa gtt ctt aaa tgt gaa gtg gaa ttg atg gcc agg atg gca aaa acc 2431 Lys Val Leu Lys Cys Glu Val Glu Leu Met Ala Arg Met Ala Lys Thr 745 750 755 att gac agc ttc act cag aat cag aca agg ctg gtg gtc atc atc gat 2479 Ile Asp Ser Phe Thr Gln Asn Gln Thr Arg Leu Val Val Ile Ile Asp 760 765 770 gga tta gat gcc tgt gag cag gac aaa gtc ctt cag atg ctg gac act 2527 Gly Leu Asp Ala Cys Glu Gln Asp Lys Val Leu Gln Met Leu Asp Thr 775 780 785 790 gtc cga gtt ctg ttt tca aaa ggc ccg ttc att gcc att ttt gca agt 2575 Val Arg Val Leu Phe Ser Lys Gly Pro Phe Ile Ala Ile Phe Ala Ser 795 800 805 gat cca cat att atc ata aag gca att aac cag aac ctc aat agt gtg 2623 Asp Pro His Ile Ile Ile Lys Ala Ile Asn Gln Asn Leu Asn Ser Val 810 815 820 ctt cgg gat tca aat ata aat ggc cat gac tac atg cgc aac ata gtc 2671 Leu Arg Asp Ser Asn Ile Asn Gly His Asp Tyr Met Arg Asn Ile Val 825 830 835 cac ttg cct gtg ttc ctt aat agt cgt gga cta agc aat gca aga aaa 2719 His Leu Pro Val Phe Leu Asn Ser Arg Gly Leu Ser Asn Ala Arg Lys 840 845 850 ttt ctc gta act tca gca aca aat gga gac gtt cca tgc tca gat act 2767 Phe Leu Val Thr Ser Ala Thr Asn Gly Asp Val Pro Cys Ser Asp Thr 855 860 865 870 aca ggg ata cag gaa gat gct gac aga aga gtt tca cag aac agc ctt 2815 Thr Gly Ile Gln Glu Asp Ala Asp Arg Arg Val Ser Gln Asn Ser Leu 875 880 885 ggg gag atg aca aaa ctt ggt agc aag aca gcc ctc aat aga cgg gac 2863 Gly Glu Met Thr Lys Leu Gly Ser Lys Thr Ala Leu Asn Arg Arg Asp 890 895 900 act tac cga aga agg cag atg cag agg acc atc act cgc cag atg tcc 2911 Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr Ile Thr Arg Gln Met Ser 905 910 915 ttt gat ctt aca aaa ctg ctg gtt acc gag gac tgg ttc agt gac atc 2959 Phe Asp Leu Thr Lys Leu Leu Val Thr Glu Asp Trp Phe Ser Asp Ile 920 925 930 agt ccc cag acc atg aga aga tta ctt aat att gtt tct gtg aca gga 3007 Ser Pro Gln Thr Met Arg Arg Leu Leu Asn Ile Val Ser Val Thr Gly 935 940 945 950 cga tta ctg aga gcc aat cag att agt ttc aac tgg gac agg ctt gct 3055 Arg Leu Leu Arg Ala Asn Gln Ile Ser Phe Asn Trp Asp Arg Leu Ala 955 960 965 agc tgg atc aac ctt act gag cag tgg cca tac cgg act tca tgg ctc 3103 Ser Trp Ile Asn Leu Thr Glu Gln Trp Pro Tyr Arg Thr Ser Trp Leu 970 975 980 ata tta tat ttg gaa gag act gaa ggt att cca gat caa atg aca tta 3151 Ile Leu Tyr Leu Glu Glu Thr Glu Gly Ile Pro Asp Gln Met Thr Leu 985 990 995 aaa acc atc tac gaa aga ata tca aag aat att cca aca act aag 3196 Lys Thr Ile Tyr Glu Arg Ile Ser Lys Asn Ile Pro Thr Thr Lys 1000 1005 1010 gat gtt gag cca ctt ctt gaa att gat gga gat ata aga aat ttt 3241 Asp Val Glu Pro Leu Leu Glu Ile Asp Gly Asp Ile Arg Asn Phe 1015 1020 1025 gaa gtg ttt ttg tct tca agg acc cca gtt ctt gtg gct cga gat 3286 Glu Val Phe Leu Ser Ser Arg Thr Pro Val Leu Val Ala Arg Asp 1030 1035 1040 gta aaa gtc ttt ttg cca tgc act gta aac cta gat ccc aaa cta 3331 Val Lys Val Phe Leu Pro Cys Thr Val Asn Leu Asp Pro Lys Leu 1045 1050 1055 cgg gaa att att gca gat gtt cgt gct gcc aga gag cag atc agt 3376 Arg Glu Ile Ile Ala Asp Val Arg Ala Ala Arg Glu Gln Ile Ser 1060 1065 1070 att gga gga ctg gcg tac ccc ccg ctc cct cta cat gag ggt cct 3421 Ile Gly Gly Leu Ala Tyr Pro Pro Leu Pro Leu His Glu Gly Pro 1075 1080 1085 cct agg gcg cca tca ggg tac agc cag ccc cca tcc gtg tgc tct 3466 Pro Arg Ala Pro Ser Gly Tyr Ser Gln Pro Pro Ser Val Cys Ser 1090 1095 1100 tcc acg tcc ttc aat ggg ccc ttc gca ggt gga gtg gtg tca cca 3511 Ser Thr Ser Phe Asn Gly Pro Phe Ala Gly Gly Val Val Ser Pro 1105 1110 1115 cag cct cac agc agc tat tac agc ggc atg acg ggc cct cag cat 3556 Gln Pro His Ser Ser Tyr Tyr Ser Gly Met Thr Gly Pro Gln His 1120 1125 1130 ccc ttc tac aac agg cca ttc ttt gcc cca tac ctt tac acg cca 3601 Pro Phe Tyr Asn Arg Pro Phe Phe Ala Pro Tyr Leu Tyr Thr Pro 1135 1140 1145 agg tat tac cct ggc ggc tcc caa cat ctc atc tca cgt cca tca 3646 Arg Tyr Tyr Pro Gly Gly Ser Gln His Leu Ile Ser Arg Pro Ser 1150 1155 1160 gta aaa acg agt ttg ccc aga gat cag aac aat ggc cta gta agt 3691 Val Lys Thr Ser Leu Pro Arg Asp Gln Asn Asn Gly Leu Val Ser 1165 1170 1175 tat caa gga gga tgc tgc tga ggggctttct tcacccacag actcctcgag 3742 Tyr Gln Gly Gly Cys Cys 1180 ggggtcaggc ccagccccag gcccagtggt attactgaat tcactgaatg tggatgcagt 3802 atgtgagaag ctgaaacaaa tagaagggct ggaccagagt atgctgcctc agtattgtac 3862 cacgatcaaa aaggcaaaca taaatggccg tgtgttagct cagtgtaaca ttgatgagct 3922 gaagaaagag atgaatatga attttggaga ctggcacctt ttcagaagca cagtactaga 3982 aatgagaaac gcagaaagcc acgtggtccc tgaagaccca cgtttcctca gtgagagcag 4042 cagtggccca gccccgcacg gtgagcctgc tcgccgcgct tcccacaacg agctgcctca 4102 caccgagctc tccagccaga cgccctacac actcaact 4140 9 1184 PRT Homo sapiens 9 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Ile Ala Ala Glu Gln 35 40 45 Gly Asn Leu Glu Ile Val Lys Glu Leu Ile Lys Asn Gly Ala Asn Cys 50 55 60 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 Glu Gly His Val His Ile Val Glu Glu Leu Leu Lys Cys Gly Val Asn 85 90 95 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 Asn Pro Ser Val Thr Gly Leu Tyr Ser Val Tyr Pro Ile Ile Trp Ala 130 135 140 Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn Gly 145 150 155 160 Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp 165 170 175 Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala Met 180 185 190 Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu Ile 195 200 205 Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys 210 215 220 Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala Leu 225 230 235 240 Met Ile Ala Ser Lys Glu Gly His Thr Glu Ile Val Gln Asp Leu Leu 245 250 255 Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr Val 260 265 270 Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala Leu 275 280 285 Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys Thr 290 295 300 Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg Asp 305 310 315 320 Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly Glu 325 330 335 Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val Glu 340 345 350 Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys Gly 355 360 365 Asp Thr Pro Leu His Ile Ala Ile Arg Gly Arg Ser Arg Lys Leu Ala 370 375 380 Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro 385 390 395 400 Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln Lys 405 410 415 Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr Glu 420 425 430 Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala 435 440 445 Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly Leu 450 455 460 Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu Glu 465 470 475 480 Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Ile Glu Pro Leu Phe Gln 485 490 495 Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly Leu 500 505 510 Gly Leu Leu Phe Ala Phe Thr Val His Pro Asn Leu Gly Ile Ala Val 515 520 525 Ser Leu Ser Phe Leu Ala Leu Leu Tyr Ile Phe Phe Ile Val Ile Tyr 530 535 540 Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Val Leu 545 550 555 560 Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Leu Lys 565 570 575 Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys Ala 580 585 590 Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser Val 595 600 605 Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp Ala 610 615 620 Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val Phe 625 630 635 640 Lys Thr Glu Asp Thr Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys 645 650 655 Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Ile Gly Cys Ile Ile Ser 660 665 670 Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu Thr 675 680 685 Val Asn Ala Val Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala Phe 690 695 700 Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu Asn 705 710 715 720 Ser Gln Arg Lys Arg Leu His Asn Ala Ala Ser Lys Leu His Lys Leu 725 730 735 Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu Met 740 745 750 Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr Arg 755 760 765 Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys Val 770 775 780 Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro Phe 785 790 795 800 Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile Asn 805 810 815 Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His Asp 820 825 830 Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg Gly 835 840 845 Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly Asp 850 855 860 Val Pro Cys Ser Asp Thr Thr Gly Ile Gln Glu Asp Ala Asp Arg Arg 865 870 875 880 Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys Thr 885 890 895 Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr 900 905 910 Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr Glu 915 920 925 Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu Asn 930 935 940 Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Ser Phe 945 950 955 960 Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp Pro 965 970 975 Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly Ile 980 985 990 Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg Ile Ser Lys Asn 995 1000 1005 Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp Gly 1010 1015 1020 Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro Val 1025 1030 1035 Leu Val Ala Arg Asp Val Lys Val Phe Leu Pro Cys Thr Val Asn 1040 1045 1050 Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala Ala 1055 1060 1065 Arg Glu Gln Ile Ser Ile Gly Gly Leu Ala Tyr Pro Pro Leu Pro 1070 1075 1080 Leu His Glu Gly Pro Pro Arg Ala Pro Ser Gly Tyr Ser Gln Pro 1085 1090 1095 Pro Ser Val Cys Ser Ser Thr Ser Phe Asn Gly Pro Phe Ala Gly 1100 1105 1110 Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly Met 1115 1120 1125 Thr Gly Pro Gln His Pro Phe Tyr Asn Arg Pro Phe Phe Ala Pro 1130 1135 1140 Tyr Leu Tyr Thr Pro Arg Tyr Tyr Pro Gly Gly Ser Gln His Leu 1145 1150 1155 Ile Ser Arg Pro Ser Val Lys Thr Ser Leu Pro Arg Asp Gln Asn 1160 1165 1170 Asn Gly Leu Val Ser Tyr Gln Gly Gly Cys Cys 1175 1180 10 5363 DNA Homo sapiens CDS (1)..(5313) 10 atg tca gtt ttg ata tca cag agc gtc ata aat tat gta gag gaa gaa 48 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 aac att cct gct ctg aaa gct ctt ctt gaa aaa tgc aaa gat gta gat 96 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 gag aga aat gag tgt ggc cag act cca ctg atg ata gct gcc gaa caa 144 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Ile Ala Ala Glu Gln 35 40 45 ggc aat ctg gaa ata gtg aag gaa tta att aag aat gga gct aac tgc 192 Gly Asn Leu Glu Ile Val Lys Glu Leu Ile Lys Asn Gly Ala Asn Cys 50 55 60 aat ctg gaa gat ttg gat aat tgg aca gca ctt ata tct gca tcg aaa 240 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 gaa ggg cat gtg cac atc gta gag gaa cta ctg aaa tgt ggg gtt aac 288 Glu Gly His Val His Ile Val Glu Glu Leu Leu Lys Cys Gly Val Asn 85 90 95 ttg gag cac cgt gat atg gga gga tgg aca gct ctt atg tgg gca tgt 336 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 tac aaa ggc cgt act gac gta gta gag ttg ctt ctt tct cat ggt gcc 384 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 aat cca agt gtc act ggt ctg tac agt gtt tac cca atc att tgg gca 432 Asn Pro Ser Val Thr Gly Leu Tyr Ser Val Tyr Pro Ile Ile Trp Ala 130 135 140 gca ggg aga ggc cat gca gat ata gtt cat ctt tta ctg caa aat ggt 480 Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn Gly 145 150 155 160 gct aaa gtc aac tgc tct gat aag tat gga acc acc cct tta gtt tgg 528 Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp 165 170 175 gct gca cga aag ggt cat ttg gaa tgt gtg aaa cat tta ttg gcc atg 576 Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala Met 180 185 190 gga gct gat gtg gat caa gaa gga gct aat tca atg act gca ctt att 624 Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu Ile 195 200 205 gtg gca gtg aaa gga ggt tac aca cag tca gta aaa gaa att ttg aag 672 Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys 210 215 220 agg aat cca aat gta aac tta aca gat aaa gat gga aat aca gct ttg 720 Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala Leu 225 230 235 240 atg att gca tca aag gag gga cat acg gag att gtg cag gat ctg ctc 768 Met Ile Ala Ser Lys Glu Gly His Thr Glu Ile Val Gln Asp Leu Leu 245 250 255 gac gct gga aca tat gtg aac ata cct gac agg agt ggg gat act gtg 816 Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr Val 260 265 270 ttg att ggc gct gtc aga ggt ggt cat gtt gaa att gtt cga gcg ctt 864 Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala Leu 275 280 285 ctc caa aaa tat gct gat ata gac att aga gga cag gat aat aaa act 912 Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys Thr 290 295 300 gct ttg tat tgg gct gtt gag aaa gga aat gca aca atg gtg aga gat 960 Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg Asp 305 310 315 320 atc tta cag tgc aat cct gac act gaa ata tgc aca aag gat ggt gaa 1008 Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly Glu 325 330 335 acg cca ctt ata aag gct acc aag atg aga aac att gaa gtg gtg gag 1056 Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val Glu 340 345 350 ctg ctg cta gat aaa ggt gct aaa gtg tct gct gta gat aag aaa gga 1104 Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys Gly 355 360 365 gat act ccc ttg cat att gct att cgt gga agg agc cgg aaa ctg gca 1152 Asp Thr Pro Leu His Ile Ala Ile Arg Gly Arg Ser Arg Lys Leu Ala 370 375 380 gaa ctg ctt tta aga aat ccc aaa gat ggg cga tta ctt tat agg ccc 1200 Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro 385 390 395 400 aac aaa gca ggc gag act cct tat aat att gac tgt agc cat cag aag 1248 Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln Lys 405 410 415 agt att tta act caa ata ttt gga gcc aga cac ttg tct cct act gaa 1296 Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr Glu 420 425 430 aca gac ggt gac atg ctt gga tat gat tta tat agc agt gcc ctg gca 1344 Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala 435 440 445 gat att ctc agt gag cct acc atg cag cca ccc att tgt gtg ggg tta 1392 Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly Leu 450 455 460 tat gca cag tgg gga agt ggg aaa tct ttc tta ctc aag aaa cta gaa 1440 Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu Glu 465 470 475 480 gac gaa atg aaa acc ttc gcc gga caa cag att gag cct ctc ttt cag 1488 Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Ile Glu Pro Leu Phe Gln 485 490 495 ttc tca tgg ctc ata gtg ttt ctt acc ctg cta ctt tgt gga ggg ctt 1536 Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly Leu 500 505 510 ggt tta ttg ttt gcc ttc acg gtc cac cca aat ctt gga ata gca gtg 1584 Gly Leu Leu Phe Ala Phe Thr Val His Pro Asn Leu Gly Ile Ala Val 515 520 525 tca ctg agc ttc ttg gct ctc tta tat ata ttc ttt att gtc att tac 1632 Ser Leu Ser Phe Leu Ala Leu Leu Tyr Ile Phe Phe Ile Val Ile Tyr 530 535 540 ttt ggt gga cga aga gaa gga gag agt tgg aat tgg gcc tgg gtc ctc 1680 Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Val Leu 545 550 555 560 agc act aga ttg gca aga cat att gga tat ttg gaa ctc ctc ctt aaa 1728 Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Leu Lys 565 570 575 ttg atg ttt gtg aat cca cct gag ttg cca gag cag act act aaa gct 1776 Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys Ala 580 585 590 tta cct gtg agg ttt ttg ttt aca gat tac aat aga ctg tcc agt gta 1824 Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser Val 595 600 605 ggt gga gaa act tct ctg gct gaa atg att gca acc ctc tcg gat gct 1872 Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp Ala 610 615 620 tgt gaa aga gag ttt ggc ttt ttg gca acc agg ctt ttt cga gta ttc 1920 Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val Phe 625 630 635 640 aag act gaa gat act cag ggt aaa aag aaa tgg aaa aaa aca tgt tgt 1968 Lys Thr Glu Asp Thr Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys 645 650 655 ctc cca tct ttt gtc atc ttc ctt ttt atc att ggc tgc att ata tct 2016 Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Ile Gly Cys Ile Ile Ser 660 665 670 gga att act ctt ctg gct ata ttt aga gtt gac cca aag cat ctg act 2064 Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu Thr 675 680 685 gta aat gct gtc ctc ata tca atc gca tct gta gtg gga ttg gcc ttt 2112 Val Asn Ala Val Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala Phe 690 695 700 gtg ttg aac tgt cgt aca tgg tgg caa gtg ctg gac tcg ctc ctg aat 2160 Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu Asn 705 710 715 720 tcc caa aga aaa cgc ctc cat aat gca gcc tcc aaa ctg cac aaa ttg 2208 Ser Gln Arg Lys Arg Leu His Asn Ala Ala Ser Lys Leu His Lys Leu 725 730 735 aaa agt gaa gga ttc atg aaa gtt ctt aaa tgt gaa gtg gaa ttg atg 2256 Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu Met 740 745 750 gcc agg atg gca aaa acc att gac agc ttc act cag aat cag aca agg 2304 Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr Arg 755 760 765 ctg gtg gtc atc atc gat gga tta gat gcc tgt gag cag gac aaa gtc 2352 Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys Val 770 775 780 ctt cag atg ctg gac act gtc cga gtt ctg ttt tca aaa ggc ccg ttc 2400 Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro Phe 785 790 795 800 att gcc att ttt gca agt gat cca cat att atc ata aag gca att aac 2448 Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile Asn 805 810 815 cag aac ctc aat agt gtg ctt cgg gat tca aat ata aat ggc cat gac 2496 Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His Asp 820 825 830 tac atg cgc aac ata gtc cac ttg cct gtg ttc ctt aat agt cgt gga 2544 Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg Gly 835 840 845 cta agc aat gca aga aaa ttt ctc gta act tca gca aca aat gga gac 2592 Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly Asp 850 855 860 gtt cca tgc tca gat act aca ggg ata cag gaa gat gct gac aga aga 2640 Val Pro Cys Ser Asp Thr Thr Gly Ile Gln Glu Asp Ala Asp Arg Arg 865 870 875 880 gtt tca cag aac agc ctt ggg gag atg aca aaa ctt ggt agc aag aca 2688 Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys Thr 885 890 895 gcc ctc aat aga cgg gac act tac cga aga agg cag atg cag agg acc 2736 Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr 900 905 910 atc act cgc cag atg tcc ttt gat ctt aca aaa ctg ctg gtt acc gag 2784 Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr Glu 915 920 925 gac tgg ttc agt gac atc agt ccc cag acc atg aga aga tta ctt aat 2832 Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu Asn 930 935 940 att gtt tct gtg aca gga cga tta ctg aga gcc aat cag att agt ttc 2880 Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Ser Phe 945 950 955 960 aac tgg gac agg ctt gct agc tgg atc aac ctt act gag cag tgg cca 2928 Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp Pro 965 970 975 tac cgg act tca tgg ctc ata tta tat ttg gaa gag act gaa ggt att 2976 Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly Ile 980 985 990 cca gat caa atg aca tta aaa acc atc tac gaa aga ata tca aag aat 3024 Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg Ile Ser Lys Asn 995 1000 1005 att cca aca act aag gat gtt gag cca ctt ctt gaa att gat gga 3069 Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp Gly 1010 1015 1020 gat ata aga aat ttt gaa gtg ttt ttg tct tca agg acc cca gtt 3114 Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro Val 1025 1030 1035 ctt gtg gct cga gat gta aaa gtc ttt ttg cca tgc act gta aac 3159 Leu Val Ala Arg Asp Val Lys Val Phe Leu Pro Cys Thr Val Asn 1040 1045 1050 cta gat ccc aaa cta cgg gaa att att gca gat gtt cgt gct gcc 3204 Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala Ala 1055 1060 1065 aga gag cag atc agt att gga gga ctg gcg tac ccc ccg ctc cct 3249 Arg Glu Gln Ile Ser Ile Gly Gly Leu Ala Tyr Pro Pro Leu Pro 1070 1075 1080 cta cat gag ggt cct cct agg gcg cca tca ggg tac agc cag ccc 3294 Leu His Glu Gly Pro Pro Arg Ala Pro Ser Gly Tyr Ser Gln Pro 1085 1090 1095 cca tcc gtg tgc tct tcc acg tcc ttc aat ggg ccc ttc gca ggt 3339 Pro Ser Val Cys Ser Ser Thr Ser Phe Asn Gly Pro Phe Ala Gly 1100 1105 1110 gga gtg gtg tca cca cag cct cac agc agc tat tac agc ggc atg 3384 Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly Met 1115 1120 1125 acg ggc cct cag cat ccc ttc tac aac agg cca ttc ttt gcc cca 3429 Thr Gly Pro Gln His Pro Phe Tyr Asn Arg Pro Phe Phe Ala Pro 1130 1135 1140 tac ctt tac acg cca agg tat tac cct ggc ggc tcc caa cat ctc 3474 Tyr Leu Tyr Thr Pro Arg Tyr Tyr Pro Gly Gly Ser Gln His Leu 1145 1150 1155 atc tca cgt cca tca gta aaa acg agt ttg ccc aga gat cag aac 3519 Ile Ser Arg Pro Ser Val Lys Thr Ser Leu Pro Arg Asp Gln Asn 1160 1165 1170 aat ggc cta gaa gtt atc aag gag gat gct gct gag ggg ctt tct 3564 Asn Gly Leu Glu Val Ile Lys Glu Asp Ala Ala Glu Gly Leu Ser 1175 1180 1185 tca ccc aca gac tcc tcg agg ggg tca ggc cca gcc cca ggc cca 3609 Ser Pro Thr Asp Ser Ser Arg Gly Ser Gly Pro Ala Pro Gly Pro 1190 1195 1200 gtg gta tta ctg aat tca ctg aat gtg gat gca gta tgt gag aag 3654 Val Val Leu Leu Asn Ser Leu Asn Val Asp Ala Val Cys Glu Lys 1205 1210 1215 ctg aaa caa ata gaa ggg ctg gac cag agt atg ctg cct cag tat 3699 Leu Lys Gln Ile Glu Gly Leu Asp Gln Ser Met Leu Pro Gln Tyr 1220 1225 1230 tgt acc acg atc aaa aag gca aac ata aat ggc cgt gtg tta gct 3744 Cys Thr Thr Ile Lys Lys Ala Asn Ile Asn Gly Arg Val Leu Ala 1235 1240 1245 cag tgt aac att gat gag ctg aag aaa gag atg aat atg aat ttt 3789 Gln Cys Asn Ile Asp Glu Leu Lys Lys Glu Met Asn Met Asn Phe 1250 1255 1260 gga gac tgg cac ctt ttc aga agc aca gta cta gaa atg aga aac 3834 Gly Asp Trp His Leu Phe Arg Ser Thr Val Leu Glu Met Arg Asn 1265 1270 1275 gca gaa agc cac gtg gtc cct gaa gac cca cgt ttc ctc agt gag 3879 Ala Glu Ser His Val Val Pro Glu Asp Pro Arg Phe Leu Ser Glu 1280 1285 1290 agc agc agt ggc cca gcc ccg cac ggt gag cct gct cgc cgc gct 3924 Ser Ser Ser Gly Pro Ala Pro His Gly Glu Pro Ala Arg Arg Ala 1295 1300 1305 tcc cac aac gag ctg cct cac acc gag ctc tcc agc cag acg ccc 3969 Ser His Asn Glu Leu Pro His Thr Glu Leu Ser Ser Gln Thr Pro 1310 1315 1320 tac aca ctc aac ttc agc ttc gaa gag ctg aac acg ctt ggc ctg 4014 Tyr Thr Leu Asn Phe Ser Phe Glu Glu Leu Asn Thr Leu Gly Leu 1325 1330 1335 gat gaa ggt gcc cct cgt cac agt aat cta agt tgg cag tca caa 4059 Asp Glu Gly Ala Pro Arg His Ser Asn Leu Ser Trp Gln Ser Gln 1340 1345 1350 act cgc aga acc cca agt ctt tcg agt ctc aat tcc cag gat tcc 4104 Thr Arg Arg Thr Pro Ser Leu Ser Ser Leu Asn Ser Gln Asp Ser 1355 1360 1365 agt att gaa att tca aag ctt act gat aag gtg cag gcc gag tat 4149 Ser Ile Glu Ile Ser Lys Leu Thr Asp Lys Val Gln Ala Glu Tyr 1370 1375 1380 aga gat gcc tat aga gaa tac att gct cag atg tcc cag tta gaa 4194 Arg Asp Ala Tyr Arg Glu Tyr Ile Ala Gln Met Ser Gln Leu Glu 1385 1390 1395 ggg ggc ccc ggg tct aca acc att agt ggc aga tct tct cca cat 4239 Gly Gly Pro Gly Ser Thr Thr Ile Ser Gly Arg Ser Ser Pro His 1400 1405 1410 agc aca tat tac atg ggt cag agt tca tca ggg ggc tct att cat 4284 Ser Thr Tyr Tyr Met Gly Gln Ser Ser Ser Gly Gly Ser Ile His 1415 1420 1425 tca aac cta gag caa gaa aag ggg aag gat agt gaa cca aag ccc 4329 Ser Asn Leu Glu Gln Glu Lys Gly Lys Asp Ser Glu Pro Lys Pro 1430 1435 1440 gat gat ggg agg aag tcc ttt cta atg aag agg gga gat gtt atc 4374 Asp Asp Gly Arg Lys Ser Phe Leu Met Lys Arg Gly Asp Val Ile 1445 1450 1455 gat tat tca tca tca ggg gtt tcc acc aac gat gct tcc ccc ctg 4419 Asp Tyr Ser Ser Ser Gly Val Ser Thr Asn Asp Ala Ser Pro Leu 1460 1465 1470 gat cct atc act gaa gaa gat gaa aaa tca gat cag tca ggc agt 4464 Asp Pro Ile Thr Glu Glu Asp Glu Lys Ser Asp Gln Ser Gly Ser 1475 1480 1485 aag ctt ctc cca ggc aag aaa tct tcc gaa agg tca agc ctc ttc 4509 Lys Leu Leu Pro Gly Lys Lys Ser Ser Glu Arg Ser Ser Leu Phe 1490 1495 1500 cag aca gat ttg aag ctt aag gga agt ggg ctg cgc tat caa aaa 4554 Gln Thr Asp Leu Lys Leu Lys Gly Ser Gly Leu Arg Tyr Gln Lys 1505 1510 1515 ctc cca agt gac gag gat gaa tct ggc aca gaa gaa tca gat aac 4599 Leu Pro Ser Asp Glu Asp Glu Ser Gly Thr Glu Glu Ser Asp Asn 1520 1525 1530 act cca ctg ctc aaa gat gac aaa gac aga aaa gcc gaa ggg aaa 4644 Thr Pro Leu Leu Lys Asp Asp Lys Asp Arg Lys Ala Glu Gly Lys 1535 1540 1545 gta gag aga gtg ccg aag tct cca gaa cac agt gct gag ccg atc 4689 Val Glu Arg Val Pro Lys Ser Pro Glu His Ser Ala Glu Pro Ile 1550 1555 1560 aga acc ttc att aaa gcc aaa gag tat tta tcg gat gcg ctc ctt 4734 Arg Thr Phe Ile Lys Ala Lys Glu Tyr Leu Ser Asp Ala Leu Leu 1565 1570 1575 gac aaa aag gat tca tcg gat tca gga gtg aga tcc agt gaa agt 4779 Asp Lys Lys Asp Ser Ser Asp Ser Gly Val Arg Ser Ser Glu Ser 1580 1585 1590 tct ccc aat cac tct ctg cac aat gaa gtg gcg gat gac tcc cag 4824 Ser Pro Asn His Ser Leu His Asn Glu Val Ala Asp Asp Ser Gln 1595 1600 1605 ctt gaa aag gca aat ctc ata gag ctg gaa gat gac agt cac agc 4869 Leu Glu Lys Ala Asn Leu Ile Glu Leu Glu Asp Asp Ser His Ser 1610 1615 1620 gga aag cgg gga atc cca cat agc ctg agt ggc ctg caa gat cca 4914 Gly Lys Arg Gly Ile Pro His Ser Leu Ser Gly Leu Gln Asp Pro 1625 1630 1635 att ata gct cgg atg tcc att tgt tca gaa gac aag aaa agc cct 4959 Ile Ile Ala Arg Met Ser Ile Cys Ser Glu Asp Lys Lys Ser Pro 1640 1645 1650 tcc gaa tgc agc ttg ata gcc agc agc cct gaa gaa aac tgg cct 5004 Ser Glu Cys Ser Leu Ile Ala Ser Ser Pro Glu Glu Asn Trp Pro 1655 1660 1665 gca tgc cag aaa gcc tac aac ctg aac cga act ccc agc acc gtg 5049 Ala Cys Gln Lys Ala Tyr Asn Leu Asn Arg Thr Pro Ser Thr Val 1670 1675 1680 act ctg aac aac aat agt gct cca gcc aac aga gcc aat caa aat 5094 Thr Leu Asn Asn Asn Ser Ala Pro Ala Asn Arg Ala Asn Gln Asn 1685 1690 1695 ttc gat gag atg gag gga att agg gag act tct caa gtc att ttg 5139 Phe Asp Glu Met Glu Gly Ile Arg Glu Thr Ser Gln Val Ile Leu 1700 1705 1710 agg cct agt tcc agt ccc aac cca acc act att cag aat gag aat 5184 Arg Pro Ser Ser Ser Pro Asn Pro Thr Thr Ile Gln Asn Glu Asn 1715 1720 1725 cta aaa agc atg aca cat aag cga agc caa cgt tca agt tac aca 5229 Leu Lys Ser Met Thr His Lys Arg Ser Gln Arg Ser Ser Tyr Thr 1730 1735 1740 agg ctc tcc aaa gat cct ccg gag ctc cat gca gca gcc tct tct 5274 Arg Leu Ser Lys Asp Pro Pro Glu Leu His Ala Ala Ala Ser Ser 1745 1750 1755 gag agc aca ggc ttt gga gaa gaa aga gaa agc att ctt tgagaaaaac 5323 Glu Ser Thr Gly Phe Gly Glu Glu Arg Glu Ser Ile Leu 1760 1765 1770 aagcaaagga gaagagtgtt actgtaccct tatgacagaa 5363 11 1771 PRT Homo sapiens 11 Met Ser Val Leu Ile Ser Gln Ser Val Ile Asn Tyr Val Glu Glu Glu 1 5 10 15 Asn Ile Pro Ala Leu Lys Ala Leu Leu Glu Lys Cys Lys Asp Val Asp 20 25 30 Glu Arg Asn Glu Cys Gly Gln Thr Pro Leu Met Ile Ala Ala Glu Gln 35 40 45 Gly Asn Leu Glu Ile Val Lys Glu Leu Ile Lys Asn Gly Ala Asn Cys 50 55 60 Asn Leu Glu Asp Leu Asp Asn Trp Thr Ala Leu Ile Ser Ala Ser Lys 65 70 75 80 Glu Gly His Val His Ile Val Glu Glu Leu Leu Lys Cys Gly Val Asn 85 90 95 Leu Glu His Arg Asp Met Gly Gly Trp Thr Ala Leu Met Trp Ala Cys 100 105 110 Tyr Lys Gly Arg Thr Asp Val Val Glu Leu Leu Leu Ser His Gly Ala 115 120 125 Asn Pro Ser Val Thr Gly Leu Tyr Ser Val Tyr Pro Ile Ile Trp Ala 130 135 140 Ala Gly Arg Gly His Ala Asp Ile Val His Leu Leu Leu Gln Asn Gly 145 150 155 160 Ala Lys Val Asn Cys Ser Asp Lys Tyr Gly Thr Thr Pro Leu Val Trp 165 170 175 Ala Ala Arg Lys Gly His Leu Glu Cys Val Lys His Leu Leu Ala Met 180 185 190 Gly Ala Asp Val Asp Gln Glu Gly Ala Asn Ser Met Thr Ala Leu Ile 195 200 205 Val Ala Val Lys Gly Gly Tyr Thr Gln Ser Val Lys Glu Ile Leu Lys 210 215 220 Arg Asn Pro Asn Val Asn Leu Thr Asp Lys Asp Gly Asn Thr Ala Leu 225 230 235 240 Met Ile Ala Ser Lys Glu Gly His Thr Glu Ile Val Gln Asp Leu Leu 245 250 255 Asp Ala Gly Thr Tyr Val Asn Ile Pro Asp Arg Ser Gly Asp Thr Val 260 265 270 Leu Ile Gly Ala Val Arg Gly Gly His Val Glu Ile Val Arg Ala Leu 275 280 285 Leu Gln Lys Tyr Ala Asp Ile Asp Ile Arg Gly Gln Asp Asn Lys Thr 290 295 300 Ala Leu Tyr Trp Ala Val Glu Lys Gly Asn Ala Thr Met Val Arg Asp 305 310 315 320 Ile Leu Gln Cys Asn Pro Asp Thr Glu Ile Cys Thr Lys Asp Gly Glu 325 330 335 Thr Pro Leu Ile Lys Ala Thr Lys Met Arg Asn Ile Glu Val Val Glu 340 345 350 Leu Leu Leu Asp Lys Gly Ala Lys Val Ser Ala Val Asp Lys Lys Gly 355 360 365 Asp Thr Pro Leu His Ile Ala Ile Arg Gly Arg Ser Arg Lys Leu Ala 370 375 380 Glu Leu Leu Leu Arg Asn Pro Lys Asp Gly Arg Leu Leu Tyr Arg Pro 385 390 395 400 Asn Lys Ala Gly Glu Thr Pro Tyr Asn Ile Asp Cys Ser His Gln Lys 405 410 415 Ser Ile Leu Thr Gln Ile Phe Gly Ala Arg His Leu Ser Pro Thr Glu 420 425 430 Thr Asp Gly Asp Met Leu Gly Tyr Asp Leu Tyr Ser Ser Ala Leu Ala 435 440 445 Asp Ile Leu Ser Glu Pro Thr Met Gln Pro Pro Ile Cys Val Gly Leu 450 455 460 Tyr Ala Gln Trp Gly Ser Gly Lys Ser Phe Leu Leu Lys Lys Leu Glu 465 470 475 480 Asp Glu Met Lys Thr Phe Ala Gly Gln Gln Ile Glu Pro Leu Phe Gln 485 490 495 Phe Ser Trp Leu Ile Val Phe Leu Thr Leu Leu Leu Cys Gly Gly Leu 500 505 510 Gly Leu Leu Phe Ala Phe Thr Val His Pro Asn Leu Gly Ile Ala Val 515 520 525 Ser Leu Ser Phe Leu Ala Leu Leu Tyr Ile Phe Phe Ile Val Ile Tyr 530 535 540 Phe Gly Gly Arg Arg Glu Gly Glu Ser Trp Asn Trp Ala Trp Val Leu 545 550 555 560 Ser Thr Arg Leu Ala Arg His Ile Gly Tyr Leu Glu Leu Leu Leu Lys 565 570 575 Leu Met Phe Val Asn Pro Pro Glu Leu Pro Glu Gln Thr Thr Lys Ala 580 585 590 Leu Pro Val Arg Phe Leu Phe Thr Asp Tyr Asn Arg Leu Ser Ser Val 595 600 605 Gly Gly Glu Thr Ser Leu Ala Glu Met Ile Ala Thr Leu Ser Asp Ala 610 615 620 Cys Glu Arg Glu Phe Gly Phe Leu Ala Thr Arg Leu Phe Arg Val Phe 625 630 635 640 Lys Thr Glu Asp Thr Gln Gly Lys Lys Lys Trp Lys Lys Thr Cys Cys 645 650 655 Leu Pro Ser Phe Val Ile Phe Leu Phe Ile Ile Gly Cys Ile Ile Ser 660 665 670 Gly Ile Thr Leu Leu Ala Ile Phe Arg Val Asp Pro Lys His Leu Thr 675 680 685 Val Asn Ala Val Leu Ile Ser Ile Ala Ser Val Val Gly Leu Ala Phe 690 695 700 Val Leu Asn Cys Arg Thr Trp Trp Gln Val Leu Asp Ser Leu Leu Asn 705 710 715 720 Ser Gln Arg Lys Arg Leu His Asn Ala Ala Ser Lys Leu His Lys Leu 725 730 735 Lys Ser Glu Gly Phe Met Lys Val Leu Lys Cys Glu Val Glu Leu Met 740 745 750 Ala Arg Met Ala Lys Thr Ile Asp Ser Phe Thr Gln Asn Gln Thr Arg 755 760 765 Leu Val Val Ile Ile Asp Gly Leu Asp Ala Cys Glu Gln Asp Lys Val 770 775 780 Leu Gln Met Leu Asp Thr Val Arg Val Leu Phe Ser Lys Gly Pro Phe 785 790 795 800 Ile Ala Ile Phe Ala Ser Asp Pro His Ile Ile Ile Lys Ala Ile Asn 805 810 815 Gln Asn Leu Asn Ser Val Leu Arg Asp Ser Asn Ile Asn Gly His Asp 820 825 830 Tyr Met Arg Asn Ile Val His Leu Pro Val Phe Leu Asn Ser Arg Gly 835 840 845 Leu Ser Asn Ala Arg Lys Phe Leu Val Thr Ser Ala Thr Asn Gly Asp 850 855 860 Val Pro Cys Ser Asp Thr Thr Gly Ile Gln Glu Asp Ala Asp Arg Arg 865 870 875 880 Val Ser Gln Asn Ser Leu Gly Glu Met Thr Lys Leu Gly Ser Lys Thr 885 890 895 Ala Leu Asn Arg Arg Asp Thr Tyr Arg Arg Arg Gln Met Gln Arg Thr 900 905 910 Ile Thr Arg Gln Met Ser Phe Asp Leu Thr Lys Leu Leu Val Thr Glu 915 920 925 Asp Trp Phe Ser Asp Ile Ser Pro Gln Thr Met Arg Arg Leu Leu Asn 930 935 940 Ile Val Ser Val Thr Gly Arg Leu Leu Arg Ala Asn Gln Ile Ser Phe 945 950 955 960 Asn Trp Asp Arg Leu Ala Ser Trp Ile Asn Leu Thr Glu Gln Trp Pro 965 970 975 Tyr Arg Thr Ser Trp Leu Ile Leu Tyr Leu Glu Glu Thr Glu Gly Ile 980 985 990 Pro Asp Gln Met Thr Leu Lys Thr Ile Tyr Glu Arg Ile Ser Lys Asn 995 1000 1005 Ile Pro Thr Thr Lys Asp Val Glu Pro Leu Leu Glu Ile Asp Gly 1010 1015 1020 Asp Ile Arg Asn Phe Glu Val Phe Leu Ser Ser Arg Thr Pro Val 1025 1030 1035 Leu Val Ala Arg Asp Val Lys Val Phe Leu Pro Cys Thr Val Asn 1040 1045 1050 Leu Asp Pro Lys Leu Arg Glu Ile Ile Ala Asp Val Arg Ala Ala 1055 1060 1065 Arg Glu Gln Ile Ser Ile Gly Gly Leu Ala Tyr Pro Pro Leu Pro 1070 1075 1080 Leu His Glu Gly Pro Pro Arg Ala Pro Ser Gly Tyr Ser Gln Pro 1085 1090 1095 Pro Ser Val Cys Ser Ser Thr Ser Phe Asn Gly Pro Phe Ala Gly 1100 1105 1110 Gly Val Val Ser Pro Gln Pro His Ser Ser Tyr Tyr Ser Gly Met 1115 1120 1125 Thr Gly Pro Gln His Pro Phe Tyr Asn Arg Pro Phe Phe Ala Pro 1130 1135 1140 Tyr Leu Tyr Thr Pro Arg Tyr Tyr Pro Gly Gly Ser Gln His Leu 1145 1150 1155 Ile Ser Arg Pro Ser Val Lys Thr Ser Leu Pro Arg Asp Gln Asn 1160 1165 1170 Asn Gly Leu Glu Val Ile Lys Glu Asp Ala Ala Glu Gly Leu Ser 1175 1180 1185 Ser Pro Thr Asp Ser Ser Arg Gly Ser Gly Pro Ala Pro Gly Pro 1190 1195 1200 Val Val Leu Leu Asn Ser Leu Asn Val Asp Ala Val Cys Glu Lys 1205 1210 1215 Leu Lys Gln Ile Glu Gly Leu Asp Gln Ser Met Leu Pro Gln Tyr 1220 1225 1230 Cys Thr Thr Ile Lys Lys Ala Asn Ile Asn Gly Arg Val Leu Ala 1235 1240 1245 Gln Cys Asn Ile Asp Glu Leu Lys Lys Glu Met Asn Met Asn Phe 1250 1255 1260 Gly Asp Trp His Leu Phe Arg Ser Thr Val Leu Glu Met Arg Asn 1265 1270 1275 Ala Glu Ser His Val Val Pro Glu Asp Pro Arg Phe Leu Ser Glu 1280 1285 1290 Ser Ser Ser Gly Pro Ala Pro His Gly Glu Pro Ala Arg Arg Ala 1295 1300 1305 Ser His Asn Glu Leu Pro His Thr Glu Leu Ser Ser Gln Thr Pro 1310 1315 1320 Tyr Thr Leu Asn Phe Ser Phe Glu Glu Leu Asn Thr Leu Gly Leu 1325 1330 1335 Asp Glu Gly Ala Pro Arg His Ser Asn Leu Ser Trp Gln Ser Gln 1340 1345 1350 Thr Arg Arg Thr Pro Ser Leu Ser Ser Leu Asn Ser Gln Asp Ser 1355 1360 1365 Ser Ile Glu Ile Ser Lys Leu Thr Asp Lys Val Gln Ala Glu Tyr 1370 1375 1380 Arg Asp Ala Tyr Arg Glu Tyr Ile Ala Gln Met Ser Gln Leu Glu 1385 1390 1395 Gly Gly Pro Gly Ser Thr Thr Ile Ser Gly Arg Ser Ser Pro His 1400 1405 1410 Ser Thr Tyr Tyr Met Gly Gln Ser Ser Ser Gly Gly Ser Ile His 1415 1420 1425 Ser Asn Leu Glu Gln Glu Lys Gly Lys Asp Ser Glu Pro Lys Pro 1430 1435 1440 Asp Asp Gly Arg Lys Ser Phe Leu Met Lys Arg Gly Asp Val Ile 1445 1450 1455 Asp Tyr Ser Ser Ser Gly Val Ser Thr Asn Asp Ala Ser Pro Leu 1460 1465 1470 Asp Pro Ile Thr Glu Glu Asp Glu Lys Ser Asp Gln Ser Gly Ser 1475 1480 1485 Lys Leu Leu Pro Gly Lys Lys Ser Ser Glu Arg Ser Ser Leu Phe 1490 1495 1500 Gln Thr Asp Leu Lys Leu Lys Gly Ser Gly Leu Arg Tyr Gln Lys 1505 1510 1515 Leu Pro Ser Asp Glu Asp Glu Ser Gly Thr Glu Glu Ser Asp Asn 1520 1525 1530 Thr Pro Leu Leu Lys Asp Asp Lys Asp Arg Lys Ala Glu Gly Lys 1535 1540 1545 Val Glu Arg Val Pro Lys Ser Pro Glu His Ser Ala Glu Pro Ile 1550 1555 1560 Arg Thr Phe Ile Lys Ala Lys Glu Tyr Leu Ser Asp Ala Leu Leu 1565 1570 1575 Asp Lys Lys Asp Ser Ser Asp Ser Gly Val Arg Ser Ser Glu Ser 1580 1585 1590 Ser Pro Asn His Ser Leu His Asn Glu Val Ala Asp Asp Ser Gln 1595 1600 1605 Leu Glu Lys Ala Asn Leu Ile Glu Leu Glu Asp Asp Ser His Ser 1610 1615 1620 Gly Lys Arg Gly Ile Pro His Ser Leu Ser Gly Leu Gln Asp Pro 1625 1630 1635 Ile Ile Ala Arg Met Ser Ile Cys Ser Glu Asp Lys Lys Ser Pro 1640 1645 1650 Ser Glu Cys Ser Leu Ile Ala Ser Ser Pro Glu Glu Asn Trp Pro 1655 1660 1665 Ala Cys Gln Lys Ala Tyr Asn Leu Asn Arg Thr Pro Ser Thr Val 1670 1675 1680 Thr Leu Asn Asn Asn Ser Ala Pro Ala Asn Arg Ala Asn Gln Asn 1685 1690 1695 Phe Asp Glu Met Glu Gly Ile Arg Glu Thr Ser Gln Val Ile Leu 1700 1705 1710 Arg Pro Ser Ser Ser Pro Asn Pro Thr Thr Ile Gln Asn Glu Asn 1715 1720 1725 Leu Lys Ser Met Thr His Lys Arg Ser Gln Arg Ser Ser Tyr Thr 1730 1735 1740 Arg Leu Ser Lys Asp Pro Pro Glu Leu His Ala Ala Ala Ser Ser 1745 1750 1755 Glu Ser Thr Gly Phe Gly Glu Glu Arg Glu Ser Ile Leu 1760 1765 1770 

What is claimed:
 1. An isolated polynucleotide which codes without interruption for a human kidins220Pc having an amino acid sequence set forth in SEQ ID NO 1, or a complement thereto.
 2. An isolated polynucleotide comprising, a human kidins220Pc polynucleotide sequence having 99% or more nucleotide sequence identity to the polynucleotide sequence set forth in SEQ ID NO 1 along its entire length, which codes without interruption for human kidins220Pc, or a complement thereto, and which has protein binding activity.
 3. An isolated polynucleotide of claim 3 having kinase substrate activity.
 4. An isolated polynucleotide which is specific for an alternative form of a human kidins220Pc of claim 1, and which codes for a polypeptide, said polypeptide consisting essentially of: amino acid residues 1138-1184 (SEQ ID NO 3), 1138-1176(SEQ ID NO 3), 1177-1184 (SEQ ID NO 3), 1138-1194 (SEQ ID NO 4), or 1177-1194 (SEQ ID NO 4), specific fragments thereof, and complements thereto.
 5. An isolated polynucleotide of claim 4, wherein said fragment is effective in a polymerase chain reaction.
 6. An isolated polynucleotide which is specific for human kidins220Pc of claim 1, and which codes for a polypeptide, said polypeptide comprising amino acid residue 136 (SEQ ID NO 2).
 7. An isolated polynucleotide of claim 6, wherein said fragment is effective in a polymerase chain reaction.
 8. An isolated humans kidins220Pc polypeptide of claim 1, having the amino acid sequence of a human kidins220Pc as set forth in SEQ ID NO
 2. 9. An isolated polypeptide of claim
 4. 10. An isolated polypeptide of claim
 6. 11. An isolated polypeptide which is human kidins220Pc having 99% or more amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO 2, and which has protein binding activity.
 12. A method of detecting expression of a gene coding for human kidins220Pc, comprising, contacting a sample comprising nucleic acid with a polynucleotide probe specific for a human kidins220Pc of claim 1 under conditions effective for said probe to hybridize specifically with said human kidins220Pc, and detecting hybridization between said probe and said human kidins220Pc.
 13. A method of claim 12, wherein said detecting is performed by: Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, or in situ hybridization.
 14. A method of treating a prostate cancer showing elevated expression of human kidins220Pc, comprising: administering to a subject in need thereof a therapeutic agent which is effective for regulating expression of a human kidins220Pc polynucleotide or polypeptide of claim
 1. 15. A method for identifying an agent that modulates a human kidins220Pc gene in cells expressing said gene, comprising, contacting cells expressing human kidins220Pc of claim 1 with a test agent under conditions effective for said test agent to modulate the expression of a gene coding for said human kidins220Pc, and determining whether said test agent modulates said human kidins220Pc.
 16. A method of claim 15, wherein said agent is an antisense polynucleotide to a target polynucleotide sequence selected from SEQ ID NO 1, and which is effective to inhibit translation of said human kidins220Pc.
 17. A method of detecting protein kinase D activity in a sample, comprising, contacting a human kidins220Pc polypeptide of claim 8 with a sample comprising a protein kinase D under conditions effective for said kinase to phosphorylate said kidins220Pc polypeptide, and detecting phosphorylation of said kidins220Pc polypeptide, whereby said kinase activity is detected.
 18. A method of determining the presence of a protein kinase D activity, comprising, contacting a human kidins220Pc polypeptide of claim 8 with a sample in which the presence of protein kinase D is to be determined, wherein said contacting is under conditions effective for said kinase to phosphorylate said kidins220Pc polypeptide, and detecting phosphorylation of said kidins220Pc polypeptide, whereby the presence of said kinase activity is determined.
 19. A method of detecting polymorphisms in human kidins220Pc comprising: comparing the structure of: genomic DNA comprising all or part of human kidins220Pc, mRNA comprising all or part of human kidins220Pc, cDNA comprising all or part of human kidins220Pc, or a polypeptide comprising all or part of human kidins220Pc, with the complete structure of human kidins220Pc as set forth in SEQ ID NO
 1. 20. A method of claim 19, wherein said polymorphism is a nucleotide deletion, substitution, inversion, or transposition.
 21. A mammalian cell whose genome comprises a functional disruption of the human kidins220Pc gene of claim 1 within amino acid residues 1138-1194 (SEQ ID NO 4) or 1138-1184 (SEQ ID NO 3).
 22. A non-human, transgenic mammal comprising a cell of claim
 22. 23. An antibody which is specific-for: an epitope comprising amino acid 136 of SEQ ID NO 2, or a polypeptide consisting essentially of amino acid residues 1138-1184 (SEQ ID,NO 3), 1138-1176(SEQ ID NO 3), 1177-1184 (SEQ ID NO 3), 1138-1194 (SEQ ID NO 4), or 1177-1194 (SEQ ID NO 4).
 24. A method of selecting a human kidins220Pc polynucleotide or amino acid sequence from a database, comprising: displaying, in a computer-readable medium, a polynucleotide sequence or polypeptide sequence for human kidins220Pc of claim 1, or complements to the polynucleotides sequence, wherein said displayed sequences have been retrieved from said database upon selection by a user. 